var title_f33_61_34768="Naphazoline: Pediatric drug information";
var content_f33_61_34768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Naphazoline: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/57/10131?source=see_link\">",
"       Naphazoline (nasal): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/60/27587?source=see_link\">",
"       Naphazoline (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12629 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34768=[""].join("\n");
var outline_f33_61_34768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/57/10131?source=related_link\">",
"      Naphazoline (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/60/27587?source=related_link\">",
"      Naphazoline (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_61_34769="Seborrheic dermatitis face PI";
var content_f33_61_34769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 247px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD3AV4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDza43Sy4BLKp6Y5NLHp8jSL5cOIiDhyQf079+egrS0yzMoaTAO0FuRx9a3rCyDwEyLk7flx3/L0rNRbOi6PO/EGjTRwwxR26B5ZPMyfvYHTn65/U9qzrW0uJ7i4luEMluXeWTcAFk2gjnPXocV6qdFH2uN3/e4+Yk8j6fnTk0Rja3gkjQGQ7lRV5IHatI3Rm4Js8lgt2+w28siA7UVg45wu07h+ec+y1f8MaW+rWL/AGoMwjbKEDkNjGWPfIC8dhn1rtbHw850hLcxfKglVyW++Duwfw3dK3PBehSW1g8EywsG5USeuMEgD1wDTUm2P2dtTx/SNMmupsOmyJJvKYDjJJ3YUdegIrs5NHlc3SzyPGsUKbVJBDAlyHHbODjP1FdnY+EzDqE0s0rwq75O1Bzzwcdj+tdbaaRa26nMKNvGA0nzflnpU62NIxivM8qtvDlyLVBHACYJQBPL8sbq2ACM9DlR689uldpbeHLuOeBWtYracsY2QuOp7uRjbgknc3oQO9dctlAiLHgsjkchNwX6Dvx3/pSmJEt2thCrhVJZieST2P8AeOOBjgZOaTNY2WyMC10m1sLWdLaJ9sWGWQr823GQVGONzEkHsMECrX2CLy+WAgk/fSLHkg7SSPXOTkZPTGPeteVpTJ5x/wBYu+TJ/wBlcA+4B4H0/Gqd1CyRskMSD92V5zxxtA/Mn6Y96RomNjuYzdLJCN07PIXCLyE2gL1GMHjj2+lWZJzACXBzExik2nG7B4xn69D0GarvHIAEiGzbudeMDnHP0wBj/GoblUDSMQ2QNoBz1xyc/X/9dNMiVilfXLi2aMYErrtyRwBn73tgcZqvY2JuJoiwZdgOV9M87j6k8CrE2x7jJwckDgdRjPT61ftMJdBmU5bg+3FQ2riSdtBbxFtLXe0WT3wMZ9v/AK9clrjebM+ACxAJK8n2/wA966/VpD9hcyYC4yD+nIriLrBmd8YG35R1x6Z/nU3udNONtTofCqPFZIAA7OOrdQe9dPpdu6IzTEtEckAnk+3rXN6G7LDESW2lfukdD3rr9Otmf5lDA5xnOfyqPQ2crJ3NOCZzGiRqTu4HB49ePSjB8lxNGu8n5gDtwPUCrMMYjKszEEDbx0pNQcxqrPEhUZ2uBkgd807W3MU7uyMtZSsrKcbCc7mG0lfTHTj/APXVO6ZV3MoIAyCTwSPU064IlJlcnJIUEnIP0/pUMpdLBw33gxIyelS5Gk1pc4xpHGoTJGx3HJj4yK3IWMiRBgAzKuCPWsOE+X4iO5WXcpO08Eev0rpLJI/JUR4Ofbp9apbXInqUNRt8wEsMt24+7TdCujbkDgSgFgp6tg8j/PrWrNHtjkfk8d+n1rONuEKMuGMJ3Bsevf8AWmjlZ0FgWlARCRJlmbBOevcevuauM6o0Y8vKFjwejHnj8yPyrK0+9S3uV+ViVxz1LcdatXZDRl1OGHyjpyOMf/X/APrVoloT1Ma/it5yiMpSRWx83AkfGSfrnbwa4rWvDsUGmyyeWJlRT84TO1ASGYZ4IznjuSCa7d0dLgeYRhtjDnOMkjn05z+YqMEzqEQbYFUghmAOSTnHYKV9epFSbtXR45ELmCWVrO6a0hhiWZotwaNQeduG4Z+QOPfsK1YNcv7eQwXmnRXIkRC08B2yRiTlMqeCSMkKDnHXrXXazpUDlUtVf7FgiOIrzIVyy7R/dLHnPFUJvDLw6TM1kJHnSTOIwXkZioG7px04zx9MYqlIylCS2ZR0nxR4enHk3DxRllCsl2hRmGODk9D0wQa2Lw6fNbCSxlRJznhH8xQD2xnjH45/CuY1TwzLZNa2FpaO8scNxLJ8m4JyqKSDngEZ4PYeprG1PwvbwSyi3haGW2uWUggowj2DGR7n361XMiVOaZ38dqAieRLdnYSeWwG9znqeckVVmsryQosl+PNJIYsmFEfGDkc5JJ4xwF+lec6da3c9vBJbXt2hyWwkzDAXdzjPyk7enTnFT213rf2u3ha9lkD4Iyuc5wRg9sgjn35q9zN1pHcakLpLK3to1D28ZJiWFc4wcCT1LM2evpWdJLALyC3ZTuWTY4ibfhF42IR94tzk+p9BXEP4i1ZYCyzSIxBZiUBJUHB+nHGeoxVUa3qm429reCF/KaRZPKAZgOSM/Q8Yxmgn2r2aOwv5JptQmldF82SVyLZTuVMk4HuF/pUUjo2HLCOKLARDzwvVmPrnt61yFne6rPmG3v2SGWI7mjiUO+OGA+nOVyM4NXLa0vMI8141wAPlcr8hB6EdP8ahuxPxGnZxYuCUDBCfuZzj39BW7aMwJMeUXHLHnJrmo2dJS05kLnqQOorfsLqJ02IrKwGcdOKSZTizpLkCOFYVVdzD7q+gpGMlqURPlJUKvGcev41aRFe5kfnzcbd38IHoKupbwI0L3IwQCeW4HvmraZMXYi0tZGRnkBxnv0NakRUttjRlx145+lFtEHmLAlIzztI5b8K19yiIFsIM/L3LU1oX1KcFkqOVG1QT36j6VYtNLAlLwsUz1Dc5q1bS7pvkiAQc72OCfpVuMK0Jbzd2T0AqWyrMgisVVAXZpZc9fSrL25xncPTP+HtTpC0UakqseeiZyT+FCFjy5AfPy852+/uaV+hS7ix7F3A5VB945+bHt6Z96YquWIRJDMxCRANnyzzkE9ePTpnJOcVdjXyhtPDhtwK9QT/Fn+96fnUdqNzNGpETOSBIjEcHgBT6e468+tOw7lNiA7xW29ckOoCg5UKSM9ehGfz96lMSzKdjeYka7VXaB6AE/j3B6D3q8LRlhfCBTvVNxHy7iwyQfQbQPbB9ahll2Fyg+RVGGLYG3P8A9YDPpmheYOV9jM1CHykZQSZHXA52hccD+uKzbhdsccO7cFX5m7nGP8/Wrt1K5C7EfePlAOM8+lZTox8uKVlbOdwB5Hp+FRKWppGLa1JWhT7Z56xkAx7VHXA9frmtGKOER20r8OoP/fXfr/kUwCHy0JYb0ODiqWr37QgqATlQMnk59B6Vk3Z6mkKblsV9fnUQFEZWI4GBxXPQw+Y7MH2qBjnnJ96t3pZsncpfGMdRmo1RfsxjjDjGGJHU/wD66o1Ss7Ghp8smU8qRNp/i4wD+PXmutsL1YokB8xgvOehY+vvXJWUASVYyyFxyqnoM108FoZIWmHM2QqHJArN3Rs1FrU6COcuvVjn7sZXBJ9MmoJxJHPE5nXylJBQj73H5Cm26LMpa4VxIONrcDr0J7in3KDyyJZGErKfvH5R6f/rNNmWzsZtxcKjGaRQYxwQBu/IdfTpVe5l+0LIAFUupxUlzEUKsrkuWALEdPXHaqckgZNx4IOAT9cc1KLkla6OY1QeXq9tKcMQpRwOfxrc0Wb/R1U5ABx83X/PNY2tRnDEA5Dbh9Km0m9KXawy5GD17Pn3q+hEVzJnTykLOYW7jg/z4qt5WLlQwyrH/ACKtlldEcgbl7nvUM8TTh2XIx0C8c+lBytEUSATMeVZmByD6cj+tXGlLo0rqx3LkZHHHXp7dqWJBtI27l4LDp+NSRxu8cccRYY5BJ79P/rVqnoQVL9WuT9oR1aJyFUFeVwAfx6HFVjZiWSPbGHwFOOvygElj/KtiC0H2PyQh35O7sVBOO/v/ADoCgugyWdRyew2j/DIP40ONy1O2iMZYEMagMzykg/N97aoywHtnjt2xmtS1jieGNEma3TbgFU2lx12nnG0E45647Ut3aSbVYxlUKllIGMDgnHtjn65p8dusUW4NmNeCHT7ozwcj3zj0OaErCk7kJtSXZ7hUYbVQsigjGc8gds+lV7qz0+8+1i5t0zO29ihO4PkHcCSeePatZlkjUISTjoM5XBHb39qiEMO3cVIYf3TVGTPMz4WFp4immgjSe1aP7zZDIfMyy8dvmJHHqO1VdR8OxxrJE0fkyJGrx8ZBdeqg9Bng/iRXok0AM5aFwzdwflJqjKZG3RTwrsZcYJ/zmkrIGrnlWo6FBDq9vNMztbyIZCeRnd8r5+oOfqtZGnaBILqxcKuLWcxPIADlGyBx36Zr1e90+MqjFMqFxiqVvpKwOZYomOcEtnr/APXo6k8qPPX8OG21H7RCsYdpw6qPuEHG4Edh1/Ot4aVFC8sW2RIs7gsmCPcZ9a6iW1hQnf5YLnOOx/wpsynaHdVZAOOfai1w0RxsuklfMJRScjHPGD0Iqo1mIjjO089K7KO2DqeioowOfun/AAqrcWduWzv2t3PfPpUuNhc3c2UtTFA8kjf6zqvv1/Kj7MLto3md2IOdp4HtVnJIOQzE9FFSKsUZCLLhhlpGbt+Nat9CIonijSNo8uPMAJPXn61pWaFstkPnpxj8vSsq6VvkWNC07/6sE9vU/wCFa9usnkqpO3gBieMf59Km5so6D2jVCu/PPKrnn8atx5Ef7rDPjCg8gUyGJPtJkCfdAAPvU6RfOxJCjoy9z75qXcYgiKuGwrN0zjjNSLC6SLlizsclgAAB3qQLkqo5IG4egpxdBgqcluhPU+n4VaWgrshlcxyERxEqM9cnIPG4/Xpn6VOGEcKbEUyzHbGp4JYDCqPYYY8egqGAM00hmdv3fzmTjdtzgY9Op4960BHEoSYjy5AvlxnPKj1H8vc0eQyFScyNu39UwrZznqB6HHH447VnXhUM0JI2ZyQo+8Qefwyf0qy+z7X+7YKQMYU9AP8A65z/AI1nzLjaCCVJzx0H1rOUi4wuzPvrmFZ41DBGkbagPOcDJNVRAsrcquXXtnJGealvkMSyyMeeRgcY9ee4qlCWd2GwLsLAup6H6/jUXvudcKel0adsgSWQZLYHzccEVka9zc7AAOOSOOnf8P8APSr0F20MJDlt0ZIwOuf845rGuHMkrPyW3ADAzjPSla5pFNNsY0IQuwIBUgleuM9T9aqoz7G4Yljxt6evWpmEgt2aVguRww+n+NOtyUuBGoBTbnIxnPfNUxLQ0dOXEMU1xHucr6YwD0H1rrLK88uNQ3ReM44rmIbjZb7GUSK+RzwB/n0rc0wbk2xncemSMn8OwrNltXV2bShZHkYShkbGRnqfwpbhvIjWOSQhT0B/lz1p1vEhUhS2WAJNPniZVUJIcZ3cgH9TQjG6vYxbuR1UlYwevTkYrC1mZTaT+ScNH95VPQ10U8DyPLvYLwe2Oa53UHSB3Ep2FwRvweTSt0NlroZ8rIyoHYtuXOSPbqarxLuwG+RlJXPofWnK3BYnkE8DpjpUbqI5kLZCHgk9jVmUNJnUWL5tdwwVyDgnv/hxVuONrSEKGYgHowyQOuD+dZlhcxtZp8wbaSpyMZHTpWpC5SE7t5Iw2SckU7WM5rUkhZTuyMMRnANXIkZid59CCvOD61m4UhS+AXyw5yR6Ant/9etO3cbTnJXPJPyge3/16FoZuPYuLF5oDNKAGG1jjgEdCfalkt8SxMYwuSvIHCkev4E59cVWgdwpYFdm45X3x1rRtZUntdrq3A5HqB/9Y1pFpmUouJUIKTLDI2Io8vsDfdXPzAY6YOfrkdKatuRA5Kh3BbcAOGAHOcdiMHH19KtyRhBukXzGjADP13D+F/y/9BqKF0jjSJmQSKQEb73I5X8B+oOKom41jGoO59m0gDnLZ9vXj8+1QlEMoT5clcgxnketTyJGzOPK3Njac8gAnofbPT04pFhCRMqMdoGSoxx9T68/r35oEVLmzV8Mx3EDjIwfzFZ0luvmGNWJcc+Ww5xW7tYjplGHLA9D6EelZd4jKrmNUaVTnBHI9uelS+4IypLBJHw6upPOBUUsflMqkEjryuMGtNrpBEuWO4k8FSMH0PoaQMWId0IPcno1NCdzBvYnuJAQFCAZBGDkemKz538uZY3w+OAewPvW9qCBGLQlVAA3Ajg9ulVmVXhKoFZmGCrdqb1F0Mu5jEQCuoKucM/v1AqpJAwmkljUCQnDZPWtKe2j+0GOUkALgZ6Z7VnOWjkCTchRgdAaTIt2NmICJPIQkuR87Ec1napK0WyGFSzsM49B7+9a1lGkMe8DDtyc+tJBaxNeNNKPmOflH86JXLhoy7pMLC3jSdi8hHzOevPXHtWmgCou1VKoee4P4+tVEdsKo6j04AH+NWpp0s4VwVyV4C9h1yRTbKUWTtvQb8gEkHH90d6dcOqRqWwsQ5YkZOKpWkk1xvDx8oNoB+9k+3arpgjUiaTaEVdzbsnB/lUcz6D5bbkyKVVXUYY/doeMMxCleOCDzz6e5/T1qGGYP88JG3bhcdvwNTtKSpKgCRgNuOw9f1ouVysBbJENsmXUOJGHQM46c+gz0H9aiuJ2w7QPlyB1/Ldjtx+lV2ARizPwMgMOeg6UiTxyxh/kO3GAOefWpcr7GsafUbHlY3JU+YAec8k1FM7ooA2uzAYI+71HGaW8m+zhTnLAEDjJI+n4/pWXLKzojRmTZ1BVc4GSASe3P8vpU7Gqg3qRX3mO7eeMryu7nDYPzFf5e1QwKY7dthy5OcEDP4/hUu94pY0uvM2hRIzKvzKG/u+56/Wqs1wHjgELStI2d56fLnj/AOvVI3S0sVrh50ySWPdQe34fjVG8jIkUIwQgEgcgtn19u/NWyzSS4IxtywKce3H4UXQiKmZGKu5Cc98DA+mKLXCUrFefYEEMZLKoGSw25Pp/hUNgmwhctK+AWk65GalEYa13kZ3N2659ajhk+zx7mDecCxLjgMOg+mKH3JjrobUDjzAwZRCoGMc5NatvdJa26MochjhUXqPX6VymnsHdC7DD88+vaupieNbfbJxIwIDY5FZPVnQ4cujOhsblRGvAVmXgDpVpsTKGLfKMgoBwf64rnNPd02xJC0hHRjkceoq8z3UsTqFXZjJZM8k9s1SMpUkmTSOzTkRpgKcY/vDoTWDrMMU1rIrgLhtucfrWqzqsYKIQNuDweKzdSkQ4jkKnOCc9x60IVrPQ5dkZQVIIKZ/IU2SQAOz52hQxGP5VNqKSrcsAGDBQf8QPakW1e6WRYlYiJS7KDyBx0HfGc4H9K0sYuVpXZZsoZms7m4JQxQ4JGCcg8g8e2c59KuR3b7kYJIySMFbaOg9c+n+NZUEIICuGEa4X5ScE/wB4jucVaEvlNtLDjK7gePY4/wA4pbGifMy+HZX81GRVc+3Ptkcn6VseY7De7Eo67Qcg+X3HTnA/rWTZIrp8ygb2wcAdD/8AXq+ubdDGxUB/ur/eHp9OKllWTZopcqrBJ0aP7Qu5AeSCODz65z0rStVxEJIyc7gynoD61kpE0sNvscMIn85UPBweCB6e4rTsh5UYRSXB5C8AhT2H+cULcwqRXQu20ofbGCzMpKFfQH1Pfg0sVsIYygTgH5DjPTqM9xj+tQKnluSMbiMqvRj7CrKTPuw33SBz/KtFLuc0o9hk0OZGdCWLHOc9Qff3H8qgit5DIjBsw5+4Bggent6jPoRVt50aVtoBIULKv+yc4bHpmneWVkKMT5gG1ST0I6H3yO/rVXI1RAMbgFYKwzuHr6fgf0NRzKpO4DcDxhjkgdh9KntZJBGwcASFsZYd/wCfJ5/Cku4cAAFCrg4AGenX9eaSel0FtTGuoSGErAFh90jqAf4TVac7Y9uzBAPGa05cspTqMfe/piqc6qQ0cjbHBIBzyOOKLhYoXEKyEBQ30PaqV9En2YhP9YgPPdv8K0EhKxAo4c45PYkVUjuxcyPDKgWaPt3I9aV11C3Yz3DSmESgLLjHzchz7e9Z1xbSLKXjYqW6j1rVvbcqzPcbkjA+Vwfun6+nSqDNM1svmrJLMDgsn8Q/vChkbF4TqiEuBsBwp9antmUcnG7OT6is1pFKwghuuSPT61Ys2fzJHJUoCQgAx+dO+pUVobUDqFCKRtHUdjTbm2kuFXco3M2doJyMd/w/nVHcUcF5MgfdJHUntWjazNt8wn5zhQOzHHT271PMnozRJrVCrD9nRYrVnCAAknqTnqT+f160+aYCHYrEP1+Y8dafGg8oKSckghh1Xnt7VUuIzKwXhFYjc2OT6YpS1RpBJ7lqONVHmDaB/EfTmrLPvRXjcKnTp1qtcRh1VQSApC7T0b2NQPgBUSTbtUbAO5zyT+FTsaRjcLlmniLsHVDhc565OOB+FWVty7q6uI4kGwKDwvY59TWfKX8qBpCFV+eADgHI6+/6daXc8yrlyykfdz8oHb9OtLY25HbQmu7cHe6t5pGXJDYwB/ET2GazVm/0WXy8ODknDYffgYY+ijOcd/wqzbi5SykW9fz5mLzEqgVArYKoB32juarxxyJNKkyKxnQfMp2jB/iA796ZSWmpVYi6VyhJRSA24EBu5Bxzjjp71RDJMxEUZRQxAXPT6dvetD50iijjfy4oCzBUXDZIwec8k/57VWby4PNfcQAQVAOetUF7XK7AQ7iWzjGSeePftUF5Mg2rjc2PMz1zmkgM0zy5cGOGMHeT95yRhceuP5VmC6E8ZuY3ALNtEYOcKAPmJ9z2ppGTd2WLm7MKoOrAHjrimoOMMXCAlm5zz6VHaESgtn58EjPPH+NXLZVEEdttwzNilIuDUSa1tmjuPMCZcnlB/CO2BXSiON7LbISzOcNjsKyoClrCMfvH3bCQf0rW0SFjMhKsIlB5Y8n61HKdDldcxJaK7iLyTKSWI+YdB2Oa0rhcRFVkKt2A659KtCPEagy/KpLAqoFPgt4wgYKNrHO8daozdRPUyTazbFLBWQZOAelZ2pWIjgMuC8ajpycc5ro9SR1aMxg+Wejf1qndM0UTIQDG427lGcfWjqS5t6nGX82ZypzwBtxyOvOT24qpbzzw3EjxSeQxYjd1AJXoPqCfzq/fp5c+4DA28FRkHmsqQLHcdl3n5WB2hT0BPtzVowq2NfT2DLLGw+RgOvOOB3/CmQwB2dmwcEZ9eKrWubeeURnKCTYx9G54x74JGKuWT7ZpFaQAMQV7YPvQxU31RsWMg8slUX51Iwcgcf1qwxQlkOxlPIGOSR6+tZlk7GZyqnjIJ9fX+dakdvb/AGlECp5hBGCPQZz6cj/PNZs32ZbeVY5GSMlCVLK3BCg8cn8+KsRT5PzkLtwDluVH179KqlEkuI8+ZuLDgKMD6+mMVbI+z3Co7HpyCO2eT0xjnmkDSt5miQRGCckAA4Iz9D+dMk807GVflyCCe4p0ICRgclAOQf4ef1p9yry4RR+7Rf4sZB/qKpnOR/J5waPIkK7HXPzMvvUzOWXBGeMAnrj/AD/Oo0MZBVsCX+7jB9/w/wDrUrnbKC2SnYkev9KNiHEkjkdbgMT8uAo3H5semCOP/r1PLlkR+qHO0HqP/wBWaqzM5DFCDnnB6EelT+cjKpQPscD+HkfTn8DVRZDiVLhUYF9x3Dk44wR3qhPEJAxdQz9PT6Vf2nLRt0B49j3FV5VYoS4zg5wPSne4WsZs6Kkg4bIwchcAe2ajliR9rhQJOzY5+n0q7IFyQRnoTz2qm7qnRMl/un09jSBq5QuHOzZKf3ZbYN39faqi2YhDJHJmMncoJ6D29qtzSJLEzZXIOGHoPeqwfswMvsoximtTOSMS3n3yTMSFQfKHHNaEdxtmiHO0c9OMkcc/SsQPtt1kVvvHK+30H1rQtZ/LXdIpIYgYzkA+ooKj3NkPG8YKYfHIPufarSShGCqduRjJ9cdKwtPmEabRu25Y5PXGf/r1dLqHMzE4Qfd9vX36VJ0Rhc3LeUqduQcgk56AelMguPOm8pkQkH5T/WqFsRMqzHGG5642/wD16s2riS4kYx4Rf+WmOD2wD3obtoVypGg+d3JZlAPB/nTWjSSMGQAEfNnGc+lSIn3Sck9FB/l+dQS/6xScAJwec8d6QRCWBHhJlhWQAfKoFRvEY9xIAD7QFzgAev096um4ETBTjJHLdaqSzyLNDKrqkpbB4xgeuD/Ki1jSLb0GiETGRxMNkf3kBByScDNVtQeRVtGZCvyCNAwB3Kvyj6HNOaN/LkwxcRvkZXkcZ4IP86gyLiRmRcqoL5OeeO2Oh4o8i1HqyF4VaE+UhBCj5W6k455rD1NgsD4TdJj5VGefUfz/ACrcunVJR5bs+w4csuA2ehI7Vy/iHUysHk+RGvy71fqWXOcc9+v69RVLUzbcdSlFIk8cSxQ7bpEJdd3EhY/KFXtwcfjTLS0kGnXToUQRBAVzjBbPAP4VVs2CKnlMHUkHAwOcZxgc4561ppaRuixTEZ+85PTOOuPQCrtoZ8zb8h1oX2RTIPvjJDEA1etiZY0bdkoxfAHP51nBgkkkiYwR8gX+EDsPrWvpkAnDRtLsyBwvB4OSKk1S1uzWQpbW/mzR5KjKrjqT/Wty12JbR4fazHgNyT7Vktid7eKSPG3nOeF9q1o2i+0IkpKt2wepqWX0Na0ha4QB1A3fwZrU8to1CeUen3jVbT4C5ZmGOMLzya0ZQLa3aNJJAi4LZGMH0oS7nNOWtjE1CKI3HBbO07hnoPpWBdzxzmRYXI8rAYD+tdPcJHncSPmH3vWuT1CRbZ/OPyRs2zp1HrRY6KfvaGLOWPm+YA4VwyEHoprF1CT9+nQEN8nUYP4VsXJmtZfKwCknBI5rE1BRI542lPugVWxFSIlve2cN6Z/KmW1l3s6svmNGzE4APGe2ataRKuw5QgMOWyWK5OQM+nasowma2u5FkiRAhlKyNgtyAQB3Oe31qexkJig2KfnO0deSOrZPbp/9YVUlcyp2VzrViJRgHAK7SWx978K1rGFIwu5iCy4VuDlc9z2Pb+Vc3Z3ZkY+UpkVW5bpketdTZRLH5soO5ZEZAc4yB2745rI3ldLUls1xenzGztDOePvD1/Kp7htj7yGEW5kII7egqKxWQTNuLbAOGJ/UH2z9KfKmYt5JdpG3dcKV5zx9eR9anoPqXbVigLTZDr9wr8wJ461a8wSRhVOxsc7eTg4BIP49PeqNtuDRv5jOF+nT/EVYhljVNqn59pYgn+HPX09OKpbGMlqOkRUCsOMN94DJUD19u1Ob7oH3SAeM8fhSPIY2XaGIOFOV7H1qAqUtgJ5MFiFBx/F2oJtce8a7sou1uu3PT6Z7U+MgoykBQT+XX9KrrLuC5ba5JwffutIJUDRjnI+YHA+b/PHFCsDixftBOWcgSg4JB6MO4P0qCSXdMuWPHGAenqKS5YtOZYyF3jkdcn1/lVK6BZyI+JMfKM8Z/wA+tK7HyJksqqhZuQTg8nv3FZ9yCGDgnYeDxwR61YEpO5HIBQ8gc7aoXsjwXEewF0lB3NnhSP8A9dOxNnexSkR0ZuCwOSG/pUMjsoUg5+UA+n1qd5QI3iZmVjk7Txisy8EoCi2ByvDZbHNNaGctdDEtpGMajK4B24HX1q214BCFJypONir2x39v51lW0q+YVIAUqBwOfrVpJ2E2WfJbJ3AAH25NWZ09TSt7wy3BjU5QYwFH3cnqfXOBV6aQlowApBy/mFskYPII7Vk2cO94pjt+QlDtPDccHFW47ZiECAmBh/Ex6nPB9uahndDlubtigwCibVPIPZ88kgeme3tWnGESOJtp3gA7WOevesbTYhC6Lv2ooA55OfT2rVkINyh3EFAcheAR6g+lApblxrtE2kgZPAJHSoomJlZZNuedxz0P/wBaovMXfvkXcgOTnkA4p0XlKoaFA5ZsLkHPft+NS27jikTrGs9r5gDCVT+7z2yefzwapXKqroApG7ruGTgH39afceazeWGKjYWbsdw5OPX8Kjht1eFXEofHPPU565Pp/wDWpG0NNbjo3IEse3Kox3Drg9ifqD+NFnNBc2sEdmjJOqssisOC/HIPvjH/AAKqscLSX00koxFgAqpAV+3zH8qmlVbeQFQRCPmVR0U56D+lMJpfMqXM2UErRq7c70yV3ccgt69fyrgb4tcTyo5ZxHyAp3BVXpknoOSc11HiG/Gy8jiKq06bhk88Hk/oa5csLjcEYFnVVIQADHBIP6fXBrWK0uctVu/KiazhDkO7hVZWkdzngDt+PpWxeAJao21h5gAAPJx3JqtBCCiksRHjLEnj2q2BNcFmcYLMVTjrjjJ+tNsuMbWKiKBbN/CS2QAOnNaOivMUJJXIHJxjk+lUJP8Aj5VHyF2gsMdPWtvTdjkhdoVunPSs2zQu6fOZrsBonbAwCe9b9uqTEGMp5idQR0rJtfNhlIJTIP8AD2Fbej4MkzGPy4w2dx70FT0V0bFoDvDAuzoPmGcBTWuqvcLGu4DcM/MOKxLB4p2kIJDbsZI4PvXUw20kkGYWHAxuA/OqjqcNV8r1MHWhHHEw4LIMEKOorlbi0EcQ+Q3MTHewfqo+ldZq9s6ysFI6YOayJidnzDJQdAeGFJ7m9OVo6HG6hHGM3MDHyzldvoe9c5qxVhvAIQkcHjIrutVSLyXMajew6Y+7nrXB6m6xxYK4L52g9MD/ADmnYtvmVykMszBUyhxkY4HPFSWJl8lkSQ5cFChwRgg549COvTnBqIf6uNiSocEnvkduKkgCopDZO09AecdcA+3WqT6GLia9hdKHaOOMxbWwI0ztUEDj5u3Tr/hXZadMUggBfcsZOFPA5Hb868+UvbFnR4jJgBQ+eQT09Me//wBauyt2kgH2eaFI3VsHaxO3p3PXqKiS7GkWpJI6BQrWiYChmBZvb2z9P1qwyARRttRiijBH55x+Gagllkjt0EeZMJsUgZPr2/8A11aZ3CEzRMqdAu7kd8fTv+NQF2MmlBgRgNxZd5AOBt9Rxx/jUcSgKiqymGMhuBjPrn1pZLlljDSqVMnADck/h+dM82FJuAYdzFtgO75ff370eY0nYuyygN8wB55JPTPrUe3zVZJsfO2PUfUiqqLJ5X3i7sc8jGR6H1J4qYOVkQyPhFYA55P/ANfmi5PLbYrShkd1WMncDuQ4OQB+vAqsX2Myk7vl4Zcjt0B+lS3ysDC8LOY1z8oydx9B3/xrPl1ErIAu10aNmAzkkZBx/wB85HHbNGxrGLkTJKI2YiTdnDKGx9Me5HvRcSll2qBheT6Hvj+tU7WNIy3lI4Xft2oudpPXOee/UdqWUxiQjO5tuCOx9ce2MUlsE4q4yeaNJmkbbnj5h0IPTP09abcbGJAzvAwc8j3xVSSXFw4LDy9uCMfe/Cq88oAZAWDBdp9Mn/PSrT0MZIbccMjKAccgfSqrSlWMuMo+NvPH4U25d2kiUHBHUHoKpyz7JpFH3VIAOflOeeKaMJnOIwSJGwxYEDjn6/hWpEEkdxyPlHPU/X2rCgYpGrBuBjcAeK1bWQeUWDFml4I9PXFW0c9NmpaShWKnAVQMOe4B4/WtW0l3RFsncOo64/CsKAZjypBx8oB64+la1kpZj853H+MHnGOD71D3OuLVjZt/NCKeM44APU+n5VbKAoQ5Uhedp5Yn/Cq1u0cse1F4OQT6cdasJtRkyRlhtz1wO1K3UtSY+dIvs/DFST0GQD6/hTo5pDbxhFHGFAIBIJxyPy/Sj5g4LYZh0P6ioph+78tJCjK6lyqE8HNSaxdxLxVXLMd64/eMx4+Y9PbPNRxTKsRMfnMegMYUgdcjPXH4ZNSTWrCVdxZ9ylME4ZSfQU+GB7WNmXaGGCwx29MnpQbcyUR9v5Qh2khM/wAIbkjHXBzk57VHq4gj01p3bdK2V2jgsAeo7YqwvlNIWjULxjHU8dCD0NZ+qgfZVgDfdJKljnGfp1BI9KNzJvVHFeIZhPApZnHzBUDJjr2z2IHP41BYwx+cGc/ukOBt6HH9Kr6qPLuUi87MavuxuOQce/XqeRxVmykaFVkZcq4xkdPatXojBO82zVRC8jQkfvAwY57itSB0jKBCHBUhf65/WseS7VYt+ASCCM/eyP6VDb367Tk7XBORUlynoLrsuT5sTMu7hSefatnwvGvlhyMy9VJ7Y4rmtcug7RqmCAOMVu+GznyTkqwX6hqNmXTlzROr00Rz3M5k+UkYOTg/WtaCIwWuN+5kHy4P3/rWVYvFcSGWQBGT5SNuM81fVApYCQFuuB1Aqbmkn0Oh00xptZlKs2AAPX0rsrZ1itGmlA8vaOc9fWuGsLxBGsp+cJjOO/4VqtqZWAJGP3ZyxTqST2+laxaRwVqbmx+tOHmaVPlRhxiuUuN3kvGGKkkgN3ya2b+4aVSqEK4HOexrEvLoRsC4BRfvMemaiW5tSTSsY13IqQkNlpQu0seuBXn+tu814xj543HA6L611viW+Ux4Q7SrfMV9K89mug145UtsPIwfzzTQ6kuVXNzhiRGFPA+ZfQdaCRC0oyArYGScgA88Y9Kpi9BdTGME5wO544q1Cm+NyFBLKDjPTP8A+o0yYtMcLiSK7G0gyBcAOof2IweMfWup0i5gOonzQ037hLXzAQPNmRcLJx0HQepxnua424bLvK+QcHaQMnGcZrW0gFrVZcvHHGAAVxy2cZ9ccdu9F7opJc56JaPIcgk4Rtp2HGTjmrEKoQSr7oskkYxk+n+NYWkyPJax4J2uTvIIJLZyfp16YrQS7CCTEq+WnASQ4HJ9R1JrHYvld7ItIVutk827e3QEBcc8Lj1H9aW5QPbsUOzIySCcjjn6A+n4UsLMzHzx8mBhlzwPoODnpmnlPNGFbLd8rkAZycZ6euTzVW0HezK1nMMHzQDMFO5sHLY4x7d+vpU5kjlkKxNyfmAHGRmo3hMauXkQB8OAq8tjgE8/iarumy5227EK5DknqOP8PzpajaTd0TylkkILptI3KeSAT3rE1K2MkOY2US4A3gZIwD0B9d3X2rZnXakcjrkkAEjJGPTFRXIjLlpNwwBjjqfUelJ6hCfLqjCm+2Ry23nOSiKVJz8wB6DP0wPwpk91KpUFAoUE7SMH0HFXbllL4kdijEgJ03GqSq4ch2LKFwO5x6GgtyTWqGXIVoxKVkZpcB84yMe4+lY7TgSFpFPJOP73PetCZwmI5W5/hUc9uM4rOdi0iFQS2MbvTHUe/WrRjLQS5lCrCuQSRkj1wOtVLp41jRSBtzkgjPzetLKBtyxOdpyV7e+ahaWMDeQTnj5SMgfjVI5ZuxzMBwgLfdHP+FaVg/7lVUhSOW+veskYEDMfmTBPptGatrIsc7N+8JdACVxjb7981o+5yU2adrIWG8DY4+YNj+dbGmyptIdMIDg49fSsODKLsDgscZOeORWxYzMVVGAVjwB0A/8Ar1m0dUZHQQHbECp3YHp29v5VbSQecFYAAcgHgf8A66y7J5N2GAZQdpOe3+eankJ8wR5+UEkM45+oqHc3hq7FmR5RGWO5JCSAqnOc/wBat2kgMAEqsWGVIbgYH86qNCsixSWsrzb05DptKtnlc9PxqxbxgW4zDKQOgc5OMdvWklqbaNEhEaS+YAxD9ycqB29qidbjezRvhANrZ5PrnPf6VZtiieYp+dmXKhV4RvU5/lTFaeMApH5o/wCeYwoXA559aCkxxum8tI55s4IQMeT64z1/rWJriSyMyxSBPlIPXqPT/Peto4n2PKCTt3AL1J9qx70+RENqLGAN2QMkcgnBPT14poSWuh55rkrnU1Ev3igbgAcZx/kVPFeIscezc2SdyMD8uO3uO9UPH8gttVhu2idoppGG1hjJIGefXvx1rPt7oPGBE5Kc4yMAj+h9Qa13OKbtJmpq+uw24MXmLxyOc7eOma4q+8bpHNJ5UTT4BTnKg+p/pW3d2iXiY2R7+Oo+RV55OOc//WrmtU8IXMFkl1H+9R2ZSEGXXHUsOw5pPTUzfNJWidBpXiS21K3jMblWjOPLY/OPc+o+lej+H7sPDAA+0oenSvnOIXOlXaz252uvy5xwQeor1DwvrIkSN43yAPmAO7b/APW96bSauiqNRxfLI9wgkLxM/wDFjGKkidxuKqC5HDGuW03UWkhAaX5x6mtWC/YAlcvjkc4rPlO2Mjas7ryQVjXBDcmr66i6ljk8dgvH51gfaRJGz7trt0yPumpILzZFskCse/NOxWj1N97pbiHhhhurgdayr+ePdtByTx8x4I96bBeRLuiKgcZCDtWRrF+E8x5Aqoo+X/apWJehyfi69KSOit8p4wOlea6p4ltdOnMEwYzkAt5XO3uM/h2rZ8beIjbxyXGFZ1YBEDbSSew9h1ryuC0nvJmmkJZ3YsxA5JNaq0VdnBWqOcuWJ6fo/iG2uF8xXBLDAJGMewHaussbxZYw5YAJwRg/njua8o0bSrqzuEd0lWN1yFxw3f8AD613+mzokXPUAAj/AOvU7lRbjubF5KUj+ViCoxjOTnvV7QZYJtPSFo5FuknLiUEGKSPALIR1DDrnPtXMXt2IEZCcOR37D6Vu+A3kdJZQGkEvG3rvXPB46Lx/KkjeDvK6PSrCZX8zk5BAB9QPb1PqKvwxRsVWfCmI7hg9Djrx68flWPpjlG3zgjcWRegwBzux27itO5dQiBslQ2eDjJ9z0rN7mmzsh80hDRhLjy48EsOm7Pbbz3pVCLJNLIzSIwxjPGRxk/h3OKowOxn8uIr13BJAAMnqc/41ZZ2IYmNZMAYKHgDsePftQjW1tC4swgh3MQoK888gEYznueOvTFVCF8xG5ATMiDA57c+1I5Zp8x7DLjY23qARzz3/AMKaZ3ikeEqjRRrhU2/dAPIXH86PUlItGdTFuhO0YyPc1ReRXfzQxyRzg5x/9alcI80ckZHlAfKnIBHbnqaqZZpshh97DDGMen5UmxLQfdsAY2lCHkADtuqm8oYspXaxH8PbPfNMvml8zEZzHjDccfWqk8rFyVKhx15xkf57UX1FYhupI1WQbhhPldsclvWs+4AXPlscRqAT6H1qRZDKQzbQTkAE43f5xVeQFWZm+UP83zckjvVLUibtoV53faVh+UAA4PYE89aqkDOI3298k1NqFysO+QrvOwhQO3bn86o28x2mRwN7YJz29q0RyVHZGQUYblwNoHzE/wAhTrZGS1jbcM8gd849qRmIKjJOAM/Sn5HlMoYZyCvHB9RWjOWJpwkNKd4b727K47f57VfjfduAxgHLE8H6f/XrKUuPLC7TtCuMjOOx/wDr1oiYHy5CoZOY2Hr/APqrNnTBmqZiuzcpb5QGIPHarDSD7SXbzVyOMfw+gHpVOyCzB9wUKg271PUetaKwFowAcBTklDyp+lZtXOuDRYtzufy2/wBbjdnOPy9KkjdvMjkt3ZZSPLAdwBjspJ7fyqOIiOQxMxO5Q3A5GM88/wAvxqCdH2brRAsjAfPIcDg+/ShHVCzNHzom8tUtXldGKO0jcMw6kKDwe2O/FXJVklVfOQMAQcbsfp2/WseznRkdAkvmkYlZ18xnyeTnsfpV5QMxqTscD5md9zfhgYAodhtcpfup0ldVVsNGArFSfl3E4yehJ9vSsXUFVgqOw8tm2lAerY4z0yMj86nnuCGUvGuwtsjP0H+eKo30rpeYaNGV1bbIFyBhQOB+HH500ZpNbHJ+N9Pk1DQjaJ+8WKYMH5HzFeMDoPSvK4b2WwuSlygDo53hh8vHHb+de3wSK1q8bbIJxG52kkrPGMEDrw3U57VR1DwzpuvReaLaN5AizMAxEjx8AunrjOCOuMHFaOLeqOWokcfol5HIin92yMehbjI6Z9q9L0trO7sIVDSLMGlaclc7yQfmYk8L2PsfauK03wQqO8Gn38kMskv3ZxiBkHzFQeQruNuCenINOsLy7t9lvfIVVRs/dguGPfn+ecUXaHS5ZPlejK3j3wijhru1gSFZBujRWzx/dx7DgfT2ry21nOjXYcq2FLb8HG8cYU9sDk9K99Go+bHDFqAk2KRu3jJx0Jx2PQV5z438MYBmgAIfnJG0HIJz9eKS0d0GIpaGp4f1aOW2SVWVgRk56g+h9TXSDU28siMqpPc9K8M0PUZdG1PZIGNu5CSJ1I9CM16LBqHm26mHcUYdxwfp6Grcb6o5qddx0Z2Nvre+LEjb9pPX+KprPUSzF2L+gQ/41xpuGiVfLDbT/CB+tSRX8qBgey5yeAKnlZ0LEI7wX5j3SM+0sCMelcv4j1geTJI02IkHJz0H+NUJLxlj3SsRuGcg5+lcB4u1s3t/JYWZK2yMVds5MjY/kOcVSh3MKmIb0RW1J5tf1hCqqYo8pHjg+9el/Dzw1BBdqLuIK5TCrLjDN1AViOM9lOM4rB8A6Q6FiY4yCu8gjjr69q9NuZjYQvDLGUcAIYpArqTgFcke2D9cUn3NKFO/qGv6NHcRSANt2Ly/Ckr05Hc56j2rgLqF7VWCSnI4z0x9K6XXdXtZ7SNobzdflyrwMdrnsCM8sTnt9K5S6sr3VyP7Nnt5AwMcrxuCIj2Abu2M5x9Khu5pJRWiMy4uZbm4Ftaq01zIfLLOxc9hu55BGOnQAfWvVfCti2n6YltbHkKeNnDAD7xJ4Aycdug7GsTw54WstMmaaWVprklSHKlcHg8/hk9/1rtlASVjuhCyoCCPlBPPUd+x49aPNmlOCiW9Nk3RAPtaVM7sDBPOOnbvWqUUoFGN6jl0OBz+pFZunySMxeVfMLudzEBSSOB/wHoef7tWnTzZCXlbOcYU45Hf0GRWbLe4qwqpRIowEzzgcD3B7D3q1EjLIYw0qOQWBUg4xyTknn155qNB5W9pYwVjIBZfmIB6ZI4I96hN00crKGhVWGAkoK7iO5I49P0o0HdsS8V5LssH8wISc7SeDyRx6/jTbfYDEoikTDbSN2Tu6jPoPYU5h+8RvPWIsAMMnX6N3NNQMUUQyy7VJ3EjOfXGTz+VBV9BZJS0mVDfKSACRu+lOuFO3DcIPfJzVRY5Um3q44JOM4LH39gKddlo4VEWNxGME9PUigzla6sULg+VE6EuAGANUJHRrlMqQ2CpIOR9amZ5ZOZiURcguMcH39f/AK9Zs7qsRDAqQxVVXrjHb0+tIbElEkMp2KrMQeegXPr/AJ71T82SSUKyh2A4CnjP+FXYh50yJIdoU9zyf949vrWfLi2CA7vLcvsfH3voe+M9a1SOaUm2MlI2BWYdAWOOvtmqDSFgMA++KnmdfI2hslhzn2qGNSoKx/eJySBkD2qonLUZlJ8yb1K5QYIqVB8qA5YEcZpsMe1WbOTu2/gaazsUUA48vJGOMnNWYovWw3A84kHqeeehzV+0Vwqc8ls8nr6ZrOVs7WdcsAOfUjtVlH2PGUbbGchhnOM9/wBaiWhtBm7bS+REXCO23sPvAd8VeiugpRD98nIfPI+lZkBYS/MJNijnHGf/AK1X7aVEVmyBHnrjkH2FZs64GrH5s6YLKcggkDGfTGe/vU6wJND+83K/I2scjOOtULecTRFwY0IyMEcn9asCZEUuFiLNgEl8ce3tQbptbDxbo674ZZpNxwHY7F9MA9+e1MlQwoisRz91uc4/i+oH50ouHuJGVhuQL8xAIwO2fSq80o+0IXXLBS+GGBtA6nHT+tJK5fO1uL8xkjd0mSPmPDHCsy4Bb04yOKp6gzG3fyJNoi+V2UEhc8AnPGTzge9VmkieNfMdiYyCqsSQcepyMH8KGUSxTsGSKVArpAeVmYtjBxzwDu+oFaKJEpgYGkukdchpI2B2kZODjac9M9R7DmpWjjW2iikebY5Ul1UsyrweAPfIOO1R+VbrELfzwsxPAYHGeMknHIORgcnsaexePMczCEnckcjIMl9y7Rg+u3PfGcYqtjFSctyV2hR5pLmSM2KkqrpGQrSFSVbBGSNwC8jiqk9nEtuXKxCLZuUM275gDgDHVjyKiiSBJ5EeGW4u4Y3Z5AoLbeSc/oTjJHSo7lpBZPc3BmaBW3KFjEbEc5XbyFCgDjqcHnmmQ3YmtLMvarN5Com7b5mRhie3r0NW7/Tor6xyrLJGcBc5OR2OPxzVaYO01tMGUEhRvfgAFSFzg8jLdPrVtmeygQ73+zxx7mJTDKc/ywOD3JxRZIrmc0eOeMvC0kFzcOiYCMAMDkcZH6Vk6PqBtLd7SRCyEkr82GV/72a97vbW2vbXM5SMMAN5UnbgHHP515v4s8DPG7TWXlnJ5UNyPf2FF3HVHNOlzHJNeThQTMfvDDZyT+FT/wBt3iyht0TseB1XA9x+FU5PDuoJKYxG+Qccc/kaifwzqLAsI3IXqO4oUzJ05Lcn1DXpTb7BM0jbQm0N8uCcnIqPwloEuo3G8D5E+Yse3ermkeDL+4mXfC2OpGOa9Y8NeHxZW8JjgUnoSYyG5PXg4YjtkcU78xUadtWM0W1jtIhHgANgKVHT198ev1qLVbdpEMcF0k9t5zmOT+/k8Y79sc9D3rpri1jghkmdXiYZZg33kUdPrmsC+hneTzLJg/lMGIHyq4zkZ7YxlT+B7VLOpTtsNg0Kyt1LXMJlkIGZHG4OrcDaMHaRnt071txfZYHNxp9gttabRGESTcEfGNwPHsPfvVKOZ4khnIkSBEzJHk4EZ5yR6qeDjGcH2q7p903lXF1FdxjaRMszEFc9Q56jJOeenrQy4akj29vdaXNLBNcR5ZPMJ4UMOgQdSx5BB6A8Gm+S6Wi/6UjBnYiJhzGuMqCe/J61Uije2mscmV5SocqHwNjsTwfxJHcjj0q0bjNxLsB8yMk7lB+bJwQo+lSzaLfQ2oXaGNFKnagyBySuRyB61eSUps3kB5BkKfQeh9KzdLuYkTy3nijjZisJccucEKgJ9Rnr1qe0k8y2RjLjadh3tglehGPx/EVLRPNq0y4H2x7DkylRt2jg/h6UTHAQtGyrnadvze2MYyKZIq+TJL0cdAy5wemfxoF0Nnl+a4U8/KdpyRjgkc8VA79UUEmVZMRXwXgrLEEUFeoxgjIJ9e9XXlkdCWdAi4XE2QfcY6fj3qCd1jdfPmTzHOVM8WHC9sEcnv7Uy5eNVwZY5I8/MNpK59qZb1HXskkbHDLgfxhfvD2qtNMUijd5EYlSQQCDtpEnhnw0UScDI2sQeO5HenbVlY7iG2E5354yOnSgzk7GRCylJXOWLAtg8YBHXnpVNWaSISs4aJsgMvBwOB/+utO72yRyKgj3OcMFPXjn8fesokqAoRjEnCgYBx249fegbd0N+eRtsX+qAIZQOh+vpVTVL1JxCmSXt1IJAA49BVl3YRhHyEOc84wPb1xVCQbBIibQ7YyWHAHarRyT3uVoED4Ynq3JJ+6tVL10WMAkqdx+4efXr6c1ZkKjJUYAwqj1OOaqTIrHg4HBJPXJq0jmm9SBSfKAPBzzn+dOlwDgYG446Ukj/u1APAyenSkl5TIGcEcemasyRYUmRSmPnTqR1NXrePcFClUIJwSOv1rKhISRgzHb75GR2rWjk3tHkEHH3sd/SoZtBmrazBbWPLDcpxyeGB/nWhAWuI7gw2+8xY8wgYwSOo9azbY/IWZlBzg8ZwfarCp8yiSPK42hg5GAeccHoDUM64l9J2V0AyMKfuoAB+P51ajRGBCAhjn+EfP9M1XjaN4o87nXGBkfKAD1HrzVe4uZnuGCrsiiO7cD1J/hHftzUmnN2JVuFTYvmb94PbOSOufWmXNytvEXZSW4BDD7vPB46/lUKusMPloVAXhVUY29+P1rOvZnWOWcSphAuEUElefb+XX8quMSXJ2J4dolsolUuzEydyWwT1zwQTxj0Bpk0m0CMGONyflRHJAGeoI5Izx+FPaYuu63kaEjc8Tqduw9CVP4n8qxlkjGpgJsDMGDRZyNuMABj1IAJ4PJrS3Qz5nua1lcWxmnnnnVG8pMybSPOPmcEYPHQ8Dk4q8ImeKOWWQv8x8t2G4jgA56Z46fSsqILgXVuwkt44xuATLqU+U4xkE5APPocVLdXWxo8KzyKAWjfqNw747dTtPBxSGmNjlmTUYlaSFlkAGGVsEHOFXAHPXJOO/Wp5CJLGeKQu0qkQhU+8SVySPU98564p8tsLiCdoz+7YDayZHmE9xnng7eadAkk2yO9l8m4cfvQCOAxO8kdOTj8VxS8gT1uOtlCrDbh1ZnjVgo4QqpB6Y75Ptmr4aF7KC3Z5onLtFIZRnBHzLg9x/KoLCMzPHNCsin7wUAEDqMEf3RwRg/0qVIJGvCLfcIGldXhVTIkciHjI6jPAB6cZ9abCL6Fq4tYoLFnuiTbRpukbsn+0R0PXtVNBEI2mPnPK7EOGOWXgfl9OvNXoXE7PDc+WXidWDocB5MdAo7jd0PtxUxtxmLehCu+GSTqOO57nrmk0NO+5ntBFHFHOABtIGxB29d3HI4BHfNVbizie4CiNN+3rtzjt0P8q2bnMboJI42QDaq44jJPGT3BPGKmntElkUiOIAZbJxuUj09qWoNLc5zT/Nt7pUljSNDGxfAwSQc/L7Adfwrc8pRbtLEQm1C20TEYGMgjrjAA/A0+QSq/nRsGkRW29Pu/wD6uCcd6qpEl1I8csJSdI08q5Tr8wLbduOxGQRkduOlNPuTJdh5tUNjGqSTkzECNppDgqCH3E8kAc4+oqi1u8c0sEuBG0xuN6HiNmb7pHYH09qsQxziGC1ciaFUaMsUKeawb5ZFAJBUkEnFZ3m/adOuLqUyGOSQPMT8rEbio46jtkfyovqTZ7jWgukFoZ8F/tJ8x4TkKmQuRnnaOPlIJOcVYtblIYfs8jpG5cosZAwzYJZR7gMSFHqcCs+V7j7NPLGFM8kpkCucKrALnDehGSB6gelWbie1a7Fu27cPm3MMkDoD06cgA9R0pbmkdNCvLLHe+TYtKICN3lSAbQ+CCrK2OnAI+var0sjEIHwreayYYdRjIbA6AH+tZd67eW0SQSyQG2AjEfCyEMCFXJ5bB6f3eOtEaCVJnRZADtLFsgfMoyEyeeMAjsTQ0Up2ZsJPFLGSCjuQcBkGd68E/ng56YxVmGQqr+bGzlcFRABnb1x64Geves+zeBmuP3hjPmeXuyWWRAoVQp7qMkHpjaR1plvMIWO24k5w4cnb16qfVfmH5jvmjlLUla5twXJW5aNtzrvLMy8hPoem0Ede1WxcFJgTwMFgVbGM8/iD19KwTcnzIiTthiXOWwCyk/KQPTOeOe9Tm8ARjmUxo6liwO9FI+YhepVSPyNS4k85uvJIyFycbjzuXeMHr9PpVG4uNh3OFX+FcjCscevT9KZbMPs3mNInlrhgVcDcp6HHcfTnGKredIWxuCjBDKpDk++Pf1qWmiozT0Q+Hzo8GMAO+WYEgFcnkDFSS3LhiG2eYQec4GP5VTZ/LQIrMzsCQHUZIz0Bx+tLI7hlG3aQQdo5H60Deu4TBFUyM22YkHavUjHas2YwqXJwZS25cDGT0B96vXFxIZS6OdycAg4xjvz1rLvnQu0bx4cqC3PJB9PbigkhMpEK5LEZ4BHLGqsjiSRpX3KOuR0NWZ8EspGCq5A649M1mu4aM+YVCA8Dpx/+uqRhNkUrjcqIAMKevqT2qpCwkXZIrLtJzk9T/wDqqS6GGxGOOw9M8DJ6VHGfJc5BXjA47VaOSRWXjygGP71crx0x60qsc4U8E7RnvjtT0EiANIAFxjA7VGCzBlXhi5OPTFW9DNFq1VpQPMxkBlweOOorRtoxNAwbIkBJ56HNZVhKrFihBOBx1zWrZOHVvOUIpYgDOcj1yP5VPqaRfY0bZgqyJuAcgAHPSrQLRqZPMB53AYGAO4FVkQFd64Ddjt4465qyW8yME7Qu7AI5x+FQ0dUHoSyzSGFZYSVc/dGegPXj+lV0aSVCxVsKxVj2BxnP1xURjLXDqCSoPIJxj2H1pWlMVxG65bacFWwdxPUnpkdiPSiKvuVKVthoZ/MgceYhC7VVucc/eY/T8earTu5tWhik3IF2AZ27W45JxnHB6ep9an1i6t1jWOTy4ZA/y95ASfzOQPTpVZD5aFgzncVOV5xxz0rS1iOZMsQOmIXkLhFXMYYZRzuwyAjPzc5xjnFRT24mMEsMglhjaRAUPPXK5yMAEgdelD71NuRHkKimQqeVIJA57fTr0qGC4KW0gtiiqBmPjB79QTwSTxQS32JtLvJSY43iCOIvmVWzlyeQCT04/WpDM0cMssoWXyzJsduoznGffoB9KqW0Ui3EMssin7pkzwoGecjk5HY9zyakldBcXDRw+e6/MI2JBBxyQfYfln1pD5ib7Vs329y0g8lC67uN46gDHvnircjOLjbOIY57sBI0kI3ZBBxwOoAycdM+tZwnNxa+bA/lsgKsgHJJzuHqOCM1qaQiTOJJWTyWiKrxkCPORnvkjH4UBzM19Jtp2vJApeC4EmZpRg+cBg4APQdB+o5q/wCUst9KY2aNkAQqrY8xfRgeCAQMH61SuR5NwWtRnaoVXTHBY8KTnAx1BPpitKaK7aV1kZ/LckYAGUOPmIYY5PbHSkzSOupWkg8yIyQywqZHZ5J2Xc3B+bHQbuMZq3AVm+ZtoT+EAYYAnoBTHgeWDy1UxBtsZYnd+7zn5c9ffIzzim6YkhuZFMaxeVwON2Ce2fbAz70hqL3EMSLfWrs0jsSyBWPUkZ25Pt39qdqdtIBGWCC4yFD54JPT8enHua04bSa4kmMyu6F8oZTwp4wMcZwc45/OoxG5j5V0jwXBUc9f1b6UymzNe1VH85tsgbnZjJRvYdhz296ndRPZzLLvjLAxAxkhkJHK5xkfUVKfIZuIpG3oN5RcEjB+ZgeR1GB7063s5J4LeOWV3AUKP3rfKw4BUduM800S3oUY4FmlMLvIk0JGXVhuUHnHXJyDx04rP1CF7f7TOpUkxGMRudyxpnlwvOGAB5Jya1IGjkMdxbnfHtZiOQBkcADoTwBn0xVSaOea4baYXhZwDsBLEdvpgjrUPcV77mZc2srWVq+IZJYwroDkK6qM7cnqCD+grHigkWd4FdpH2GNC/DsNoB5HU5UH610mrXChJoxEhJcYCH+FhyozzkEcge9c8tvdJD5KNE8aPwenkjBzjH3uTk00K5TeEtaxFp3W4SMqhRyVZd3PHpwD+JFWYpY0kus+fI6/PI7uT8pAyE/uhemPeqVzpggaKF5S5jKlAU2PnJJUY7EHGPf61ETIoi3hxNJJtIBKufQYXg+gPXNO4X1NS0lFtIN7hUYMduAFGWAAJ7txkDuc96fcfNOP9IEkS5ONpZo2PB79cAcH6DtVWOSOW1miV4lTLby2W5yMqcdff0NOheKVpIF3OrQ7sMwBmyc7ePcZzTQubqWrJJXtktt527GRS/OxfvE55zgfXgY5pNNa7jvt8zQpFMm9iCRlhjC8+oIPHTFQySXItAdQKMS2GzhcjJwSAecZI9vep5LpLpJCEiWYP5cvlybtqlQMr3JwASBz14qrC51c0bhcQSqEkkBJX7QjbCDx0HXOM+xIpyTLcRmVHWRlwMpwUHXrxgfWsJ5yvkorxpKjbgzjIlT+4+D6Z27eQT1q0hnhbcVdozgKzHGFJ43AcHbwM1DV0NSaZsRTiQEbQGQ5KtkYz/jTnLlMoRxjA3Ek+uQazJZ5rpmMzBpRktufG4r6E9eOR1q05/eGOMmNnA2OOVP/ANf2rO1jRyK+zzXfej253fMHGOnXHqPT1qg5ZZ/lAMITBcnvnge3etaKOQ7EK78k/KOQGAyQT+dUriQmJ2lXykQgbioCnPQqR1H1osPnvoyhuLJtBkKnqQaq3YEW4yKpJ6Y6ZxwKnud+CzfLg8KP4qpyygIWk6KBhv8AaPenEwqPUpYkaVVcDbtJPHc/1qxGQhLSEE8Cq5bEgO/IznJ6/nRK26Vgg53H3GK1SOaW44BGhEnzYCgHJqk0i7gA+4MxKkGnRyBY3UhjuwQG6HNQnaXTdsDAHkdQPSrkZosQgCQgLgjBXnA57VrWbjylEuFOScryDWPvDW8Z/wCWig559K0dOVRGrOSGIJII4A7c9+azZrE3IJEkjVCCp3Z/yPemSErMkRhd+rDZ93d2yT1+lUbW4R8EqSRwe1T3M7xyIWiZpHGGcnCqvoM/zqTboJcSSLEAWYTb9xBPT1J9cdlqvLeeVMqFjKSQskQGNozkkt/CcZxUjWu/ZsxbRqd20Nu3D3bkgUsdokKhbeOMInG3jgj19fxp7C3EuzFmOc7UuFyqu43KPUg9TgHGB1Ax3qc3SPOoDlXADF1C71XPLDtk9frx0qveWgumikKtGUU4VcDdn6+3FWIHgT/RzGYwUwfL4wR0JP6ZP4VSYNNalWYRyyP9mOyMN1CncRxhvY8Z9aatokVy4Cu8U6jcGb5mGckHHSi4U2x2W8JUlgPmwwIbru9cdj1piySbiYZQkhUIXfkHByaNyLlqWPzHYybfLYhQpAAJJGcn+7weKvmCL5vOUszMqk5LYGc9e9Z9qyzPIZBh25AB+8B6e9aaoHuRubGE2jnGD3xSRSVyO3tLaCSJC8YKnzPL67cfTvjrV2OKBEvEUlHng3Od3Hpn8yBimSbLVkOwHzRsYD7xPTt+Aq+jxrAI9yEt8uw9B64/z71LZvCNzb0K3jO6KVWZiRIXBP7wAAD6hen41vSIu2RGYKuRslIz+fv05rE0e5jiAEpZdgBBHrnjPt61sRX0c1vl/KfcvAJ9844p7ovks9BGsTM4Erna5ygLY3gD/Dvx0qRLaH7JIWUIkhJfZwx9c9eT1qezk8x3lOBuGzqOnv6dABUsIA2nYSJGJCqDt3A8/r/Siw2ys0aQ3QEjHZtYZzlQOOp7U54lcE24/ibdn+MDufTrU0sbyiZXVRsJBbb1GOc+/rTWlWFQ7yjHAGR9B070mSylKjFxtMYAGfnB65HIPsM8Hg1Na2iqWaFYXjdd0rspDkgALx0I4/lTiN0gmlkK9AGbgcjoB6Z6VegPlsUzGwCDgL8oIGDx357VSE9jGmsYQS6xx+YCQ4wBkdfyx9OKyLhI47+EgSshU8HhQRzj/PtXQ3dzCIA7qSCQQhGSxHGcj/JrJvFt5YWMyRsjKzZHYHqAffuai1mUl3MPUEjmZS/+qWVSi7du1wTtI/Wsx18q/mlIRlmIG4HBVR1JPQ5IA9q1buLcRGHcsrBgzrjBxjr/AJ6VVlYIpWOQLhcbiucj0+ntQTKJkKjzLKQMSF9zSFsEnGM9+w/SqSxrd6jKkZYEPsy6AfOMdPbnIP8AStWS0j8mFMhVYcqPvcnO39TVVQscagkOmGj8zuCBgf4U0ZttGdNcFHdo4sQr8wmPBfn75PRuec9e3Q0loY3vXlk+TysAq6kE8ckkevbuKluEaSaCNnXyYgcRlcKAPuke4PQ1PFaRLE+VDgY4OcEHtj8TmncydxkMCc3MrSOjAhVjIUrkYyeOM+pGfQd6uCzhjVTHNErxIjfu1yBIv3VI9cdc+uOlFqjwhGgK+YrbSynDPjIzg8ZA4HTil8tMsqOjKcjcULFvTH69fWquUkygTGtlBcghkkJYxv8AfX5+Rxx36jPTFWlijWUI100cqMsiiRsbiSRtVugBPY9KcYjFHEZGISKUMwV8xrjup/I8daYZImadJYEihjB2sI94fB7d/f1/KkO+upZYqbho1LIXYkO2FIJwSPQHv+Yq3M/k9Yvm3ZKDB2+4Hes2+uVCbYXDQnYyufmDc9c+n9atwDzgs0rRKhByqnO4D+lQ0WmWLh1IVHAKk9FyCpzxg1RvCR/Ed33AccP9f1q5CS2MbOTuyRkN/n+dQPGXfaGBVs5BHQ+nvUo0aSMmcs0j7o9oQfIdwwx/pWfcM77SYzErMdwY5z6/hWjfgQ4IGFByx67fQD1rPvmDQqGU4I3Lxncf6CrRzSM25mSAlEXgjgEds9fpUk+0OFAJ+UE9ue9VL2P/AEtXkYEO2Pft/wDqqd51N3MwC/LheR0rVHPJlBnlkt/7jsu0MegqOEKskbhGLoNjE+lVrGdpNNQJIHYg4JFFq4keWEuX3L8xU42+1U1qQnoaVoAHlYvu3HHAHGe1aFviMALxvHKjrWVA48yOP5Y48DLE9MHA461pWwwytgFs53Z5x6VnI1iy2shW4LL8zL0UdDU0wS8cLMqxzKc7SxKjHPPr7VFGVEjAYVSNxwOBnrUiL9lleTAii27kUfNuI45P/wCs1FjVs0QX3SRxBDkgyYUcEjgBjyfpVqO2WK2VI8g8nBUHPqM9/WoLbfLBEzO8hUYUE/6vJ5wvb9TUoulMRMilVQgMCdhx647nPemOLIyXkDYkZv4kLn7v4en8qql5YsblSRn4HbH0xx0q24V0d1OznkPjd+Hrms+4eVomZAyoAeTxn29/pSKY2S7R0OH54JHpVdrplGCQVJOR6mud1TUIobgs0rbCCXO35iewHYnP4dapHXU2SfMx4BCg9/YmrTM5Hc6dOiEK56EBT9fWpbi5Im4YM249e3/1687HiBkZSpD4454I/wDrUs3iNmctnAPDL/XNDsOErM9JedZbVssPLjbcVBHGe3rUcF/BKd7MnI4PT8vSvM38RkZ2SAY4OD19KSHX8ZEgYg5zgVDRvGtY9WbVg4XOJCnGN3Df/rrUs9ah2xIkq7hyUxjn0H515JBrUZCqZPm49vpWpb6qJCGZwABxuGQPrQo2NVWTPYNO1xXUC2lj+T5WBH3s+nv710VldiZned8MQAcc5Hbnt36V4fZa28IAypQfeO2um07xdFFIHMLMIwMkN27UepbtLY9gm2PavIzHzIxgNjbnJyMjoBkcn/Gs2Vh5ivJIPKICg56E9/bvzXIw+L4ZI2Mu3iMnkjnnP4/SsZ/FzXxkSMKhX7vmtxjPSnNoiEGehzX8EA+UptDBipblRjjjv/8AWrF1nxUlmqG2AZnbLgnOeP0rgNV8TSmVfs4X930brx71iy6xM+/Eis78Nkdam72NFGK+I9J/4SMOuTtWMrnAP8qhuNX3sWEsbowI2se/Hb8q81bUHxtLbkGAOe3OT9Khk1RxH98r2Jzzj2oabE5wWx6P/aJdnYyAqnyKFBwM/Xr/AEphuQWKBSisRkDn9fyrzdtb2jiUcfMOe/YVMviZFiAmlJVeQo6n/PpQl3MpTT2O6uJ0wVZwGU7eB0z1/wD11TnlDsqStiL2GMgf5Fcnb+J4dz7kKnhdxGD78VYfXIJmVllVQOm7sarRmU5GyjdZHG1sfKck8fSrKSbolLlVLcnkc+gFcpda5C7ERSDYpBY56f45qrPruZFZX2IMMuerD1Ht1obRG538BADPI7HKnhSBx7/j+noKtKivwhUsB95jkLnuAD+VcXp2ttMoTOTwDhS2f/rV09ozyorzykx/fVAAOP8APakUmS3EIhgWZ92N2UzkDH3dx7dTUUcI+a5ErvOE2rIpyR83Zu4z2xnrVyYkIVAPmEdWTKheo749KbFbKzSG5DqWbJCEY3Y5IHuccdfxo5ugrdSrex2zwSvGxKnAxIwG/J+YE9s9qkjRFkxBGwVXwVIyFBPJ9uhNMtDGZHFwWZiojcyRYVnGRyPQD9asXLMluq+XcIjHjyHG9mHufYU7BeyJpJiybWRVRXKZB4HoR/nrVZZP3wBAwASxB4HPSmXizXNvvVFTcwZ4844x98fnyOtJCiwQ/OC2OnbJP86hrUuL01IZSHJDZbJxnHGe+fwrEmcM7ssgKIcKmOvvWhdTFc45C55zjn+tYuGjVyz53LlR2B/wqkZTZVnlH21FwSCCQR0BHPNRQ3Jk3sGVcseT3qORxuYuWycmQE5A6dKjfY0rIzKo+96ZrVK5ytnL+GZyYY1UE/Ny59fpXQpALW8LSIwj5LhcDjvRRWhK3GwSN5zzRKXiX5Uz19c+1a9vM2yFtuM8H2+lFFYy0NYl47dzxn5lbBPHUDpV5LhRGRKSY4D85XOc4yFHtRRSW5o9i/FMbYGNwokwS+0dPUZ71faJBHHLMpwEDJJ1746etFFJ9So6pBMyGQFmO3Awccr+FQ3FukrocGQHowwvH0ooqeptEqroti3mvdWsVxHyoSX5kA6M2P7wxx9ax9Q+H+kXHn/ZybSYDIEBbaDjOMH/AGcHP4UUVrZPRjSRx934CmEwWDWQ0bNtXKMCf8OeKiHw7YhjNqSsisV+RSfmH17Z4oooUUJwRatfh7pssTb9Qn81WBJ8sBNmOffOf0qRvh1DLLHa2l6UvJAdqFTgkE5OewCgk9TxxnpRRTcUTypGP/wiVxEjSwXpaAH5WIxu/CnR6HqShkgkR/k3HnB2jkn60UVCjcvlS6Cx3s8ZAm+Q7A0asc7g3Qkj6Vcg1DazYYllXIP97vRRWcZNlfDsWob2RnWVzujTrnuKjku2ExZMAliACM9aKKuyBTbB7p9sjbtxTJPbgdf51Xn1KGCdVYEjaDnb97j/ABooqZycVoEVzPUi8y+uApt4PkA3N5kgyW/DtS3Glaw0ZeWaFcHJIOSfzooqkr7sJQSdiW38Haheafd3S38Ra1kQTx4IKRuPklB6EFgV29RweQeJofh9fuqAavGS8SzoMMMq33R7E4P5UUVagmZtWIZvAV/DOYm1VFdW28FyDnGCD75HFPh8CX8jAHVvmOcDB5I6j+dFFJwVxqKauauleAreUedPfXVzCOGG7y8EYBHGehI6dR+VdNaeENHtVP8AoUUsa5y8mXPbrn1Pp70UVD0NlBFoeE7KBjJYRrEHY/u42IBPXgHp/LitOK3dlO6feQu5cAjI657flRRRIysk9C6I/s0fUKqLy23dkn+VVLsTSwmS2ckluNx+YnGMZ7UUUiWtLjmtUaSKOYsRyroxyJDz39s1XvLS1jktZLhpo0XYqsrkkMOELevpkc+vFFFNMiSLajMrIxBlI2EY49RVHUgiyrnhkPykEjHt9DRRQUzCubpHErsGRYThiPUf05rOnLNGCOrYAOevGaKKcdTGorGaF2ozFj8o5/Osm6uZVvJvLSM4wCx9aKK2ic0j/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Seborrheic dermatitis can cause redness and flaky patches on the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's photoguide of common skin disorders, 2nd ed., Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34769=[""].join("\n");
var outline_f33_61_34769=null;
var title_f33_61_34770="Neurovascular abnormalities in the pathogenesis of primary (essential) hypertension";
var content_f33_61_34770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurovascular abnormalities in the pathogenesis of primary (essential) hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/61/34770/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34770/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/61/34770/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34770/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/61/34770/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34770/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/61/34770/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of primary (essential) hypertension remains incompletely understood. It is generally felt that different factors may contribute in an individual patient. Among the factors that have been intensively studied and that are reviewed separately are salt intake, obesity and insulin resistance, the renin-angiotensin system, and the sympathetic nervous system. In the past few years, a number of other factors have been evaluated, including genetics; endothelial dysfunction; low birth weight; and neurovascular anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34770/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possible role of a specific neurovascular abnormality, compression of the left lateral medulla, in the pathogenesis of primary hypertension is presented in this topic review. Other central and peripheral sympathetic nervous system abnormalities are almost certainly involved in the pathogenesis of primary hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUROVASCULAR ANOMALIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimentally, lesions of the nucleus tractus solitaire in the medulla produce a labile form of hypertension in rats. Clinically, manifestations of sympathetic nervous system hyperfunction may be seen in \"hyperkinetic\" hypertensives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34770/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An intriguing connection between the experimental and clinical evidence has been claimed by Dr. Peter Jannetta, a neurosurgeon at the University of Pittsburgh School of Medicine. In 1966, he began performing \"microvascular decompression\" (MVD) of one or another cranial nerves at the lateral aspect of the medulla by placing a plastic implant between the nerve and blood vessels which were thought to be compressing the nerve and thereby giving rise to hemifacial spasm, trigeminal neuralgia, tinnitus or various other cranial nerve problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34770/abstract/4\">",
"     4",
"    </a>",
"    ]. In the course of over 1000 MVDs, compression of the left lateral medulla by looping arteries was noted in 53 hypertensive patients having the procedure for unrelated cranial nerve dysfunction. Vascular decompression of the medulla was performed in 42 of these patients, 32 of whom had relief from hypertension. The duration of follow-up was not provided. Subsequently, Jannetta and colleagues produced hypertension in baboons by connecting a balloon placed at the ventrolateral medulla to another balloon in the thoracic aorta, producing continuous pulsatile compression of the medulla [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34770/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apparent confirmation of this connection came from two subsequent studies. In the first, neurovascular compression of the left ventrolateral medulla was found at autopsy in 24 of 24 patients with essential hypertension but in none of 10 renal hypertensives or 21 normotensives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34770/abstract/6\">",
"     6",
"    </a>",
"    ]. In the second report, the vessels in this area were evaluated by T2-weighted imaging and magnetic resonance angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34770/abstract/7\">",
"     7",
"    </a>",
"    ]. Evidence of left-sided vascular compression of the ventrolateral medulla was seen in 20 of 24 patients with essential hypertension as compared to only two of 12 with renal parenchymal hypertension and one of 14 normotensive subjects.",
"   </p>",
"   <p>",
"    Although hypertension in a few patients with neurologic manifestations of compression of the lateral medulla has been helped by decompression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34770/abstract/8\">",
"     8",
"    </a>",
"    ], the majority of published series claiming success have been poorly documented and were only short-term studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34770/abstract/9\">",
"     9",
"    </a>",
"    ]. Moreover, carefully performed magnetic resonance imaging of the brainstem finds neurovascular contact in almost as many normotensives as hypertensives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34770/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best study of MVD involved 14 patients with severe hypertension that was not controllable medically and who had radiographic evidence of MVC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34770/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients had a significant reduction of blood pressure and peripheral sympathetic nervous activity (assessed by muscle microneurography) for up to 18 to 24 months after MVD. However, thereafter both the sympathetic hyperactivity and blood pressure returned to their preoperative levels.",
"   </p>",
"   <p>",
"    Patients should not be subjected to decompression in the absence of larger well-controlled, long-term outcome studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compression of the left lateral medulla has been implicated in the pathogenesis of primary hypertension. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive data are from animal studies and clinical observations. Neurovascular compression of the left ventrolateral medulla has been shown in an autopsy study of patients with essential hypertension. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Neurovascular anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Microvascular decompression (MVD) of the medulla has been associated with relief from hypertension in uncontrolled short-term case series; in the best study however, both the sympathetic hyperactivity and blood pressure returned to their preoperative levels 18 to 24 months after MVD. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Neurovascular anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Until properly controlled, long-term outcome trials are available, microvascular decompression of the medulla should not be performed for the relief of hypertension. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Neurovascular anomalies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kaplan, NM, Victor, RG. Primary hypertension: Pathogenesis. In: Kaplan's Clinical Hypertension, 10th ed, Williams &amp; Wilkins, Philadelphia 2010. p.42-107.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34770/abstract/2\">",
"      Julius S. Abnormalities of autonomic nervous control in human hypertension. Cardiovasc Drugs Ther 1994; 8 Suppl 1:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34770/abstract/3\">",
"      Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med 2003; 139:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34770/abstract/4\">",
"      Jannetta PJ, Segal R, Wolfson SK Jr. Neurogenic hypertension: etiology and surgical treatment. I. Observations in 53 patients. Ann Surg 1985; 201:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34770/abstract/5\">",
"      Jannetta PJ, Robbins LJ. Trigeminal neuropathy--new observations. Neurosurgery 1980; 7:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34770/abstract/6\">",
"      Naraghi R, Gaab MR, Walter GF, Kleineberg B. Arterial hypertension and neurovascular compression at the ventrolateral medulla. A comparative microanatomical and pathological study. J Neurosurg 1992; 77:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34770/abstract/7\">",
"      Naraghi R, Geiger H, Crnac J, et al. Posterior fossa neurovascular anomalies in essential hypertension. Lancet 1994; 344:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34770/abstract/8\">",
"      Salvi F, Mascalchi M, Bortolotti C, et al. Hypertension, hyperekplexia, and pyramidal paresis due to vascular compression of the medulla. Neurology 2000; 55:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34770/abstract/9\">",
"      Schobel HP, Frank H, Naraghi R, et al. Hypertension in patients with neurovascular compression is associated with increased central sympathetic outflow. J Am Soc Nephrol 2002; 13:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34770/abstract/10\">",
"      Smith PA, Meaney JF, Graham LN, et al. Relationship of neurovascular compression to central sympathetic discharge and essential hypertension. J Am Coll Cardiol 2004; 43:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34770/abstract/11\">",
"      Hohenbleicher H, Schmitz SA, Koennecke HC, et al. Neurovascular contact and blood pressure response in young, healthy, normotensive men. Am J Hypertens 2002; 15:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34770/abstract/12\">",
"      Zizka J, Ceral J, Elias P, et al. Vascular compression of rostral medulla oblongata: prospective MR imaging study in hypertensive and normotensive subjects. Radiology 2004; 230:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34770/abstract/13\">",
"      Frank H, Heusser K, Geiger H, et al. Temporary reduction of blood pressure and sympathetic nerve activity in hypertensive patients after microvascular decompression. Stroke 2009; 40:47.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3844 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-2DA2A50332-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34770=[""].join("\n");
var outline_f33_61_34770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUROVASCULAR ANOMALIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_61_34771="Cefotaxime: Patient drug information";
var content_f33_61_34771=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cefotaxime: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     see \"Cefotaxime: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"     see \"Cefotaxime: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F147493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Claforan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F147494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cefotaxime Sodium For Injection;",
"     </li>",
"     <li>",
"      Claforan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701741",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cefotaxime or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store as you have been told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11317 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34771=[""].join("\n");
var outline_f33_61_34771=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147493\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147494\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014469\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014468\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014473\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014474\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014476\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014471\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014472\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014477\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014478\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=related_link\">",
"      Cefotaxime: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=related_link\">",
"      Cefotaxime: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_61_34772="Erythromycin and benzoyl peroxide: Patient drug information";
var content_f33_61_34772=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Erythromycin and benzoyl peroxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/41/5779?source=see_link\">",
"     see \"Erythromycin and benzoyl peroxide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Benzamycin&reg;;",
"     </li>",
"     <li>",
"      Benzamycin&reg; Pak",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14225984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Benzamycin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691244",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may take 2 months to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to erythromycin, benzoyl peroxide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use of other skin products may cause more irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697705",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain clothing or fabric.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697667",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain hair.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696242",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash and rinse affected skin with warm water, then pat dry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on 2 times a day, once in the morning and once in the evening, or as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705498",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Packets:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix in the palm of your hand.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705438",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Jar:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705498",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Packets:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705438",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Jar:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part not used after 3 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10996 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34772=[""].join("\n");
var outline_f33_61_34772=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166700\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14225984\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011713\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011712\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011717\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011718\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011720\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011715\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011716\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011721\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011722\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/41/5779?source=related_link\">",
"      Erythromycin and benzoyl peroxide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_61_34773="Coronary artery stent types in development";
var content_f33_61_34773=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coronary artery stent types in development",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/61/34773/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34773/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34773/contributors\">",
"     J Dawn Abbott, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/61/34773/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34773/contributors\">",
"     Stephan Windecker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/61/34773/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34773/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/61/34773/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H103379741\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The coronary stents currently available are permanent implants composed of a metallic alloy. Drug eluting stents (DES) have additional durable polymer and anti-restenotic drug components. While bare metal stents (BMS) and DES have improved outcomes for patients, they have several limitations. The development of stent thrombosis after placement of BMS or DES and the residual rate of restenosis after DES are two reasons for the development of newer coronary artery stents. This topic will present studies of coronary artery stent types that show promise for reduction in rates of these adverse outcomes, including DES with bioresorbable polymers vascular scaffolds. Stent types that have been approved for use are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1081?source=see_link\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16360?source=see_link\">",
"     \"Comparison of drug-eluting intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289441181\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms bioresorbable (also called biodegradeable) and bioabsorbable are used in this topic. Bioresorbable refers to the complete breakdown and removal of a material over time and often by a known mechanism. Bioabsorbable refers to incomplete breakdown; the material may be partially digested and remain indefinitely in local tissue. Stent material and polymer may be bioresorbable or bioabsorbable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103379877\">",
"    <span class=\"h1\">",
"     BIORESORBABLE POLYMER DES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential method to decrease the rate of late stent thrombosis with DES is to shorten the length of exposure to the drug-containing polymer. Under these circumstances, the polymer is removed as a potential chronic inflammatory stimulus, and the patient is left in effect with a bare-metal stent. The currently approved DES all have a durable polymer, which remains permanently on the stent after the drug is eluted. The polymer itself may result in vascular inflammation or delay endothelialization and healing therefore contributing to the risk of stent thrombosis.",
"   </p>",
"   <p>",
"    Multiple stents with a bioresorbable polymer have been tested. The following studies, which used different stent designs and drugs, were similar in that the polymer was bioresorbable:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the COSTAR II trial, 1675 patients with native coronary artery disease were randomly assigned to stents with either a new design (struts made of a novel alloy into which multiple reservoirs were laser-cut) or to standard",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      -eluting stents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/1\">",
"       1",
"      </a>",
"      ]. The reservoirs were filled with a bioresorbable polymer containing paclitaxel. The new design was not effective, as it was associated with a significantly higher rate of target vessel revascularization (8.1 versus 4.3 percent).",
"     </li>",
"     <li>",
"      There have been multiple trials evaluating biolimus-eluting, bioresorbable polymer stents:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the LEADERS trial, 1707 patients with both stable and unstable coronary artery disease were randomly assigned to either a biolimus- (a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      analog) eluting stent with a bioresorbable polymer applied only to the abluminal (outer) surface or to a first generation sirolimus-eluting permanent polymer stent (SES) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. The biolimus-eluting stent was non-inferior to the SES for the primary composite endpoint of cardiac death, myocardial infarction (MI), or clinically indicated target vessel revascularization at nine months (9 versus 11 percent, respectively) and at four years (18.7 versus 22.6, respectively; relative risk [RR] 0.81, 95% CI 0.66-1.00). In LEADERS, differences in favor of biolimus, including a lower rate of stent thrombosis, began to emerge after one year and may reflect late safety advantage of bioabsorbable polymer.",
"     </li>",
"     <li>",
"      The SORT OUT V trial also compared a biolimus-eluting biodegradable polymer stent (Norobi) to a first generation",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      -eluting permanent polymer stent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/4\">",
"       4",
"      </a>",
"      ]. In SORT OUT V, 1229 patients with stable and unstable disease were randomly assigned one stent or the other. At one-year follow-up, the biolimus stent was not shown to be non-inferior to the sirolimus-eluting stent for the primary composite safety and efficacy end point (4.1 versus 3.1 percent, respectively).",
"      <br/>",
"      <br/>",
"      While there appear to be some differences between the LEADERS and SORT OUT V trials, including lower event rates in the latter, the two studies are of different designs.",
"     </li>",
"     <li>",
"      In the NOBORI 1 trial, 243 patients were randomly assigned in a 2:1 manner to either the Nobori stent with biolimus and an abluminal bioresorbable polymer that dissolves over approximately nine months or the PES Libert&eacute; stent. At nine months, the in-stent late loss was significantly lower in the Nobori group compared with the Taxus group",
"      <span class=\"nowrap\">",
"       (0.11+/-0.30",
"      </span>",
"      mm versus",
"      <span class=\"nowrap\">",
"       0.32+/-0.50",
"      </span>",
"      mm); this met the non-inferiority criteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The COMPARE II trial randomly assigned 2707 patients to a biodegradable polymer biolimus-eluting stent (Norobi) or a second generation",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      -eluting stent in a 2:1 manner [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/6\">",
"       6",
"      </a>",
"      ]. At 12 months, there was no significant difference in the rates of the primary end point (5.2 versus 4.8 percent, respectively), which was a composite of safety and efficacy outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ISAR-TEST 4 trial randomly assigned 2603 patients to either bioresorbable polymer SES or permanent polymer (durable) stents (with either an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      -eluting (EES) or a (SES) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/7\">",
"       7",
"      </a>",
"      ]. At three years, there was no significant difference between the two stent types with regard to the primary composite end point of cardiac death, target vessel-related myocardial infarction, or target lesion revascularization versus 1.39 percent; hazard ratio 0.95, 95% CI 0.80-1.13). The rates of restenosis or stent thrombosis were similar between the two groups.",
"     </li>",
"     <li>",
"      The EVOLVE trial compared two dose formulations of the SYNERGY stent, an EES with a bioresorbable polymer, with the durable polymer platinum chromium EES. Two hundred and ninety-one patients with de novo coronary lesions were randomized 1:1:1. At 30 days, target lesion failure occurred in 0 percent, 1.1 percent, and 3.1 percent of patients in the durable polymer EES, SYNERGY, and SYNERGY half dose groups, respectively. At six months, no difference was observed in the three groups in in-stent late loss. No stent thromboses occurred through six-month follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/8\">",
"       8",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2012 meta-analysis of pooled individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS trials found that the risks of target lesion revascularization and stent thrombosis at four years were lower in patients treated with bioresorbable polymer DES compared to durable polymer SES (hazard ratios 0.82, 95% CI 0.68-0.98 and 0.56, 95% CI 0.35-0.90) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/9\">",
"     9",
"    </a>",
"    ]. The lower rate of stent thrombosis was driven by a lower risk of very late stent thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103379884\">",
"    <span class=\"h1\">",
"     POLYMER-FREE DES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A polymer-free stent, similar to a bioresorbable polymer stent, may be associated with less chronic inflammation and improved vascular healing. The difficulty in designing a polymer-free stent is achieving adequate levels of antiproliferative drugs over time to effectively inhibit neointimal hyperplasia and restenosis. In the ISAR-TEST trial, 450 patients with de novo native coronary artery lesions not involving the left main trunk were randomly assigned to a polymer-free",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    stent or a conventional polymer-based",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    stent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/10\">",
"     10",
"    </a>",
"    ]. There were no significant differences between the groups in terms of late lumen loss, angiographic restenosis, or TLR due to restenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103379891\">",
"    <span class=\"h1\">",
"     BIORESORBABLE STENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principle benefit of stenting is to reduce the risk of restenosis after balloon angioplasty; however, restenosis is uncommonly seen 9 to 12 months after the procedure. As a result, the clinical need for stent scaffolding after this period is likely limited. Disadvantages of DES include the potential for permanent side branch occlusion, restriction of noninvasive imaging of coronary arteries with multislice CT and MRI, and the interference with the ability to place a bypass graft at the stented site.",
"   </p>",
"   <p>",
"    Fully biodegradable stents, which are also referred to as bioresorbable stents or bioresorbable scaffolds, are being tested in clinical trials in an attempt to overcome some of the disadvantages of DES. In these devices, the scaffold is in place only long enough to protect against subacute closure, wall recoil, and restenosis. These stents have the potential to reduce the problems of very late stent thrombosis and the requirement for prolonged dual antiplatelet therapy. In addition, the use of these devices might improve outcomes in patients who need repeat percutaneous coronary intervention or coronary artery bypass surgery. Early trials suggested short-term benefit and no harm from these stents whose scaffolding and polymer components are resorbable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first-in-human bioresorbable stent, the Igaki-Tamai stent, was made of a thick",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/21/13651?source=see_link\">",
"     poly-L-lactic acid",
"    </a>",
"    polymer scaffold and was not drug-eluting. In a report of the long-term (10 years) outcomes of the first 50 patients treated with 84 stents, survival rates free of all-cause death, cardiac death, and major adverse cardiac events were 87, 98, and 50 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/13\">",
"     13",
"    </a>",
"    ]. The cumulative rates of target vessel revascularization were 16, 18, and 28 percent at 1, 5, and 10 years, comparable to bare-metal stents. One case of definite stent thrombosis according to the Academic Research Consortium definition was noted. Most stent struts were noted to reabsorb by three years using intravascular ultrasound.",
"   </p>",
"   <p>",
"    The safety and efficacy of one type of bioresorbable stent, the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    -eluting stent system, were evaluated in the open label ABSORB cohort A study, which enrolled 30 selected patients with single de novo coronary lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. While the two-year results showed promise, subsequent reports suggested less than optimal mechanical integrity of the device at six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/16\">",
"     16",
"    </a>",
"    ]. As a consequence, the strut design and manufacturing process of the polymer were modified to provide better vascular support and a slower release of everolimus.",
"   </p>",
"   <p>",
"    The newer design included a vascular scaffold with in-phase zig-zag hoops linked by brides of poly-L-lactide which degrades over two years and a controlled release polymer coating that elutes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    over 30 days. The vascular scaffold degrades over several years and is replaced by a proteoglycan matrix. This design has been evaluated in the ABSORB B study in which 101 patients received a single stent. Follow-up at 6 and 24 months was intended for 45 patients (cohort B1), while 56 patents were intended for clinical and imaging follow-up at 12 and 36 months (cohort B2). The following results have been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At six-month follow-up of cohort B1, this stent performed comparably to current generation",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      -eluting stents with regard to parameters such as extent of late lumen loss, reduction in scaffold area, and minimal luminal area [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At 12-month follow-up of cohort B2, despite early signs of bioresorption, there was no change in mean luminal area and pharmacologic vasomotion was restored [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/17\">",
"       17",
"      </a>",
"      ]. These findings, as well as nearly complete coverage of the struts with endothelium, suggest that this stent type delivers the benefits provided by all DES and that its use may avoid some of the potential downsides. The ABSORB II trial, a randomized study comparing this bioresorbable stent to a metallic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      -eluting stent, is in progress [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bioresorbable metallic alloys (magnesium or iron) have been tested as alternatives to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/21/13651?source=see_link\">",
"     poly-L-lactic acid",
"    </a>",
"    backbone. Initial results appear promising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/12,19\">",
"     12,19",
"    </a>",
"    ]. In the BIOSOVLE-1 trial, 46 symptomatic patients with de novo coronary lesions were treated with a magnesium-based scaffold coated with a bioabsorbable polymer and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (drug-eluting absorbable metal scaffold [DREAMS]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/20\">",
"     20",
"    </a>",
"    ]. The primary end point of target lesion failure (a composite of cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization) at 6 and 12 months occurred in 4 and 7 percent of patients, respectively. No safety issues were identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103380109\">",
"    <span class=\"h1\">",
"     OTHER",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drug eluting stent models, including abciximab-coated, beta-estradiol, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    stents, have been tested and not carried forward into regulatory approval clinical trials in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34773/abstract/21-25\">",
"     21-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103379749\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer stent types are being developed to overcome some of the limitations of current stents, such as the development of stent thrombosis after placement of any intracoronary stent and the residual rate of restenosis after drug-eluting stent (DES). These newer stent types fall into three broad categories: stents with bioresorbable polymer; drug-eluting stents that are polymer free; or stents with a bioresorbable scaffold. (See",
"    <a class=\"local\" href=\"#H103379877\">",
"     'Bioresorbable polymer DES'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H103379884\">",
"     'Polymer-free DES'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H103379891\">",
"     'Bioresorbable stents'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/1\">",
"      Krucoff MW, Kereiakes DJ, Petersen JL, et al. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol 2008; 51:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/2\">",
"      Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008; 372:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/3\">",
"      Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011; 378:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/4\">",
"      Christiansen EH, Jensen LO, Thayssen P, et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet 2013; 381:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/5\">",
"      Chevalier B, Silber S, Park SJ, et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Libert&eacute; paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2. Circ Cardiovasc Interv 2009; 2:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/6\">",
"      Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013; 381:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/7\">",
"      Byrne RA, Kastrati A, Massberg S, et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2011; 58:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/8\">",
"      Meredith IT, Verheye S, Dubois CL, et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol 2012; 59:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/9\">",
"      Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012; 33:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/10\">",
"      Mehilli J, Kastrati A, Wessely R, et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006; 113:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/11\">",
"      Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000; 102:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/12\">",
"      Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007; 369:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/13\">",
"      Nishio S, Kosuga K, Igaki K, et al. Long-Term (&gt;10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation 2012; 125:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/14\">",
"      Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008; 371:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/15\">",
"      Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/16\">",
"      Serruys PW, Onuma Y, Ormiston JA, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010; 122:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/17\">",
"      Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011; 58:1578.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT01425281 (Accessed on August 31, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/19\">",
"      Haude M, Erbel R, Verheye S, et al. Comparison of intermediate term late lumen loss after coronary implantation of bare or paclitaxel eluting absorbable metal scaffold: results from the PROGRESS-AMS and BIOSOLVE-1 trials. J Am Coll Cardiol 2012; 59:E203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/20\">",
"      Haude M, Erbel R, Erne P, et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/21\">",
"      Kim W, Jeong MH, Kim KH, et al. The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarction. J Am Coll Cardiol 2006; 47:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/22\">",
"      Abizaid A, Albertal M, Costa MA, et al. First human experience with the 17-beta-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial. J Am Coll Cardiol 2004; 43:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/23\">",
"      Airoldi F, Di Mario C, Ribichini F, et al. 17-beta-estradiol eluting stent versus phosphorylcholine-coated stent for the treatment of native coronary artery disease. Am J Cardiol 2005; 96:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/24\">",
"      Adriaenssens T, Mehilli J, Wessely R, et al. Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. J Am Coll Cardiol 2007; 49:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34773/abstract/25\">",
"      Patti G, Pasceri V, Carminati P, et al. Effect of dexamethasone-eluting stents on systemic inflammatory response in patients with unstable angina pectoris or recent myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2005; 95:502.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83567 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-33503A3141-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34773=[""].join("\n");
var outline_f33_61_34773=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H103379749\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103379741\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H289441181\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103379877\">",
"      BIORESORBABLE POLYMER DES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103379884\">",
"      POLYMER-FREE DES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103379891\">",
"      BIORESORBABLE STENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103380109\">",
"      OTHER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103379749\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16360?source=related_link\">",
"      Comparison of drug-eluting intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1081?source=related_link\">",
"      Drug-eluting compared to bare metal intracoronary stents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_61_34774="MHC class I and II structure";
var content_f33_61_34774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Structure of MHC class I and II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Since the principal role of MHC encoded proteins is the presentation of peptide antigen, all such proteins have an antigen-binding groove. The floor of the groove is provided by a beta sheet region upon which rests two alpha helical regions. MHC class I and II proteins differ in the details of structure and function. The large figures show the MHC molecules viewed \"face on\" as they would be encountered by T cell receptors. The inset figures depict the MHC molecules as viewed \"side on.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34774=[""].join("\n");
var outline_f33_61_34774=null;
var title_f33_61_34775="Intestinal sites of nutrient absorption";
var content_f33_61_34775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Intestinal sites of nutrient absorption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 663px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34775=[""].join("\n");
var outline_f33_61_34775=null;
var title_f33_61_34776="Acoustic neuroma Light";
var content_f33_61_34776=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 587px\">",
"   <div class=\"ttl\">",
"    Acoustic neuroma light",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 567px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acoustic neuroma. Low and high power magnification of acoustic neuroma with zones of alternately dense and sparse cellularity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ivo P Janecka, MD, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34776=[""].join("\n");
var outline_f33_61_34776=null;
var title_f33_61_34777="Pathogenesis of preeclampsia";
var content_f33_61_34777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of preeclampsia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/61/34777/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34777/contributors\">",
"     S Ananth Karumanchi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34777/contributors\">",
"     Kee-Hak Lim, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34777/contributors\">",
"     Phyllis August, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/61/34777/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34777/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/61/34777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34777/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/61/34777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preeclampsia is a syndrome characterized by the onset of hypertension and proteinuria after 20 weeks of gestation (",
"    <a class=\"graphic graphic_table graphicRef79977 \" href=\"mobipreview.htm?4/31/4603\">",
"     table 1",
"    </a>",
"    ). Additional signs and symptoms that can occur include visual disturbances, headache, epigastric pain, thrombocytopenia, and abnormal liver function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/1\">",
"     1",
"    </a>",
"    ]. These clinical manifestations result from mild to severe microangiopathy of target organs, including the brain, liver, kidney, and placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/2\">",
"     2",
"    </a>",
"    ]. Potential maternal sequelae include pulmonary edema, cerebral hemorrhage, hepatic failure, renal failure, and death. The",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    burden of disease results from placental hypoperfusion and the frequent need for preterm delivery.",
"   </p>",
"   <p>",
"    The pathophysiology of preeclampsia likely involves both maternal and",
"    <span class=\"nowrap\">",
"     fetal/placental",
"    </span>",
"    factors. Abnormalities in the development of placental vasculature early in pregnancy may result in relative placental",
"    <span class=\"nowrap\">",
"     underperfusion/hypoxia/ischemia,",
"    </span>",
"    which then leads to release of antiangiogenic factors into the maternal circulation that alter maternal systemic endothelial function and cause hypertension and other manifestations of the disease. However, the molecular basis for placental dysregulation of these pathogenic factors remains unknown, and the role of angiogenic proteins in early placental vascular development are under investigation.",
"   </p>",
"   <p>",
"    Our current understanding of mechanisms causing the pathologic changes observed in preeclampsia will be reviewed here. The clinical features and management of preeclampsia, and treatment of hypertension during pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ABNORMAL DEVELOPMENT OF THE PLACENTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The critical role of the placenta in the pathophysiology of preeclampsia is supported by epidemiologic and experimental data that show:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Placental tissue is necessary for development of the disease, but the fetus is not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Preeclampsia is always cured after delivery of the placenta",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examination of human placentas at various stages of gestation in women with normal pregnancies, as well as those with preeclampsia, has led to an understanding of normal placental morphology and pathologic changes in the uteroplacental circulation that are likely to be relevant to preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Abnormal remodeling of spiral arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal pregnancies, the cytotrophoblast cells of the developing placenta migrate through the decidua and part of the myometrium to invade both the endothelium and highly muscular tunica media of the maternal spiral arteries, the terminal branches of the uterine artery that supply blood to the developing",
"    <span class=\"nowrap\">",
"     fetus/placenta",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef57301 \" href=\"mobipreview.htm?37/42/38563\">",
"     figure 1",
"    </a>",
"    ). As a result, these vessels undergo transformation from small muscular arterioles to large capacitance vessels of low resistance, thus greatly facilitating blood flow to the placenta compared with other areas of the uterus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Remodeling of the spiral arteries probably begins in the late first trimester and is completed by 18 to 20 weeks of gestation, although the exact gestational age at which trophoblast invasion of these arteries ceases is unclear.",
"   </p>",
"   <p>",
"    By comparison, in preeclampsia, cytotrophoblast cells infiltrate the decidual portion of the spiral arteries, but fail to penetrate the myometrial segment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The spiral arteries fail to develop into large, tortuous vascular channels created by replacement of the musculoelastic wall with fibrinoid material; instead, the vessels remain narrow, resulting in placental hypoperfusion (",
"    <a class=\"graphic graphic_figure graphicRef61445 \" href=\"mobipreview.htm?3/29/3541\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78926 \" href=\"mobipreview.htm?14/45/15066\">",
"     figure 3",
"    </a>",
"    ). This defect in deep placentation has been associated with development of multiple adverse pregnancy outcomes, including second trimester fetal death, placental infarcts, abruptio placentae, preeclampsia with or without intrauterine growth restriction, intrauterine growth restriction without maternal hypertension, premature rupture of membranes, and preterm labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not known why the normal sequence of events in development of the uteroplacental circulation does not occur in some pregnancies. Vascular, environmental, immunological, and genetic factors all appear to play a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/11\">",
"     11",
"    </a>",
"    ]. These factors will be reviewed in the following discussion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Defective trophoblast differentiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defective differentiation of trophoblast is one possible mechanism responsible for defective trophoblast invasion of the spiral arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/12\">",
"     12",
"    </a>",
"    ]. Trophoblast differentiation during endothelial invasion involves alteration in expression of a number of different classes of molecules, including cytokines, adhesion molecules, extracellular matrix molecules, metalloproteinases, and the class Ib major histocompatibility complex molecule, HLA-G [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. During normal differentiation, invading trophoblasts alter their adhesion molecule expression from those that are characteristic of epithelial cells (integrin",
"    <span class=\"nowrap\">",
"     alpha6/beta1,",
"    </span>",
"    <span class=\"nowrap\">",
"     alphav/beta5,",
"    </span>",
"    and E-cadherin) to those of endothelial cells (integrin",
"    <span class=\"nowrap\">",
"     alpha1/beta1,",
"    </span>",
"    <span class=\"nowrap\">",
"     alphav/beta3,",
"    </span>",
"    and VE-cadherin), a process referred to as pseudo-vasculogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/6\">",
"     6",
"    </a>",
"    ]. Trophoblasts obtained from women with preeclampsia do not show upregulated adhesion molecule expression or pseudo-vasculogenesis. The resulting impaired placentation and accompanying ischemia are thought to be the primary events leading to placental release of soluble factors that cause systemic endothelial dysfunction resulting in the preeclamptic phenotype (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Systemic endothelial dysfunction'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypoperfusion, hypoxia, ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoperfusion appears to be both a cause and a consequence of abnormal placental development. A causal relationship between poor placental perfusion, abnormal placental development, and preeclampsia is supported by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Animal models that have successfully reproduced at least some of the findings of preeclampsia have involved mechanically reducing uteroplacental blood flow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Medical conditions associated with vascular insufficiency (eg, hypertension, diabetes, systemic lupus erythematosus, renal disease, acquired and inherited thrombophilias) increase the risk of abnormal placentation and preeclampsia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/1,17\">",
"       1,17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Obstetrical conditions that increase placental mass without correspondingly increasing placental blood flow (eg, hydatidiform mole, hydrops fetalis, diabetes mellitus, twin gestation) result in relative ischemia and are associated with preeclampsia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Preeclampsia is more common in women who live at high altitudes (&gt;3100 meters) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypoperfusion is also a result of abnormal placental development. Hypoperfusion becomes more pronounced as pregnancy progresses since the abnormal uterine vasculature is unable to accommodate the normal rise in blood flow to the",
"    <span class=\"nowrap\">",
"     fetus/placenta",
"    </span>",
"    with increasing gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Late placental changes consistent with ischemia include atherosis (lipid-laden cells in the wall of the arteriole), fibrinoid necrosis, thrombosis, sclerotic narrowing of arterioles, and placental infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/1,6,19,20,22,23\">",
"     1,6,19,20,22,23",
"    </a>",
"    ]. Although all of these lesions are not uniformly found in patients with preeclampsia, there appears to be a correlation between the severity of the disease and the extent of the lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypoperfusion, hypoxia, and ischemia is a critical component in the pathogenesis of preeclampsia because the hypoperfused, ischemic placenta elaborates a variety of factors into the maternal bloodstream that alter maternal endothelial cell function and lead to the characteristic systemic signs and symptoms of preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/16,26-31\">",
"     16,26-31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Systemic endothelial dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IMMUNOLOGIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The focus on immunologic factors as a possible contributor to abnormal placental development was based, in part, upon the observation that prior exposure to",
"    <span class=\"nowrap\">",
"     paternal/fetal",
"    </span>",
"    antigens appears to protect against preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/32-38\">",
"     32-38",
"    </a>",
"    ]. Nulliparous women and women who change partners between pregnancies, have long interpregnancy intervals, use barrier contraception, and conceive via intracytoplasmic sperm injection have less exposure to paternal antigens and higher risks of developing preeclampsia.",
"   </p>",
"   <p>",
"    Immunologic abnormalities, similar to those observed in organ rejection graft versus host disease, have been observed in preeclamptic women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/39\">",
"     39",
"    </a>",
"    ]. The extravillous trophoblast (EVT) cells express an unusual combination of HLA class I antigens: HLA-C, HLA-E, and HLA-G. Natural killer (NK) cells that express a variety of receptors (CD94, KIR, and ILT) known to recognize class I molecules infiltrate the maternal decidua in close contact with the EVT cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/40\">",
"     40",
"    </a>",
"    ]. Interaction between NK cells and EVT cells has been hypothesized to control placental implantation. In preeclampsia, conflict between maternal and paternal genes is believed to induce abnormal placental implantation through increased NK cell activity.",
"   </p>",
"   <p>",
"    Placental bed biopsies from women with preeclampsia have revealed increased dendritic cell infiltration in preeclamptic decidual tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/41\">",
"     41",
"    </a>",
"    ]. The dendritic cells are an important initiator of antigen-specific T-cell responses to transplantation antigens. It is possible that increased number of dendritic cells may result in alteration in presentation of maternal and fetal antigens at the decidual level, leading to either abnormal implantation or altered maternal immunologic response to fetal antigens.",
"   </p>",
"   <p>",
"    However, definitive evidence for this theory is lacking. Genetic studies looking at polymorphisms in the killer immunoglobulin receptors (KIR) on maternal NK cells and the fetal HLA-C haplotype suggest that women with KIR&ndash;AA genotype and fetal HLA-C2 genotype were at greatly increased risk of preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/42\">",
"     42",
"    </a>",
"    ]. A systematic review found no clear evidence that one or several specific HLA alleles were involved in the pathogenesis of preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/43\">",
"     43",
"    </a>",
"    ]. The authors suggested that interaction between maternal, paternal, and fetal HLA types, rather than any individual genotype alone, was probably an important factor to consider when studying immunogenetic determinants of preeclampsia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36201?source=see_link\">",
"     \"Immunology of the maternal-fetal interface\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A more promising finding is that patients with preeclampsia have increased levels of agonistic antibodies to the angiotensin AT-1 receptor. This antibody can mobilize intracellular free calcium and may account for increased plasminogen activator inhibitor-1 production and shallow trophoblast invasion seen in preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. In addition, angiotensin AT-1 receptor antibody stimulates sFlt-1 secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/48\">",
"     48",
"    </a>",
"    ]. It is unclear if these alterations are pathogenic or epiphenomena.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INCREASED SENSITIVITY TO ANGIOTENSIN II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased sensitivity to angiotensin II has been described in preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/49\">",
"     49",
"    </a>",
"    ], and may be related to increased bradykinin (B2) receptor upregulation in preeclamptic patients. Upregulation leads to heterodimerization of B2 receptors with angiotensin II type I receptors (AT1), and this",
"    <span class=\"nowrap\">",
"     AT1/B2",
"    </span>",
"    heterodimer increases responsiveness to angiotensin II in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As discussed above, patients with preeclampsia have increased levels of agonistic antibodies to the angiotensin AT-1 receptor. Angiotensin II is the endogenous ligand for the AT-1 receptor, thus increased activation of this receptor by auto-antibodies could induce the hypertension and vascular injury observed in preeclampsia. Studies in mice support this theory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     GENETIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most cases of preeclampsia are sporadic, genetic factors are thought to play a role in disease susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/53-62\">",
"     53-62",
"    </a>",
"    ]. A genetic predisposition to preeclampsia is suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primigravid women with a family history of preeclampsia (eg, affected mother or sister) have a two- to five-fold higher risk of the disease than primigravid women with no such history [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/54,55,62,63\">",
"       54,55,62,63",
"      </a>",
"      ]. The maternal contribution to development of preeclampsia can be partially explained by imprinted genes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/64\">",
"       64",
"      </a>",
"      ]. In a study of sisters with preeclampsia, it was demonstrated that the mother developed preeclampsia only when the",
"      <span class=\"nowrap\">",
"       fetus/placenta",
"      </span>",
"      inherited a maternal STOX1 missense mutation on 10q22; when the",
"      <span class=\"nowrap\">",
"       fetus/placenta",
"      </span>",
"      carried the imprinted paternal homolog, the preeclampsia phenotype was not expressed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21097?source=see_link&amp;anchor=H1497302#H1497302\">",
"       \"Basic principles of genetic disease\", section on 'Imprinting'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of preeclampsia is increased more than seven-fold in women who have had preeclampsia in a previous pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/65\">",
"       65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The spouses of men who were the product of a pregnancy complicated by preeclampsia are more likely to develop preeclampsia than spouses of men without this history [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/56,62\">",
"       56,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A woman who becomes pregnant by a man whose previous partner had preeclampsia is at higher risk of developing the disorder than if the pregnancy with the previous partner was normotensive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although a study of preeclampsia in twins failed to find a genetic link [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/66\">",
"     66",
"    </a>",
"    ], the bulk of data suggests that both maternal and paternal contributions to fetal genes may have a role in defective placentation and subsequent preeclampsia.",
"   </p>",
"   <p>",
"    The genes for sFlt-1 and Flt-1 are carried on chromosome 13. Fetuses with an extra copy of this chromosome (eg, trisomy 13) should produce more of these gene products than their normal counterparts. In fact, the incidence of preeclampsia in mothers who carry fetuses with trisomy 13 is greatly increased compared to all other trisomies or to control pregnant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/67\">",
"     67",
"    </a>",
"    ]. In addition, the ratio of circulating sFlt-1 to PlGF is significantly increased in these women, thus accounting for their increased risk of preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A different locus at 12q may be linked to HELLP syndrome, but not preeclampsia without HELLP syndrome, suggesting that genetic factors important in HELLP syndrome (H = hemolysis, EL = elevated liver function tests, LP = low platelets) may be distinct from those in preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/60\">",
"     60",
"    </a>",
"    ]. Alterations in long non-coding RNA at 12q23 have been implicated as one potential mechanism that may lead to HELLP syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/69\">",
"     69",
"    </a>",
"    ]. This long non-coding RNA regulates a large set of genes&nbsp;that may be important for extravillous trophoblast migration.",
"   </p>",
"   <p>",
"    Several other candidate genes, such as the angiotensinogen gene variant (T235), endothelial nitric oxide synthase (eNOS), and genes causing thrombophilia, have been linked with preeclampsia, but large studies have not shown them to be important for susceptibility to the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/53\">",
"     53",
"    </a>",
"    ]. Genome wide scanning of 343 Icelandic women with preeclampsia, eclampsia, and gestational hypertension revealed a significant maternal susceptibility for preeclampsia locus at 2p13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/58\">",
"     58",
"    </a>",
"    ] and a large GWAS from Australia demonstrated a modest association (OR ~1.5) between two single-nucleotide polymorphisms (SNPs) near the beta inhibin gene on 2q14.2 and preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/70\">",
"     70",
"    </a>",
"    ]. Other potentially significant loci have been identified at 2p12, 2p25, and 9p13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/59,71,72\">",
"     59,71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIET",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of calcium and calciotropic hormones in the pathogenesis of preeclampsia is unclear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41609?source=see_link&amp;anchor=H12#H12\">",
"     \"Prevention of preeclampsia\", section on 'Calcium supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SYSTEMIC ENDOTHELIAL DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the clinical features of preeclampsia can be explained as clinical responses to generalized endothelial dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. As an example, hypertension results from disturbed endothelial control of vascular tone, proteinuria and edema are caused by increased vascular permeability, and coagulopathy is the result of abnormal endothelial expression of procoagulants. Headache, seizures, visual symptoms, epigastric pain, and fetal growth restriction are the sequelae of endothelial dysfunction in the vasculature of target organs, such as the brain, liver, kidney, and placenta.",
"   </p>",
"   <p>",
"    Laboratory evidence supporting generalized endothelial dysfunction in preeclamptic women includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased concentrations of circulating cellular fibronectin, factor VIII antigen, and thrombomodulin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/75-77\">",
"       75-77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Impaired flow-mediated vasodilation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/78,79\">",
"       78,79",
"      </a>",
"      ] and impaired acetylcholine mediated vasorelaxation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decreased production of endothelial-derived vasodilators, such as nitric oxide and prostacyclin, and increased production of vasoconstrictors, such as endothelins and thromboxanes.",
"     </li>",
"     <li>",
"      Enhanced vascular reactivity to angiotensin II [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum from preeclamptic women causes endothelial activation in human umbilical vein endothelial cell culture studies in some in vitro studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Impaired endothelial function can be demonstrated by brachial artery flow-mediated dilation three years after a preeclamptic pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/82\">",
"       82",
"      </a>",
"      ]. It is unknown whether this is a cause or effect of the preeclamptic pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationship between preexisting vascular disease and susceptibility to developing preeclampsia may be due to preexisting endothelial cell damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/83\">",
"     83",
"    </a>",
"    ]. Preexisting endothelial damage may also explain why women who develop preeclampsia are also at increased risk of developing cardiovascular disease later in life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Women with a history of preeclampsia are also at increased risk for end stage renal disease and hypothyroidism in the long term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=see_link&amp;anchor=H21332973#H21332973\">",
"     \"Preeclampsia: Management and prognosis\", section on 'Cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathogenesis of systemic endothelial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammalian placentation requires extensive angiogenesis for the establishment of a suitable vascular network to supply oxygen and nutrients to the fetus. A variety of proangiogenic (VEGF, PlGF) and antiangiogenic factors (sFlt-1) are elaborated by the developing placenta, and the balance among these factors is important for normal placental development. Increased production of antiangiogenic factors disturbs this balance and results in the systemic endothelial dysfunction characteristic of preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     sFlt-1, VEGF, PIGF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soluble fms&ndash;like tyrosine kinase 1 (sFlt-1 or sVEGFR-1) is a naturally occurring, circulating antagonist to vascular endothelial growth factor (VEGF) (",
"    <a class=\"graphic graphic_figure graphicRef54562 \" href=\"mobipreview.htm?4/0/4110\">",
"     figure 4",
"    </a>",
"    ). VEGF is an endothelial specific mitogen that has a key role in promoting angiogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Its activities are mediated primarily by interaction with two high-affinity receptor tyrosine kinases, VEGFR-1 (VEGF receptor-1 or fms-like tyrosine kinase-1 [Flt-1]) and VEGFR-2 (kinase-insert domain region",
"    <span class=\"nowrap\">",
"     [KDR]/Flk-1),",
"    </span>",
"    which are selectively expressed on the vascular endothelial cell surface. VEGFR-1 has two isoforms: a transmembranous isoform and a soluble isoform (sFlt-1 or sVEGFR-1). Placental growth factor (PlGF) is another member of the VEGF family that is made predominantly in the placenta. It also binds to the VEGFR-1 receptor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/60/1994?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of angiogenesis inhibitors\", section on 'Vascular endothelial growth factor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    sFlt-1 antagonizes the proangiogenic biologic activity of circulating VEGF and PlGF by binding to them and preventing their interaction with their endogenous receptors. Increased placental expression and secretion of sFlt-1 appear to play a central role in the pathogenesis of preeclampsia, based on the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/90-99\">",
"     90-99",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      sFlt-1 administered to pregnant rats induces albuminuria, hypertension, and the unique renal pathologic changes of glomerular endotheliosis (",
"      <a class=\"graphic graphic_picture graphicRef78879 graphicRef59970 graphicRef68634 \" href=\"mobipreview.htm?41/36/42570\">",
"       picture 1A-C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In vitro, removal of sFlt-1 from supernatants of preeclamptic tissue culture restores endothelial function and angiogenesis to normal levels. Conversely, exogenous administration of VEGF and PlGF reverses the antiangiogenic state induced by excess sFlt-1.",
"     </li>",
"     <li>",
"      Compared with normotensive controls, circulating levels of sFlt-1 levels are increased and free VEGF and free PlGF are decreased in preeclamptic women. Studies using banked sera showed that preeclamptic women had decreases in PlGF and VEGF levels well before the onset of clinical disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/97,100-105\">",
"       97,100-105",
"      </a>",
"      ]. As an example:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A nested case-control study using banked sera to measure serum sFlt-1, as well as PlGF and VEGF, across gestation found that changes in sFlt-1 were predictive of the subsequent development of preeclampsia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/97\">",
"       97",
"      </a>",
"      ]. sFlt-1 levels increased during pregnancy in all women; however, compared to normotensive controls, women who went on to develop preeclampsia began this increase earlier in gestation (at 21 to 24 weeks versus 33 to 36 weeks) and reached higher levels (",
"      <a class=\"graphic graphic_figure graphicRef74345 \" href=\"mobipreview.htm?40/12/41165\">",
"       figure 5",
"      </a>",
"      ). A significant difference in the serum sFlt-1 concentration between the two groups was apparent five weeks before the onset of clinical disease. PlGF and VEGF levels fell concurrently with the rise in sFlt-1 (",
"      <a class=\"graphic graphic_figure graphicRef58442 \" href=\"mobipreview.htm?20/24/20878\">",
"       figure 6",
"      </a>",
"      ), which may have been related, in part, to binding by sFlt-1.",
"     </li>",
"     <li>",
"      In another study, the concentration of sVEGFR-1 correlated with increasing severity of disease: sVEGFR-1 concentrations were higher in women with severe or early (&lt;34 weeks) preeclampsia than in those with mild or late preeclampsia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/94\">",
"       94",
"      </a>",
"      ]. Furthermore, women with preeclampsia had higher sVEGFR-1 levels than women who remained normotensive two to five weeks before onset of clinical disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the aggregate, these observations suggest a major role for sFlt-1 in the pathogenesis of at least some features of preeclampsia (",
"    <a class=\"graphic graphic_figure graphicRef73060 \" href=\"mobipreview.htm?30/40/31373\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/106\">",
"     106",
"    </a>",
"    ]. However, the trigger for increased sFlt-1 production by the placenta is unknown. The most likely trigger is placental ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/107\">",
"     107",
"    </a>",
"    ]. In vitro, placental cytotrophoblasts possess a unique property to enhance sFlt-1 production when oxygen availability is reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/108\">",
"     108",
"    </a>",
"    ]. The increased expression of hypoxia-inducible transcription factors (HIFs) in preeclamptic placentas is consistent with this hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/109\">",
"     109",
"    </a>",
"    ]. It is not known whether increased sFlt-1 secretion is responsible for the early placental developmental abnormalities characteristic of preeclampsia or a secondary response to placental ischemia caused by some other factor. Genetic factors may also play a role in excess production of sFlt-1 and placental size (eg, multiple gestation) may play a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical applications for these observations have not been established. Measurement of serum sFlt-1 is still investigational and its ability to predict development of preeclampsia needs to be determined in prospective, longitudinal studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/106\">",
"     106",
"    </a>",
"    ]. Measurement of sFlt-1:VEGF (or sFlt-1:PlGF) ratio in urine appears to be a better test to identify those women at high risk of developing preeclampsia, and also for confirming clinical diagnosis of the disorder. A high sFlt-1:PIGF may also identify women at risk of requiring delivery within two weeks because of severe preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/111\">",
"     111",
"    </a>",
"    ]. In the future, apheresis or drugs that bind to sFlt-1 may be used to reduce sFlt-1 levels and thereby to prevent or treat preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Soluble endoglin",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is likely that synergistic factors elaborated by the placenta other than sFlt-1 also play a role in the pathogenesis of the generalized endothelial dysfunction noted in preeclampsia. Consistent with this hypothesis is the observation that the plasma concentration of sFlt-1 protein needed to produce the preeclampsia phenotype in rats was several fold higher than the levels typically seen in patients with preeclampsia, and no coagulation or liver function abnormalities were reported in the sFlt-1 treated animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eng is a coreceptor for transforming growth factor (TGF)-beta and is highly expressed on cell membranes of vascular endothelium and syncytiotrophoblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/113\">",
"     113",
"    </a>",
"    ]. A novel placenta-derived soluble form of Eng, referred to as soluble endoglin (sEng), is an anti-angiogenic protein that appears to be another important mediator of preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/50,113-115\">",
"     50,113-115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the precise relationship of sEng to sFlt-1 is unknown, it appears that both sEng and sFlt-1 contribute to the pathogenesis of the maternal syndrome through separate mechanisms. Several lines of evidence support this hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/50,113-115\">",
"     50,113-115",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      sEng is elevated in the sera of preeclamptic women two to three months before the onset of clinical signs of preeclampsia, correlates with disease severity, and falls after delivery. An increased level of sEng accompanied by an increased ratio of sFlt-1:PlGF is most predictive of developing preeclampsia.",
"     </li>",
"     <li>",
"      In vivo, sEng increases vascular permeability and induces hypertension. In pregnant rats, as an example, it appears to potentiate the vascular effects of sFlt-1 to induce a severe preeclampsia-like state, including the development of HELLP syndrome and restriction of fetal growth.",
"     </li>",
"     <li>",
"      sEng inhibits TGF-beta-1 signaling in endothelial cells and blocks TGF-beta-1 mediated activation of eNOS and vasodilation, suggesting that dysregulated TGF-beta signaling may be involved in the pathogenesis of preeclampsia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fetuses of preeclamptic mothers do not have high circulating concentrations of either sEng or sFlt-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/116\">",
"     116",
"    </a>",
"    ]. This suggests that fetuses do not experience proteinuria or hypertension like their mothers because they are not exposed to high concentrations of antiangiogenic factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INFLAMMATION/INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulating syncytiotrophoblast debris have been hypothesized to contribute to maternal inflammation and some of the features of the maternal syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/117\">",
"     117",
"    </a>",
"    ]. Signs of maternal inflammation which appear to be present in normal pregnancies at term are exaggerated in preeclampsia. Trophoblastic debris and the microparticles shed during normal pregnancy are proinflammatory and this process is amplified in preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/118\">",
"     118",
"    </a>",
"    ]. These microparticles carry anti-angiogenic proteins such as sFlt1 and sEng [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34777/abstract/119\">",
"     119",
"    </a>",
"    ]. It is likely that the inflammatory state may also increase the vascular endothelial sensitivity to toxic factors such as sFlt1 and sEng, although definitive evidence is lacking.",
"   </p>",
"   <p>",
"    A systematic review and metaanalysis of observational studies that examined the relationship between maternal infection and preeclampsia reported that the risk of preeclampsia was increased in pregnant women with urinary tract infection (pooled OR 1.57; 95% CI 1.45-1.70) and periodontal disease (pooled OR 1.76; 95% CI 1.43-2.18). There were no associations between preeclampsia and presence of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus; treated and nontreated HIV infection; malaria; herpes simplex virus type 2; bacterial vaginosis; or Mycoplasma hominis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/58/40867?source=see_link\">",
"       \"Patient information: Preeclampsia (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Development abnormalities of the uteroplacental circulation occur long before clinical manifestations of preeclampsia become evident. In preeclampsia, the cytotrophoblast infiltrates the decidual portion of the spiral arteries, but fails to penetrate the myometrial portion. Thus, the large, tortuous vascular channels characteristic of the normal placenta do not develop; instead, the vessels remain narrow, resulting in hypoperfusion. Environmental, immunological, and genetic factors all appear to play a role in this process. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Abnormal development of the placenta'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The focus on immunologic factors as a possible contributor to the placental abnormality is based, in part, upon the observation that prior exposure to",
"      <span class=\"nowrap\">",
"       paternal/fetal",
"      </span>",
"      antigens appears to protect against preeclampsia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Immunologic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both maternal and paternal contributions to fetal genes may have a role in defective placentation and subsequent preeclampsia. In particular, a genetic locus on chromosome 13 appears to be associated with development of preeclampsia and may be responsible for the production of circulating anti-endothelial factors. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Genetic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ischemic placenta appears to elaborate factors into the maternal bloodstream that alter maternal endothelial cell function and lead to the characteristic systemic signs and symptoms of preeclampsia. Many of the clinical features of preeclampsia can be explained as clinical responses to generalized endothelial dysfunction. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Systemic endothelial dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Soluble fms&ndash;like tyrosine kinase 1 (sFlt-1) is a circulating antagonist to vascular endothelial growth factor (VEGF). It is released by the diseased placenta (",
"      <a class=\"graphic graphic_algorithm graphicRef79431 \" href=\"mobipreview.htm?31/28/32207\">",
"       algorithm 1",
"      </a>",
"      ) and is an important mediator of the maternal signs and symptoms of preeclampsia. Soluble endoglin (sEng) appears to be another important mediator, but the precise relationship between sEng and sFlt-1 is unknown. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pathogenesis of systemic endothelial dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The relationship between preexisting vascular disease and susceptibility to developing preeclampsia may be due to preexisting endothelial cell damage. Preexisting endothelial damage may also explain why women who develop preeclampsia are also at increased risk of developing cardiovascular disease later in life. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Systemic endothelial dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/1\">",
"      ACOG Committee on Practice Bulletins--Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/2\">",
"      Lain KY, Roberts JM. Contemporary concepts of the pathogenesis and management of preeclampsia. JAMA 2002; 287:3183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/3\">",
"      Moore-Maxwell CA, Robboy SJ. Placental site trophoblastic tumor arising from antecedent molar pregnancy. Gynecol Oncol 2004; 92:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/4\">",
"      Nugent CE, Punch MR, Barr M Jr, et al. Persistence of partial molar placenta and severe preeclampsia after selective termination in a twin pregnancy. Obstet Gynecol 1996; 87:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/5\">",
"      Matsuo K, Kooshesh S, Dinc M, et al. Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. Am J Perinatol 2007; 24:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/6\">",
"      Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997; 99:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/7\">",
"      Zhou Y, Damsky CH, Chiu K, et al. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest 1993; 91:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/8\">",
"      Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993; 341:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/9\">",
"      Meekins JW, Pijnenborg R, Hanssens M, et al. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994; 101:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/10\">",
"      Brosens I, Pijnenborg R, Vercruysse L, Romero R. The \"Great Obstetrical Syndromes\" are associated with disorders of deep placentation. Am J Obstet Gynecol 2011; 204:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/11\">",
"      Ilekis JV, Reddy UM, Roberts JM. Preeclampsia--a pressing problem: an executive summary of a National Institute of Child Health and Human Development workshop. Reprod Sci 2007; 14:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/12\">",
"      Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008; 51:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/13\">",
"      Cross JC, Werb Z, Fisher SJ. Implantation and the placenta: key pieces of the development puzzle. Science 1994; 266:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/14\">",
"      Lim KH, Zhou Y, Janatpour M, et al. Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia. Am J Pathol 1997; 151:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/15\">",
"      Casper FW, Seufert RJ. Atrial natriuretic peptide (ANP) in preeclampsia-like syndrome in a rat model. Exp Clin Endocrinol Diabetes 1995; 103:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/16\">",
"      Makris A, Thornton C, Thompson J, et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007; 71:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/17\">",
"      Dekker GA. Risk factors for preeclampsia. Clin Obstet Gynecol 1999; 42:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/18\">",
"      Palmer SK, Moore LG, Young D, et al. Altered blood pressure course during normal pregnancy and increased preeclampsia at high altitude (3100 meters) in Colorado. Am J Obstet Gynecol 1999; 180:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/19\">",
"      Robertson WB, Brosens I, Dixon HG. The pathological response of the vessels of the placental bed to hypertensive pregnancy. J Pathol Bacteriol 1967; 93:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/20\">",
"      Gerretsen G, Huisjes HJ, Elema JD. Morphological changes of the spiral arteries in the placental bed in relation to pre-eclampsia and fetal growth retardation. Br J Obstet Gynaecol 1981; 88:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/21\">",
"      Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1972; 1:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/22\">",
"      Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/23\">",
"      De Wolf F, Robertson WB, Brosens I. The ultrastructure of acute atherosis in hypertensive pregnancy. Am J Obstet Gynecol 1975; 123:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/24\">",
"      Salafia CM, Pezzullo JC, Ghidini A, et al. Clinical correlations of patterns of placental pathology in preterm pre-eclampsia. Placenta 1998; 19:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/25\">",
"      Walker JJ. Pre-eclampsia. Lancet 2000; 356:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/26\">",
"      Wang X, Athayde N, Trudinger B. A proinflammatory cytokine response is present in the fetal placental vasculature in placental insufficiency. Am J Obstet Gynecol 2003; 189:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/27\">",
"      Redman CW, Sargent IL. Preeclampsia and the systemic inflammatory response. Semin Nephrol 2004; 24:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/28\">",
"      Roberts JM, Speer P. Antioxidant therapy to prevent preeclampsia. Semin Nephrol 2004; 24:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/29\">",
"      Yinon Y, Nevo O, Xu J, et al. Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. Am J Pathol 2008; 172:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/30\">",
"      Rusterholz C, Hahn S, Holzgreve W. Role of placentally produced inflammatory and regulatory cytokines in pregnancy and the etiology of preeclampsia. Semin Immunopathol 2007; 29:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/31\">",
"      Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Annu Rev Med 2008; 59:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/32\">",
"      Robillard PY, Hulsey TC, P&eacute;rianin J, et al. Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. Lancet 1994; 344:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/33\">",
"      Koelman CA, Coumans AB, Nijman HW, et al. Correlation between oral sex and a low incidence of preeclampsia: a role for soluble HLA in seminal fluid? J Reprod Immunol 2000; 46:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/34\">",
"      Wang JX, Knottnerus AM, Schuit G, et al. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet 2002; 359:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/35\">",
"      Einarsson JI, Sangi-Haghpeykar H, Gardner MO. Sperm exposure and development of preeclampsia. Am J Obstet Gynecol 2003; 188:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/36\">",
"      Smith GN, Walker M, Tessier JL, Millar KG. Increased incidence of preeclampsia in women conceiving by intrauterine insemination with donor versus partner sperm for treatment of primary infertility. Am J Obstet Gynecol 1997; 177:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/37\">",
"      Klonoff-Cohen HS, Savitz DA, Cefalo RC, McCann MF. An epidemiologic study of contraception and preeclampsia. JAMA 1989; 262:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/38\">",
"      Mills JL, Klebanoff MA, Graubard BI, et al. Barrier contraceptive methods and preeclampsia. JAMA 1991; 265:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/39\">",
"      Gleicher N. Why much of the pathophysiology of preeclampsia-eclampsia must be of an autoimmune nature. Am J Obstet Gynecol 2007; 196:5.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/40\">",
"      Loke YW, King A. Immunology of implantation. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/41\">",
"      Huang SJ, Chen CP, Schatz F, et al. Pre-eclampsia is associated with dendritic cell recruitment into the uterine decidua. J Pathol 2008; 214:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/42\">",
"      Hiby SE, Walker JJ, O'shaughnessy KM, et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 2004; 200:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/43\">",
"      Saftlas AF, Beydoun H, Triche E. Immunogenetic determinants of preeclampsia and related pregnancy disorders: a systematic review. Obstet Gynecol 2005; 106:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/44\">",
"      Xia Y, Wen H, Bobst S, et al. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig 2003; 10:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/45\">",
"      Dechend R, M&uuml;ller DN, Wallukat G, et al. AT1 receptor agonistic antibodies, hypertension, and preeclampsia. Semin Nephrol 2004; 24:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/46\">",
"      Dechend R, Homuth V, Wallukat G, et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000; 101:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/47\">",
"      Thway TM, Shlykov SG, Day MC, et al. Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation 2004; 110:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/48\">",
"      Zhou CC, Ahmad S, Mi T, et al. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 2008; 51:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/49\">",
"      Granger JP, Alexander BT, Bennett WA, Khalil RA. Pathophysiology of pregnancy-induced hypertension. Am J Hypertens 2001; 14:178S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/50\">",
"      AbdAlla S, Lother H, el Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001; 7:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/51\">",
"      Zhou CC, Zhang Y, Irani RA, et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008; 14:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/52\">",
"      Wenzel K, Rajakumar A, Haase H, et al. Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension 2011; 58:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/53\">",
"      Lachmeijer AM, Dekker GA, Pals G, et al. Searching for preeclampsia genes: the current position. Eur J Obstet Gynecol Reprod Biol 2002; 105:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/54\">",
"      Mogren I, H&ouml;gberg U, Winkvist A, Stenlund H. Familial occurrence of preeclampsia. Epidemiology 1999; 10:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/55\">",
"      Cincotta RB, Brennecke SP. Family history of pre-eclampsia as a predictor for pre-eclampsia in primigravidas. Int J Gynaecol Obstet 1998; 60:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/56\">",
"      Esplin MS, Fausett MB, Fraser A, et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 2001; 344:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/57\">",
"      Lie RT, Rasmussen S, Brunborg H, et al. Fetal and maternal contributions to risk of pre-eclampsia: population based study. BMJ 1998; 316:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/58\">",
"      Arngr&iacute;msson R, Sigur&otilde;ard&oacute;ttir S, Frigge ML, et al. A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. Hum Mol Genet 1999; 8:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/59\">",
"      Moses EK, Lade JA, Guo G, et al. A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. Am J Hum Genet 2000; 67:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/60\">",
"      Lachmeijer AM, Arngr&iacute;msson R, Bastiaans EJ, et al. A genome-wide scan for preeclampsia in the Netherlands. Eur J Hum Genet 2001; 9:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/61\">",
"      Cnattingius S, Reilly M, Pawitan Y, Lichtenstein P. Maternal and fetal genetic factors account for most of familial aggregation of preeclampsia: a population-based Swedish cohort study. Am J Med Genet A 2004; 130A:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/62\">",
"      Skjaerven R, Vatten LJ, Wilcox AJ, et al. Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. BMJ 2005; 331:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/63\">",
"      Carr DB, Epplein M, Johnson CO, et al. A sister's risk: family history as a predictor of preeclampsia. Am J Obstet Gynecol 2005; 193:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/64\">",
"      van Dijk M, Mulders J, Poutsma A, et al. Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family. Nat Genet 2005; 37:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/65\">",
"      Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/66\">",
"      Treloar SA, Cooper DW, Brennecke SP, et al. An Australian twin study of the genetic basis of preeclampsia and eclampsia. Am J Obstet Gynecol 2001; 184:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/67\">",
"      Tuohy JF, James DK. Pre-eclampsia and trisomy 13. Br J Obstet Gynaecol 1992; 99:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/68\">",
"      Bdolah Y, Palomaki GE, Yaron Y, et al. Circulating angiogenic proteins in trisomy 13. Am J Obstet Gynecol 2006; 194:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/69\">",
"      van Dijk M, Thulluru HK, Mulders J, et al. HELLP babies link a novel lincRNA to the trophoblast cell cycle. J Clin Invest 2012; 122:4003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/70\">",
"      Johnson MP, Brennecke SP, East CE, et al. Genome-wide association scan identifies a risk locus for preeclampsia on 2q14, near the inhibin, beta B gene. PLoS One 2012; 7:e33666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/71\">",
"      Laasanen J, Hiltunen M, Romppanen EL, et al. Microsatellite marker association at chromosome region 2p13 in Finnish patients with preeclampsia and obstetric cholestasis suggests a common risk locus. Eur J Hum Genet 2003; 11:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/72\">",
"      Laivuori H, Lahermo P, Ollikainen V, et al. Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Genet 2003; 72:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/73\">",
"      Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/74\">",
"      Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 1991; 4:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/75\">",
"      Friedman SA, Schiff E, Emeis JJ, et al. Biochemical corroboration of endothelial involvement in severe preeclampsia. Am J Obstet Gynecol 1995; 172:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/76\">",
"      Hsu CD, Iriye B, Johnson TR, et al. Elevated circulating thrombomodulin in severe preeclampsia. Am J Obstet Gynecol 1993; 169:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/77\">",
"      Taylor RN, Crombleholme WR, Friedman SA, et al. High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. Am J Obstet Gynecol 1991; 165:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/78\">",
"      McCarthy AL, Woolfson RG, Raju SK, Poston L. Abnormal endothelial cell function of resistance arteries from women with preeclampsia. Am J Obstet Gynecol 1993; 168:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/79\">",
"      Cockell AP, Poston L. Flow-mediated vasodilatation is enhanced in normal pregnancy but reduced in preeclampsia. Hypertension 1997; 30:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/80\">",
"      Pascoal IF, Lindheimer MD, Nalbantian-Brandt C, Umans JG. Preeclampsia selectively impairs endothelium-dependent relaxation and leads to oscillatory activity in small omental arteries. J Clin Invest 1998; 101:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/81\">",
"      Roberts JM, Edep ME, Goldfien A, Taylor RN. Sera from preeclamptic women specifically activate human umbilical vein endothelial cells in vitro: morphological and biochemical evidence. Am J Reprod Immunol 1992; 27:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/82\">",
"      Chambers JC, Fusi L, Malik IS, et al. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001; 285:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/83\">",
"      Levine RJ, Qian C, Maynard SE, et al. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol 2006; 194:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/84\">",
"      Harskamp RE, Zeeman GG. Preeclampsia: at risk for remote cardiovascular disease. Am J Med Sci 2007; 334:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/85\">",
"      Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/86\">",
"      Vikse BE, Irgens LM, Leivestad T, et al. Preeclampsia and the risk of end-stage renal disease. N Engl J Med 2008; 359:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/87\">",
"      Levine RJ, Vatten LJ, Horowitz GL, et al. Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ 2009; 339:b4336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/88\">",
"      Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/89\">",
"      Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/90\">",
"      Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/91\">",
"      Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002; 160:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/92\">",
"      Vuorela P, Helske S, Hornig C, et al. Amniotic fluid--soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol 2000; 95:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/93\">",
"      Koga K, Osuga Y, Yoshino O, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/94\">",
"      Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004; 190:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/95\">",
"      McKeeman GC, Ardill JE, Caldwell CM, et al. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/96\">",
"      Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/97\">",
"      Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/98\">",
"      Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88:5555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/99\">",
"      Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004; 95:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/100\">",
"      Taylor RN, Grimwood J, Taylor RS, et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/101\">",
"      Tjoa ML, van Vugt JM, Mulders MA, et al. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001; 98:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/102\">",
"      Su YN, Lee CN, Cheng WF, et al. Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol 2001; 97:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/103\">",
"      Tidwell SC, Ho HN, Chiu WH, et al. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/104\">",
"      Polliotti BM, Fry AG, Saller DN, et al. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003; 101:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/105\">",
"      Thadhani R, Mutter WP, Wolf M, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/106\">",
"      Widmer M, Villar J, Benigni A, et al. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol 2007; 109:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/107\">",
"      Gilbert JS, Ryan MJ, LaMarca BB, et al. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008; 294:H541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/108\">",
"      Nagamatsu T, Fujii T, Kusumi M, et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004; 145:4838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/109\">",
"      Rajakumar A, Doty K, Daftary A, et al. Impaired oxygen-dependent reduction of HIF-1alpha and -2alpha proteins in pre-eclamptic placentae. Placenta 2003; 24:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/110\">",
"      Bdolah Y, Lam C, Rajakumar A, et al. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? Am J Obstet Gynecol 2008; 198:428.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/111\">",
"      Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/112\">",
"      Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/113\">",
"      Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/114\">",
"      Luft FC. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant 2006; 21:3052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/115\">",
"      Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/116\">",
"      Staff AC, Braekke K, Johnsen GM, et al. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol 2007; 197:176.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/117\">",
"      Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/118\">",
"      Germain SJ, Sacks GP, Sooranna SR, et al. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol 2007; 178:5949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34777/abstract/119\">",
"      Rajakumar A, Cerdeira AS, Rana S, et al. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension 2012; 59:256.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6760 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-218.28.111.102-5CC63B1F68-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34777=[""].join("\n");
var outline_f33_61_34777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ABNORMAL DEVELOPMENT OF THE PLACENTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Abnormal remodeling of spiral arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Defective trophoblast differentiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypoperfusion, hypoxia, ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IMMUNOLOGIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INCREASED SENSITIVITY TO ANGIOTENSIN II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      GENETIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIET",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SYSTEMIC ENDOTHELIAL DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathogenesis of systemic endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - sFlt-1, VEGF, PIGF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Soluble endoglin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INFLAMMATION/INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6760\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6760|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?31/28/32207\" title=\"algorithm 1\">",
"      Pathogenesis preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6760|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/42/38563\" title=\"figure 1\">",
"      Myometrial and endometrial arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/29/3541\" title=\"figure 2\">",
"      Anchoring villi and intervillous space",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/45/15066\" title=\"figure 3\">",
"      Abnormal placentation in preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/0/4110\" title=\"figure 4\">",
"      Flt 1 and sFlt 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/12/41165\" title=\"figure 5\">",
"      Concentration of sFlt-1 in preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/24/20878\" title=\"figure 6\">",
"      Concentration of PIGF in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/40/31373\" title=\"figure 7\">",
"      Role of sFlt in preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6760|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/2/15401\" title=\"picture 1A\">",
"      Preeclampsia light micrograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/15/28921\" title=\"picture 1B\">",
"      Preeclampsia electron micrograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/21/20831\" title=\"picture 1C\">",
"      Preeclampsia immunofluorescence microscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6760|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/31/4603\" title=\"table 1\">",
"      Criteria for preeclampsia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21097?source=related_link\">",
"      Basic principles of genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36201?source=related_link\">",
"      Immunology of the maternal-fetal interface",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/58/40867?source=related_link\">",
"      Patient information: Preeclampsia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41609?source=related_link\">",
"      Prevention of preeclampsia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_61_34778="Chronic renal allograft nephropathy";
var content_f33_61_34778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic renal allograft nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/61/34778/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34778/contributors\">",
"     John Vella, MD, FACP, FRCP, FASN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34778/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/61/34778/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34778/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/61/34778/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/61/34778/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/61/34778/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14609957\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal allograft failure is one of the most common causes of end-stage renal disease, accounting for 25 to 30 percent of patients awaiting renal transplantation. Similarly, over 20 percent of kidney transplants performed in the United States go to patients who have failed one or more renal allografts.",
"   </p>",
"   <p>",
"    The most common cause of graft failure after the first year is an incompletely understood clinicopathological entity variously called chronic rejection, transplant nephropathy, chronic renal allograft dysfunction, transplant glomerulopathy, chronic allograft injury, or (as referred to in this topic review) chronic renal allograft nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/1-10\">",
"     1-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The revised Banff 2005 classification system which was reported in 2007 renamed chronic allograft nephropathy, \"Interstitial fibrosis and tubular atrophy (IFTA), without evidence of any specific etiology\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/11\">",
"     11",
"    </a>",
"    ]. This was done because the term chronic allograft nephropathy was thought to diminish attempts to determine the underlying cause of the histologic lesions.",
"   </p>",
"   <p>",
"    The Banff 2005 classification also added the term and added the category \"chronic active antibody mediated rejection\" as a subset of antibody mediated rejection. It is characterized by C4d+, presence of circulating antidonor antibodies, morphologic evidence of chronic tissue injury, such as glomerular double contours",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peritubular capillary basement membrane multilayering",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interstitial",
"    <span class=\"nowrap\">",
"     fibrosis/tubular",
"    </span>",
"    atrophy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibrous intimal thickening in arteries.",
"   </p>",
"   <p>",
"    Although the term chronic allograft nephropathy may be inaccurate, the newer attempts at terms do not to seem to produce a significant improvement, which we have retained in this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS, DIAGNOSIS, AND PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact incidence of chronic renal allograft nephropathy is unclear, since there are no universally accepted diagnostic criteria for this disorder. In general, it is a poorly understood process that is defined as renal allograft dysfunction (occurring at least three months post-transplant) in the absence of active acute rejection, drug toxicity (principally calcineurin inhibitors), or other diseases. There are also diagnostic features on biopsy (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathology'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The clinical diagnosis is usually suggested by gradual deterioration of graft function as manifested by slowly rising plasma creatinine concentration, increasing proteinuria (occasionally causing nephrotic range proteinuria), and worsening hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. However, the reliance on these clinical features commonly results in the late identification of chronic renal allograft nephropathy, frequently culminating in allograft loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/1/2072?source=see_link\">",
"     \"Differential diagnosis of renal allograft dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic changes of chronic allograft nephropathy involve all parts of the renal parenchyma including the blood vessels, glomeruli, interstitium, and tubules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/4,13-15\">",
"     4,13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vessel walls are thickened by the subintimal accumulation of loose and then organized connective tissue, variable mononuclear cellular infiltration, proliferation of myofibroblasts, and disruption and duplication of the internal elastic lamina (",
"      <a class=\"graphic graphic_picture graphicRef72574 graphicRef52555 graphicRef65391 \" href=\"mobipreview.htm?33/40/34442\">",
"       picture 1A-C",
"      </a>",
"      ). It has been proposed that endothelial inflammation and injury is one of the primary events, leading to progressive intimal thickening and narrowing of the vascular lumen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/14\">",
"       14",
"      </a>",
"      ]. These changes are similar to those seen in the thrombotic microangiopathies, such as the hemolytic-uremic syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link\">",
"       \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"      </a>",
"      .) Immunofluorescence staining in chronic renal allograft nephropathy may be positive for IgG, C3, and fibrin. Excess fibrin deposition may arise from persistent induction of type 1 plasminogen activator inhibitor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The glomerular capillary walls are thickened with an occasional double-contour appearance resembling that seen in membranoproliferative glomerulonephritis (MPGN) but without dense deposits. Interstitial fibrosis with tubular atrophy and the presence of this type of double-contour appearance are considered the most characteristic findings for chronic nephropathy within the Banff classification system (see below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/15,17,18\">",
"       15,17,18",
"      </a>",
"      ]. The glomeruli may also be enlarged, and show a lobular pattern; segmental or, in severe cases, global sclerosis also may be seen. Electron microscopy may show mesangial cell interposition and subendothelial accumulation of electron-lucent material (",
"      <a class=\"graphic graphic_picture graphicRef58239 graphicRef79914 \" href=\"mobipreview.htm?39/61/40922\">",
"       picture 2A-B",
"      </a>",
"      ). Immune complex deposition is generally not a prominent part of transplant glomerulopathy. The term transplant glomerulopathy (TG) is now most commonly used to describe this picture of MPGN without prominent immune complex definition. In some cases, however, the pattern resembles that seen in membranous nephropathy with prominent subepithelial deposits. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34088?source=see_link\">",
"       \"Membranous nephropathy and renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The interstitium shows variable degrees of patchy fibrosis and focal cellular infiltrates with lymphocytes and plasma cells, associated with a variable degree of tubular atrophy and tubular cell dropout. These non-specific findings are also found to varying degrees with many disorders, particularly calcineurin inhibitor nephrotoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Peritubular capillary basement membrane splitting and lamination may be relatively specific; these abnormalities, which are only observed by electron microscopy, are found in 60 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Banff grading system",
"    </span>",
"    &nbsp;&mdash;&nbsp;A classification of the severity of chronic renal allograft nephropathy, called the Banff classification, was formulated in 1997 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/15\">",
"     15",
"    </a>",
"    ] and updated in 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/11\">",
"     11",
"    </a>",
"    ] with further comments without substantial change in 2007 and 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/18,20,21\">",
"     18,20,21",
"    </a>",
"    ]. Although glomerular and vascular findings may be more specific for the disorder, this schema grades disease severity according to the amount of interstitial fibrosis, and the degree of atrophy and loss of tubules",
"    <span class=\"nowrap\">",
"     (IF/TA):",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade",
"      I &mdash; Mild fibrosis of the interstitium (eg, affecting 6 to 25 percent of the cortical area) and mild atrophy of the tubules (eg, up to 25 percent of the area of the cortical tubules) either with or without specific glomerular or vascular findings suggestive of chronic allograft nephropathy (see above).",
"     </li>",
"     <li>",
"      Grade II &mdash; Moderate interstitial fibrosis (eg, affecting 25 to 50 percent of the cortical area) and moderate tubular atrophy (eg, involving 26 to 50 percent of the area of the cortical tubules) with or without specific changes as in Grade I.",
"     </li>",
"     <li>",
"      Grade III &mdash; Severe interstitial fibrosis (eg, affecting greater than 50 percent of the cortical area) and tubular atrophy (eg, involving greater than 50 percent of the area of the cortical tubules) with or without specific changes as in Grade I.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Within this system, the severity of glomerular, mesangial matrix, and vascular change is also quantified, but is not integrated within the grading system.",
"   </p>",
"   <p>",
"    Histopathologic evidence of chronic nephropathy using different versions of this system correlate with adverse long-term outcomes, including elevated concentrations of serum creatinine and lower rates of graft survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. As an example, one study evaluated the outcomes of 280 transplant patients in whom 282 protocol biopsies were obtained three months after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/24\">",
"     24",
"    </a>",
"    ]. At 10 years after surgery, allograft survival was 95, 82, and 41 percent among those without chronic nephropathy (175 patients), with chronic nephropathy but without vasculopathy (87 patients), and with both chronic nephropathy and vasculopathy (21 patients), respectively. The impact of the various stages of",
"    <span class=\"nowrap\">",
"     IF/TA",
"    </span>",
"    as described above on allograft prognosis has yet to be defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     C4d deposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic renal allograft nephropathy may also be observed in association with humoral anti-donor antibodies and the deposition of complement fragment C4d. These findings have been also described in patients with acute allograft rejection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25946?source=see_link&amp;anchor=H8#H8\">",
"     \"C4d staining in renal allografts and treatment of antibody mediated rejection\", section on 'chronic allograft nephropathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12505?source=see_link&amp;anchor=H124260175#H124260175\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\", section on 'Histopathologic diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     APPROACH TO DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of progressive loss of allograft function is fairly broad (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Differential diagnosis'",
"    </a>",
"    below), although chronic allograft nephropathy is the most common cause. The evaluation of an individual with chronic allograft dysfunction begins with renal ultrasonography and estimation of proteinuria.",
"   </p>",
"   <p>",
"    There is substantial variability between programs regarding obtaining biopsy material for histological analysis. It is the view of the authors that allograft histology is useful for confirming the diagnosis and also to rule out other processes such as acute rejection or recurrent glomerulonephritis. In addition, a percutaneous allograft biopsy provides prognostic information that assists in patient counseling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of chronic allograft nephropathy involves distinguishing among the many factors that cause progressive allograft dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    are associated with similar histologic findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Kidney dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than chronic renal allograft nephropathy, the principal causes of chronic kidney dysfunction in the renal transplant setting include recurrent and de novo glomerulonephritis, BK-induced nephropathy, late or recurrent acute rejection, renal artery stenosis, and, occasionally, ureteric obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/8,25\">",
"     8,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent and de novo glomerulonephritis &mdash; A previous history of glomerulonephritis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      findings on renal biopsy help distinguish recurrent or de novo glomerular disease from chronic renal allograft nephropathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=see_link&amp;anchor=H20#H20\">",
"       \"Risk factors for graft failure in kidney transplantation\", section on 'Recurrent or de novo glomerular disease'",
"      </a>",
"      .) Issues related to MPGN are discussed below. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Similar histologic findings'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      More specifically, the presence of focal segmental glomerulosclerosis on transplant biopsy must be distinguished from recurrent disease in those patients in whom primary FGS was responsible for the initial renal failure. The history is often helpful in this setting. The onset of proteinuria typically occurs within days or a few weeks in recurrent FGS and is rapid in onset; in comparison, protein excretion does not begin to increase until three months or more after transplantation and then rises slowly in the chronic de novo disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33722?source=see_link\">",
"       \"Focal segmental glomerulosclerosis in the transplanted kidney\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Polyoma virus allograft nephropathy &mdash; Polyoma virus allograft nephropathy (PVAN) typically presents with subacutely progressive allograft dysfunction. The diagnosis may be suggested by the presence of \"decoy\" cells by urine cytology (Papanicolou stain), more specifically, by the presence of the virus in blood (or urine) by polymerase chain reaction (PCR).",
"      <br/>",
"      <br/>",
"      The diagnosis of BK-induced nephropathy is established by specific findings with allograft biopsy, particularly results with immunohistochemical staining",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ultrastructural examination of the specimen by electron microscopy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/7/6266?source=see_link\">",
"       \"Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/45/42712?source=see_link\">",
"       \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Late or recurrent acute rejection &mdash; Late or recurrent acute rejection, commonly occurring as a result of non-compliance with immunosuppressive medications, may present with renal allograft dysfunction. Acute allograft rejection, which is diagnosed by characteristic histologic findings, is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12505?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal artery stenosis &mdash; The administration of an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) to a patient with transplant renal artery stenosis can lead to a reversible decline in glomerular filtration rate. Thus, an elevation in plasma creatinine concentration in this setting is suggestive but not diagnostic of renovascular disease in the allograft. Persistent uncontrolled hypertension, flash pulmonary edema, and an acute elevation in blood pressure are other common features of this disorder. The diagnosis of renal artery stenosis is based on findings with imaging studies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=see_link\">",
"       \"Hypertension after renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ureteric obstruction &mdash; Ureteric obstruction may present with an increase in the serum creatinine concentration. However, since the renal transplant is not innervated, pain and discomfort that may be observed in non-transplant patients are normally absent. Radiologic evidence of obstruction is most commonly determined by initial evaluation with ultrasonography, showing hydronephrosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25190?source=see_link\">",
"       \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Similar histologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic renal allograft nephropathy must primarily be distinguished histologically from those disorders that can cause a MPGN-pattern",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a predominant interstitial fibrosis on renal biopsy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MPGN &mdash; The MPGN-pattern of transplant glomerulopathy must be distinguished from other glomerular disorders, particularly MPGN that is associated with hepatitis C virus infection or is due to recurrent or de novo disease. These disorders may appear similar on light microscopy.",
"      <br/>",
"      <br/>",
"      The distinction may be made on electron microscopy, which typically shows thickening and duplication of the glomerular basement membranes without immune deposits in transplant glomerulopathy; by comparison, there are prominent subendothelial immune deposits in HCV-associated MPGN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/26\">",
"       26",
"      </a>",
"      ]. HCV-positivity alone is not sufficient to make the distinction since it may be present concurrently in patients with chronic renal allograft nephropathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=see_link\">",
"       \"Renal disease associated with hepatitis C virus after renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Interstitial fibrosis &mdash; The presence of marked interstitial fibrosis due to chronic renal allograft nephropathy must be differentiated from other causes of fibrosis, particularly that induced by calcineurin inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ). In this setting, histologic evidence of the characteristic glomerulopathy, or the presence of peritubular capillary basement membrane splitting and lamination are most consistent with chronic renal allograft nephropathy. By comparison, the detection of newly formed hyaline arteriolar changes are specific for cyclosporine nephrotoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/15\">",
"       15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, chronic renal allograft nephropathy is not always associated with these characteristic findings and the arteriolar changes suggestive of cyclosporine disease may not be new. It is therefore frequently difficult if not impossible to distinguish between these two possibilities based upon the results of microscopy alone. Some individuals also have pathologic changes resulting from both disorders. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"       \"Cyclosporine and tacrolimus nephrotoxicity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors, both alloantigen-dependent as well as alloantigen-independent, appear to contribute to the pathogenesis of chronic graft dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/1,2,27-30\">",
"     1,2,27-30",
"    </a>",
"    ]. Some investigators suggest that these factors place stress upon the renal allograft to varying degrees, thereby accelerating the normal endogenous \"aging\" process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/3\">",
"     3",
"    </a>",
"    ]; this process culminates in chronic allograft dysfunction.",
"   </p>",
"   <p>",
"    It is increasingly clear that inflammation early after transplantation precedes the development of",
"    <span class=\"nowrap\">",
"     IF/TA.",
"    </span>",
"    As an example, a prospective, protocol biopsy study that examined 256 patients who had undergone rapid steroid withdrawal reported that the presence of subclinical inflammation (\"Borderline changes\" by Banff criteria) or rejection (Banff grade rejection &ge;1a) at one and four months after transplantation predicted the subsequent development and severity of",
"    <span class=\"nowrap\">",
"     IF/TA",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Immunologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from experimental models and humans indicate a role for all elements of the immune system. This includes cell-mediated immune responses (delayed-type hypersensitivity responses mediated by macrophages and CD4-positive T cells), humoral alloantibody responses (acute or chronic) against donor antigens (such as the glomerular basement membrane protein agrin), inflammatory cytokines (such as interferon gamma), effectiveness of anti-inflammatory cytokines (hepatocyte growth factor), growth factors (such as platelet-derived growth factor and transforming growth factor-beta), and the vasoactive and mitogenic peptide endothelin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/31-44\">",
"     31-44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/27/10682?source=see_link\">",
"     \"Transplantation immunobiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Supportive general evidence for immunologic injury in humans comes from the observations that the half-lives of better-matched renal allografts are longer than those for less well matched deceased donor grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/2,45\">",
"     2,45",
"    </a>",
"    ], and that withdrawal of immunosuppression (due, for example, to noncompliance) frequently leads to accelerated chronic renal allograft nephropathy and allograft loss. Direct support for ongoing immunologic factors in chronic allograft loss is reported by a retrospective study in which, among over 4000 recipients of HLA-identical sibling transplants, patients with no panel reactive antibodies had significantly higher 10 year survival (72 percent) versus those with either 1 to 50 percent PRA (63 percent) or greater than 50 percent PRA (56 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Importance of acute rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have attempted to identify risk factors for the development of biopsy-proven chronic allograft nephropathy. Logistic regression analysis has revealed that chronic renal allograft nephropathy was more likely in patients with acute rejection, infection, or those on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    at a dose of less than 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day after the first year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/47\">",
"     47",
"    </a>",
"    ]. These observations are consistent with an important role for immunologic injury related in part to underimmunosuppression or to cytokine activation during infection.",
"   </p>",
"   <p>",
"    Subsequent studies have further documented the prognostic importance of acute rejection episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The incidence of chronic renal allograft nephropathy is less than 1 percent in patients who had had no episodes of acute rejection. By comparison, the incidence of chronic renal allograft nephropathy is increased in patients with a history of acute rejection: 20 percent for living related and 36 percent for cadaver kidneys if acute rejection occurred within 60 days after transplantation; and 43 percent for living related and 60 percent for cadaver kidneys if acute rejection occurred more than 60 days posttransplantation.",
"   </p>",
"   <p>",
"    Other findings associated with an increased risk of chronic renal allograft nephropathy include: more than one acute rejection episode with the first one occurring in the first year; one or more late rejection episodes occurring after the first year; increased severity of the acute rejection episodes; and noncompliance with immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. In one report, for example, the incidence of chronic renal allograft nephropathy as a cause of graft loss was significantly higher in the 307 patients with more than one acute rejection episode compared to the 354 treated for only one episode (35 versus 9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased incidence of chronic renal allograft nephropathy in these patients is associated with a worse long-term renal outcome in grafts surviving for more than one year. When compared to patients with no acute rejection, those with episodes of acute rejection had reductions in the estimated half-life of graft survival (6.6 versus 12.5 years) and in the creatinine clearance one to five years after transplantation (45 to 47",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    versus 54 to 60",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also some evidence that chronic antibody mediated rejection may have a role in this disorder. Anti-HLA antibodies are associated with chronic allograft nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/53\">",
"     53",
"    </a>",
"    ]. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25946?source=see_link\">",
"     \"C4d staining in renal allografts and treatment of antibody mediated rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Immunosuppressive regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate levels of immunosuppression provide some protection against the development of chronic allograft nephropathy. This helps prevent acute, subclinical,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic immunologic rejection. By comparison, some immunosuppressive agents, particularly calcineurin inhibitors, may also be associated with impaired long-term allograft function, which is frequently difficult if not impossible to distinguish from chronic allograft nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Similar histologic findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A large variety of different immunosuppressive approaches and alterations in medical regimens have been evaluated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    are the subject of ongoing study to limit the risk of developing or aggravating chronic renal allograft nephropathy. These include regimens with or without calcineurin inhibitors, the addition or substitution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , substitution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and many others. As an example, a study based upon an analysis of the UNOS database found that the improvement in overall renal allograft function in the 1990s could largely be attributed to the period that coincided with the introduction of mycophenolate mofetil and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    into maintenance immunosuppressive regimens with or without acute rejection, although a minority of this benefit was due to a decreased rate of acute rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/54\">",
"     54",
"    </a>",
"    ]. The different immunosuppressive regimens are discussed separately. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Immunosuppressive issues'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nonimmunologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are also nonimmunologic mechanisms that can promote injury and poor function in the renal transplant. These include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/1,2,27,31,55,56\">",
"     1,2,27,31,55,56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=see_link\">",
"       \"Hypertension after renal transplantation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Glomerular hyperfiltration and hypertrophy",
"     </li>",
"     <li>",
"      Superimposed recurrent or de novo renal parenchymal disease",
"     </li>",
"     <li>",
"      Delayed graft function",
"     </li>",
"     <li>",
"      Hyperlipidemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional factors, including donor and recipient characteristics, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=see_link\">",
"     \"Risk factors for graft failure in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Glomerular hyperfiltration and hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glomeruli hypertrophy and increase their filtration rate after transplantation, since the graft contains only about one-half the number of nephrons as two normal native kidneys. In some patients, for example, the glomeruli in the transplant show areas of focal segmental glomerulosclerosis, rather than the \"membranoproliferative\" pattern described above. These lesions are more likely to occur in larger glomeruli, suggesting that the hypertrophic response to too few nephrons and the associated intraglomerular hypertension eventually injure the glomerular capillary wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/57-60\">",
"     57-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This mechanism of renal injury, which is similar to that seen on many forms of slowly progressive chronic renal failure, could explain the reduced transplant survival (3.5 to 12.5 percent at three years) in settings in which the kidney is too \"small\" for the recipient: child to adult; female to male; and transplantation into patients weighing more than 100 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .) Similar findings have been demonstrated in rats in which renal transplantation was performed with or without one functioning native kidney left in place [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/60\">",
"     60",
"    </a>",
"    ]. Animals with the native kidney (and therefore twice the number of nephrons) had less hyperfiltration and hypertrophy and less proteinuria and glomerulosclerosis.",
"   </p>",
"   <p>",
"    However, subsequent data have not confirmed the importance of nephron number on transplant survival. Two studies failed to find any evidence that disparities between donor and recipient kidney size affected eventual allograft outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. One study, for example, evaluated 169 patients whose graft functioned for at least three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/61\">",
"     61",
"    </a>",
"    ]. The kidney volume to body surface ratio was not a predictor of graft survival or of the development of chronic renal allograft nephropathy.",
"   </p>",
"   <p>",
"    The possible importance of relative renal size may not be limited to the transplant recipient. It has been proposed that decreased renal size (presumably due to poor maternal nutrition) may explain the apparent association between low birth weight and an increased incidence of hypertension in adulthood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39477?source=see_link\">",
"     \"Possible role of low birth weight in the pathogenesis of essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A related issue is the finding that increasing interstitial fibrosis is closely associated with decreasing renal function. This was shown in a study of 59 patients in which tubulointerstitial fibrosis, glomerular filtration rate, serum creatinine concentration, and protein excretion were closely correlated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/63\">",
"     63",
"    </a>",
"    ]. Similar findings were observed in a study in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Delayed graft function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with delayed graft function are at significantly higher risk of developing chronic allograft rejection. In one study, for example, patients with grafts which failed to function for at least nine days had a five year graft survival of only 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/65\">",
"     65",
"    </a>",
"    ]; chronic renal allograft nephropathy was responsible for nearly two-thirds of these lost kidneys.",
"   </p>",
"   <p>",
"    Acute tubular necrosis is the most common cause of delayed graft function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/1/2072?source=see_link\">",
"     \"Differential diagnosis of renal allograft dysfunction\"",
"    </a>",
"    .) Early injury may result in fewer functioning nephrons, thereby resulting in increased glomerular hyperfiltration in the remaining normal nephrons which may then lead to progressive renal dysfunction (see above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Hyperlipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prominence of the vascular lesions in chronic allograft nephropathy and some pathologic similarities to atherosclerosis has led to the suggestion that lipid abnormalities may contribute in this setting. One review of 706 patients found that hypertriglyceridemia, but not hypercholesterolemia, was independently associated with an increased risk of graft loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/66\">",
"     66",
"    </a>",
"    ]. Similarly, a multivariable analysis of 606 renal allograft recipients found that impaired long-term renal allograft function was independently associated with hypertriglyceridemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/67\">",
"     67",
"    </a>",
"    ]. Whether this represents a cause-and-effect relationship is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=see_link\">",
"     \"Lipid abnormalities after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Time-dependence of various factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insight into the interplay and time-dependence of different pathogenetic factors as well as the natural history of chronic renal allograft nephropathy among recipients of kidney-pancreas transplants was provided by a study of 120 such recipients who underwent sequential protocol biopsies over a 10 year post-transplantation period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/68\">",
"     68",
"    </a>",
"    ]. Triple agent immunosuppressive therapy consisting of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"      cyclosporine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"      tacrolimus",
"     </a>",
"     ,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"      azathioprine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"      mycophenolate",
"     </a>",
"    </span>",
"    mofetil was administered.",
"   </p>",
"   <p>",
"    Based upon the time post-transplant, two types of histologic injury, early and late, could be distinguished:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early damage, which was observed within one year post-transplantation, resulted primarily from immunologic factors, such as severe acute rejection and persistent early subclinical rejection, as well as from ischemic injury.",
"     </li>",
"     <li>",
"      After one year, damage was characterized by progressive high-grade arteriolar hyalinosis with vessel narrowing, glomerulosclerosis, and additional tubulointerstitial injury. This was thought to principally be the result of calcineurin injury. By comparison, chronic immune rejection was uncommon with prolonged follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At 10 years, severe allograft nephropathy was present in 60 percent of patients, with glomerulosclerosis being observed in almost 40 percent of glomeruli. These findings suggest that different treatment strategies for chronic nephropathy based in part upon time post-transplantation (prevention of rejection in the first year and, in stable patients, limiting calcineurin exposure in the subsequent years) may prove effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However a later study of adult recipients of solitary kidneys transplanted between 1998 and 2004 suggested that severe histologic changes are not common in the first five years after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/70\">",
"     70",
"    </a>",
"    ]. Among 447 one-year biopsies, interstitial fibrosis was minimal or mild in 87 and moderate or severe in only 13 percent of biopsies; arterial hyalinosis was mild or absent in the majority of biopsies. Among 343 five-year biopsies, moderate or severe fibrosis was present in 17 percent and moderate or severe arteriolar hyalinosis in 19 percent. Transplant glomerulopathy occurred in only 2 and 9 percent at one and five years. Analysis of paired biopsies showed that mild interstitial fibrosis observed at one year progressed to a more severe lesion in only 23 percent of cases.",
"   </p>",
"   <p>",
"    The disparity in severity of histologic lesions observed in these two studies may reflect differences in the rate of acute rejection incurred in simultaneous kidney-pancreas transplants performed in an earlier immunosuppressive era using higher levels of primarily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -based immunosuppression compared with more recent solitary kidney transplants, or reflect complications from chronic dehydration or recurrent urinary tract infections caused by a bladder-drained pancreas in the kidney-pancreas transplants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     GENERAL PREVENTION AND TREATMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention and management of chronic renal allograft rejection remains one of the major challenges facing transplant nephrologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/1,2,7,27,71\">",
"     1,2,7,27,71",
"    </a>",
"    ]. As previously mentioned, findings concerning the time-dependence of various factors suggest that different prevention and treatment strategies for chronic nephropathy based in part upon time post-transplantation may prove effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/68\">",
"     68",
"    </a>",
"    ]. In the first year, for example, attention may generally be directed at the prevention of rejection, and, in subsequent years among stable patients, treatment may focus upon limiting exposure to calcineurin inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Immunosuppressive issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that multiple studies have documented the importance of acute rejection episodes in chronic allograft nephropathy, general measures aimed at preventing these episodes should help prevent the development of chronic allograft dysfunction. General discussions of induction and maintenance immunosuppressive therapy are discussed separately. However, some maintenance regimens may be less likely to be associated with chronic allograft nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunosuppressive therapy is generally ineffective in patients with established nephropathy, except for those in whom the precipitating cause is inadequate immunosuppression due to noncompliance or aggressive drug tapering. Intravenous pulse or oral minipulse corticosteroid administration may be beneficial if there is evidence of active acute rejection on allograft biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4938?source=see_link\">",
"     \"Acute renal allograft rejection: Treatment\"",
"    </a>",
"    .) Issues surrounding the possible role of humoral rejection in chronic allograft nephropathy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25946?source=see_link\">",
"     \"C4d staining in renal allografts and treatment of antibody mediated rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Dosing and type of immunosuppressive regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The various immunosuppressive regimens may be associated with an increased or decreased risk of developing chronic allograft nephropathy. To provide a general overview of the outcomes associated with attempts to manage this disorder, a 2009 systematic review was performed that evaluated 12 randomized trials with 635 patients with chronic allograft nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/72\">",
"     72",
"    </a>",
"    ]. All patients were administered a calcineurin inhibitor (most commonly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) and were randomly assigned to switch to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , or rapamycin OR to add",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , mycophenolate, or rapamycin to the existing regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/72\">",
"     72",
"    </a>",
"    ]. Overall, there was a suggestion that calcineurin inhibitor withdrawal was safe and that benefits could be obtained with the conversion to mycophenolate or rapamycin. However, the methodological quality of the trials was low and no consensus could be drawn concerning management issues.",
"   </p>",
"   <p>",
"    The following sections provide an overview of some of the different studies that have addressed this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15268107\">",
"    <span class=\"h4\">",
"     Changes in calcineurin inhibitor exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies have evaluated the effect of limiting exposure to calcineurin inhibitors, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/73-101\">",
"     73-101",
"    </a>",
"    ]. Such studies involved either decreasing or withdrawing cyclosporine therapy in patients with or without renal dysfunction, or the administration of immunosuppressive regimens that do not include cyclosporine.",
"   </p>",
"   <p>",
"    The best data are from a 2011 meta-analysis that compared calcineurin inhibitor-sparing regimens (those that employed complete avoidance, minimization or delayed introduction of calcineurin inhibitors) to standard calcineurin inhibitor-containing regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/101\">",
"     101",
"    </a>",
"    ]. In a pooled analysis of 56 studies comprising 11,337 patients, there was no difference in graft failure or death-censored graft failure. However, among 17 studies (4131 patients) calcineurin inhibitor-minimizing regimens were associated with reduced overall graft failure (odds ratio (OR) 0.73, 95% CI 0.58-0.92), death-censored graft failure (OR 0.73, 95% CI 0.34-1.31), and there was no difference in graft failure secondary to rejection.",
"   </p>",
"   <p>",
"    Among 2688 patients there was an increase in overall graft failure and death-censored graft failure among patients treated with MTOR inhibitors and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    compared with calcineurin-containing regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2005 systematic review which specifically evaluated the outcomes of calcineurin inhibitor withdrawal from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -based therapy in six trials of 1045 patients, calcineurin inhibitor withdrawal was associated with a higher creatinine clearance (mean difference of 7.49",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and a decreased risk of hypertension (relative risk of 0.87), but an increased risk of acute rejection (risk difference of 6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/89\">",
"     89",
"    </a>",
"    ]. At one year, allograft loss and patient death were similar.",
"   </p>",
"   <p>",
"    Other studies have compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    -based regimens. In one such study, 150 renal transplant recipients were randomly assigned to one of three maintenance immunosuppressive regimens: tacrolimus plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ; tacrolimus plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil; and cyclosporine (Neoral) plus sirolimus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. Patients in each arm also received induction therapy with daclizumab and maintenance therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    . Interim analysis at three years found that patient and allograft survival was similar in all three groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/104\">",
"     104",
"    </a>",
"    ]. There was a trend toward better allograft function and fewer acute rejections with tacrolimus plus mycophenolate, which was also associated with a significantly decreased incidence of post-transplant diabetes mellitus and dyslipidemia.",
"   </p>",
"   <p>",
"    Similar findings showing better protection from chronic renal dysfunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    - or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -based regimens than with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -based regimen were reported in two prospective protocol biopsy studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. With the sirolimus study, there was a significantly higher serum creatinine level, lower glomerular filtration rate, and increased prevalence of histologic findings of chronic allograft nephropathy with cyclosporine than that observed with the sirolimus-based regimen at two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/106\">",
"     106",
"    </a>",
"    ]. At five years, the sirolimus-based regimen continued to be associated with a higher glomerular filtration rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, one study found that conversion to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    did not decrease the progression of chronic allograft nephropathy in patients on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/108\">",
"     108",
"    </a>",
"    ]. In this multicenter Canadian clinical trial of 106 patients, cyclosporine-treated patients with biopsy-proven chronic allograft nephropathy and impaired renal function were randomly assigned (2:1) to convert to tacrolimus or continue on cyclosporine therapy. At five years, allograft survival was the same in both groups (73 and 81 percent for the tacrolimus and cyclosporine groups, respectively).",
"   </p>",
"   <p>",
"    A related issue is whether a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    -based regimen is similar to a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -based regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. This was addressed in a prospective study with 163 low-risk patients randomly assigned to sirolimus-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or tacrolimus-mycophenolate mofetil-prednisone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/109\">",
"     109",
"    </a>",
"    ]. At one year, similar outcomes were reported in both arms concerning patient and allograft survival, incidence of acute rejection, and iothalamate measured GFR; a similar GFR was also measured at two years. Biopsy at one year also found similar interstitial, tubular and glomerular changes, although sirolimus was associated with fewer tubular changes. More prolonged follow-up will be necessary to better understand the relative efficacy and safety of tacrolimus- and sirolimus-based regimens.",
"   </p>",
"   <p>",
"    The efficacy and safety of conversion from calcineurin inhibitors to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    was evaluated in the CONVERT trial, in which 830 renal allograft recipients were randomly assigned 6 to 120 months posttransplant to either continued calcineurin inhibitor therapy or the conversion from the calcineurin inhibitor to sirolimus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/111\">",
"     111",
"    </a>",
"    ]. Enrollment of patients with GFRs less than 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    was halted because of excess pneumonia and death among those in whom the sirolimus substitution had been performed. Among those with GFRs greater than 40",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    intention to treat analysis found no difference in GFR between the two arms at 12 and 24 months. Both groups also had similar allograft and patient survival rates as well as incidence of acute rejection. With subgroup analysis, improvements in GFR at 12 and 24 months were noted in patients with GFRs greater than 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and urine",
"    <span class=\"nowrap\">",
"     protein/creatinine",
"    </span>",
"    ratio less than 0.11. Even in this select group, the mean daily proteinuria rate increased from less than 110",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to 720",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    by two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15268121\">",
"    <span class=\"h4\">",
"     Use of mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another general strategy is the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil as opposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , either for prevention or as treatment of established nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. Mycophenolate mofetil may also be useful in patients with established disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/75,83,114,115\">",
"     75,83,114,115",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the \"Creeping Creatinine\" study, 122 patients with progressive renal dysfunction were randomly assigned to continuation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      plus the discontinuation of cyclosporine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/114\">",
"       114",
"      </a>",
"      ]. At six months, a significantly higher rate of stabilization or reduction in serum creatinine level was observed in the mycophenolate group (58 versus 32 percent). No acute rejections were observed in the mycophenolate group.",
"     </li>",
"     <li>",
"      In a second study, the initial immunosuppressive regimens of 121 patients with biopsy-proven chronic allograft nephropathy were either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (59 patients) or cyclosporine, prednisone, plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (62) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/75\">",
"       75",
"      </a>",
"      ]. If being administered, azathioprine was terminated, and all patients were subsequently given",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      (2 grams per day). At a median follow-up of 36 months, the change in the glomerular filtration rate slope was significantly better with mycophenolate (+0.00045 versus -0.0144).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Benefits may also be observed in CNI sparing and minimization strategies in which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    is used as sole adjunctive immunosuppression. A 2009 systematic review and meta-analysis found that such a strategy was associated with short-term improvement in glomerular filtration rate and allograft survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15268114\">",
"    <span class=\"h4\">",
"     Corticosteroid withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroid withdrawal appears to be associated with an increased risk of chronic renal allograft nephropathy. The first prospective, randomized, double-blind, placebo-controlled study compared early steroid cessation to low-dose long-term steroid therapy in kidney recipients receiving modern maintenance immunosuppression therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/117\">",
"     117",
"    </a>",
"    ]. All patients received antibody induction therapy, with maintenance",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and seven days of corticosteroids followed by blinded randomization to either withdrawal of corticosteroids or continued corticosteroids tapered to 5 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    by six months. At five years, corticosteroid withdrawal was associated with a significant increase in the rate of chronic allograft nephropathy (10 versus 4 percent) and biopsy-proven acute rejection (18 versus 11 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Summary immunosuppressive issues",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention &mdash; We treat patients with triple maintenance immunosuppressive therapy, aiming for a regimen that includes a calcineurin inhibitor (such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , and an antimetabolite. Despite the possible increased risk of chronic allograft nephropathy due to calcineurin-inhibitor therapy with this approach, we feel that the immunosuppressive benefits of this regimen outweigh its possible adverse effects. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"       \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      There are additional preventive measures related to immunosuppressive issues and chronic allograft nephropathy. These include optimizing HLA matching, reducing acute rejection episodes and ischemic injury (which increases proinflammatory cytokines and others), and avoiding sensitization. These issues are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link\">",
"       \"Induction immunosuppressive therapy in renal transplantation in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"       \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11159?source=see_link\">",
"       \"HLA matching and graft survival in kidney transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34570?source=see_link\">",
"       \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment &mdash; Among patients with chronic allograft nephropathy receiving calcineurin inhibitors (particularly those with histologic lesions most consistent with injury associated with calcineurin inhibitor therapy [eg, arteriolar hyalinosis]), some evidence suggests that a decrease in or withdrawal of such therapy may be effective. There is some limited evidence of less induction of TGF-beta and fibrosis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      that might be associated with improved GFR. However, as previously noted, a change from cyclosporine to tacrolimus was not associated with improvement in GFR in a large multicenter prospective study. In addition, both registry and limited clinical trial data indicate similar long-term patient and graft survival rates for patients on tacrolimus and cyclosporine. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"       \"Cyclosporine and tacrolimus nephrotoxicity\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Among those with low calcineurin inhibitor levels and a glomerular filtration rate higher than 50",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      consideration is given to substituting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      for the calcineurin inhibitor. Caution must be exercised in this setting, as an arm of the CONVERT trial was terminated because of excess pneumonia and death among those with GFRs less than 40",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      in whom this substitution was performed. In addition, we do not use sirolimus in patients with proteinuria of greater than 110",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      unless there are other overriding concerns. The substitution of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, if not being administered, for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      may also ameliorate progressive renal dysfunction.",
"      <br/>",
"      <br/>",
"      The finding of a positive C4d staining",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      positive donor specific antibody in the chronic setting is now classified according to the current BANFF classification as chronic antibody-mediated rejection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/18\">",
"       18",
"      </a>",
"      ] The optimal management of this condition has yet to be defined. Therapeutic options include augmenting the maintenance immunotherapy, conversion to tacrolimus and mycophenolate if the patient had not previously been on such medications, and consideration to plasmapheresis and IVIg. The role of the latter invasive therapy, while accepted in the management of acute antibody mediated rejection, has not been studied in chronic AMR. The role of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      for the treatment of this disorder is currently being investigated with funding through",
"      <span class=\"nowrap\">",
"       NIH/NIAID",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/118\">",
"       118",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25946?source=see_link\">",
"       \"C4d staining in renal allografts and treatment of antibody mediated rejection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Nonimmunologic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonimmunologic interventions for chronic renal allograft rejection should be focused primarily on aggressive control of the blood pressure and hyperlipidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/1,2,27\">",
"     1,2,27",
"    </a>",
"    ]. Other therapeutic modalities that have been considered, but were not proven to be effective in controlled human trials, include antiplatelet agents, thromboxane antagonists, fish oil, and a low protein diet, and have largely been abandoned. A retrospective study found that low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    treatment, after multivariate analysis, was significantly associated with improved long-term allograft function and allograft survival (14 versus 8 years in those not receiving aspirin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With respect to blood pressure control and nephroprotection, it remains to be determined if angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) provide special benefit by preferential lowering of the intraglomerular pressure or other effects. Clinicians have generally been reluctant to use these agents in renal allograft recipients because of the increased risk of hyperkalemia and decreased perfusion in a single kidney. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effects of ACE inhibitors or ARBs in kidney transplant recipients were best evaluated in a systematic review of 21 randomized trials with 1549 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/120\">",
"     120",
"    </a>",
"    ]. None of these trials specifically included patients with chronic renal allograft nephropathy. At a median follow-up of 27 months, these agents significantly decreased the glomerular filtration rate (-5.8",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    hematocrit (-3.5 percent), and proteinuria (-0.47",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    but did not change the serum potassium. However, inadequate data were available to assess the effect of ACE inhibitors or ARBs on allograft and patient survival.",
"   </p>",
"   <p>",
"    Among all kidney transplant recipients, there are also conflicting retrospective data concerning the use of ACE inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ARBs and the risk of death and allograft failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Based upon an analysis of 17,209 renal and 1744 heart transplant recipients, the use of ACE",
"      <span class=\"nowrap\">",
"       inhibitors/ARBs",
"      </span>",
"      was not associated with an improvement in patient or transplant survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/121\">",
"       121",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective open cohort study of 2031 patients found that the use of such agents may decrease the risk of death and allograft failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/122\">",
"       122",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A double-blind, randomized, placebo-controlled trial compared the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    , 100 mg (n = 77), or placebo (n = 76) initiated within three months of transplantation and continuing for five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/123\">",
"     123",
"    </a>",
"    ]. The composite outcome included doubling of the fraction of renal cortical volume occupied by interstitium (or &ldquo;interstitial expansion,&rdquo; which is a measure of interstitial fibrosis and tubular atrophy",
"    <span class=\"nowrap\">",
"     [IF/TA])",
"    </span>",
"    at five years, or ESRD from",
"    <span class=\"nowrap\">",
"     IF/TA",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/123\">",
"     123",
"    </a>",
"    ]. Use of losartan tended to be protective with an odds ratio (OR) of 0.39 (95% CI 0.13&ndash;1.15, p = .08). However, losartan had no significant effect on time to a composite of ESRD, death, or doubling of creatinine level. The mean time to doubling of serum creatinine was longer in the losartan group compared with placebo (1065 versus 450 days, HR, 7.28 [95% CI 2.22&ndash;32.78]). In a secondary analysis, losartan appeared to reduce the risk of a composite endpoint including of doubling of interstitial volume or all-cause ESRD (OR 0.36, 95% CI 0.13&ndash;0.99). Blood pressure, GFR, and serum creatinines did not differ between groups, possibly due to the small number of patients enrolled.",
"   </p>",
"   <p>",
"    Most data in patients with chronic renal allograft nephropathy are derived from retrospective observational studies. As an example, among patients with biopsy-proven chronic allograft nephropathy, the efficacy and safety of ACE inhibitors and ARBs were evaluated in a retrospective nonrandomized study of 63 patients, of whom 32 received therapy with these drugs (group 1) and 31 did not (group 2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/124\">",
"     124",
"    </a>",
"    ]. Among 101 initially eligible for this study, only two were excluded because of documented renal artery stenosis and intolerance to ACE inhibitor therapy. At a follow-up of 27 months, there was a trend for fewer patients in group 1 to have had at least a 50 percent increase in the serum creatinine concentration (19 versus 39 percent, p = 0.10). In addition, patients who received ACE inhibitor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ARB therapy were significantly less likely to have died or to have had allograft failure (9.4 versus 35.5 percent). The incidence of anemia and hyperkalemia was similar in the two groups. Additional retrospective uncontrolled studies found similar benefits in slowing the rate of decline in renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/125,126\">",
"     125,126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin D may slow the progression of chronic kidney disease in renal transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/127\">",
"     127",
"    </a>",
"    ]. A case-controlled study showed superior graft survival at three years of followup among 26 renal transplant recipients who were receiving 1,25-OH vitamin D3 (calcitriol) compared with 50 control patients; the rate of decline of the GFR was also significantly slower by 300 days after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/127\">",
"     127",
"    </a>",
"    ]. There are no prospective studies of the use of vitamin D to slow progression of chronic kidney disease in renal transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/61/34778/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although reversing metabolic acidosis may slow the progression of chronic kidney disease in nontransplant patients, there have been no studies reported in kidney transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41353?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\", section on 'Slowing of CKD progression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Summary nonimmunosuppressive issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with established chronic allograft nephropathy, a trial of ACE inhibitor or ARB therapy, particularly in those with diabetes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria, may be helpful. Since the decline in glomerular filtration rate induced by an ACE inhibitor typically occurs within the first few days of therapy, the plasma creatinine and potassium concentrations should be remeasured two to five days after the institution of therapy. We also routinely measure hemoglobin levels, since ACE inhibitors can induce anemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H11#H11\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10857?source=see_link\">",
"     \"Erythrocytosis following renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines which recommend that the target blood pressure should be less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg. For those with significant proteinuria (greater than a urine total protein to creatinine ratio of 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/g),",
"    </span>",
"    we aim for a blood pressure goal of less than",
"    <span class=\"nowrap\">",
"     125/75",
"    </span>",
"    mmHg. These issues are discussed further elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=see_link\">",
"     \"Hypertension after renal transplantation\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic allograft nephropathy is the second most common cause of allograft failure after the most common cause, death with a functioning graft. The clinical diagnosis is suggested by gradual deterioration of graft function as manifested by slowly rising plasma creatinine concentration, increasing proteinuria, and worsening hypertension. Pathologic changes involve all parts of the renal parenchyma including the blood vessels, glomeruli, interstitium, and tubules. The glomerular capillary walls are thickened with an occasional double-contour appearance resembling that seen in membranoproliferative glomerulonephritis (MPGN) but without dense deposits. Interstitial fibrosis with tubular atrophy and the presence of this type of double-contour appearance are considered the most characteristic findings for chronic nephropathy within the Banff classification system. (See",
"      <a class=\"local\" href=\"#H14609957\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations, diagnosis, and pathology'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      The evaluation of chronic allograft dysfunction begins with renal ultrasonography and estimation of proteinuria. Although there is variability concerning the need for histologic analysis, we perform an allograft biopsy to confirm the diagnosis and provide prognostic information as well as to exclude other processes such as acute rejection or recurrent glomerulonephritis. The differential diagnosis of chronic allograft nephropathy involves distinguishing among the many factors that cause progressive allograft dysfunction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      are associated with similar histologic findings. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Approach to diagnostic evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevention and management of chronic renal allograft rejection remains one of the major challenges facing transplant nephrologists. To prevent general immunologic rejection, we maintain patients with triple immunosuppressive therapy, aiming for a regimen that includes a calcineurin inhibitor,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , and an antimetabolite. Despite the possible increased risk of chronic allograft nephropathy due to calcineurin-inhibitor therapy, we feel that the immunosuppressive benefits of this regimen outweigh its possible adverse effects. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'General prevention and treatment issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Changes in immunotherapy have largely been ineffective in changing the prognosis for patients with established chronic allograft nephropathy. However, consideration should be given to calcineurin inhibitor therapy minimization or withdrawal, or conversion from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      . For those few patients on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , conversion to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      may be helpful. Finally, for those without proteinuria and with a glomerular filtration rate &gt;50",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      conversion from calcineurin inhibitor therapy to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      may be associated with an improvement in glomerular filtration rate. Nonimmunologic interventions for chronic renal allograft rejection should be focused primarily on aggressive control of the blood pressure and hyperlipidemia. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'General prevention and treatment issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Non-immunosuppressive interventions include control of blood pressure particularly with the use of ACEI or ARBs, the use of statins for control of dyslipidemia and possible vitamin D supplementation and control of metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Nonimmunologic interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/1\">",
"      Hostetter TH. Chronic transplant rejection. Kidney Int 1994; 46:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/2\">",
"      Carpenter CB. Long-term failure of renal transplants: adding insult to injury. Kidney Int Suppl 1995; 50:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/3\">",
"      Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 1999; 10:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/4\">",
"      Monaco AP, Burke JF Jr, Ferguson RM, et al. Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Kidney Dis 1999; 33:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/5\">",
"      Paul LC. Chronic allograft nephropathy: An update. Kidney Int 1999; 56:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/6\">",
"      Suri DL, Tomlanovich SJ, Olson JL, Meyer TW. Transplant glomerulopathy as a cause of late graft loss. Am J Kidney Dis 2000; 35:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/7\">",
"      Joosten SA, Sijpkens YW, van Kooten C, Paul LC. Chronic renal allograft rejection: pathophysiologic considerations. Kidney Int 2005; 68:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/8\">",
"      Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16:3015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/9\">",
"      Afzali B, Taylor AL, Goldsmith DJ. What we CAN do about chronic allograft nephropathy: role of immunosuppressive modulations. Kidney Int 2005; 68:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/10\">",
"      Cosio FG, Gloor JM, Sethi S, Stegall MD. Transplant glomerulopathy. Am J Transplant 2008; 8:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/11\">",
"      Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/12\">",
"      Yakupoglu U, Baranowska-Daca E, Rosen D, et al. Post-transplant nephrotic syndrome: A comprehensive clinicopathologic study. Kidney Int 2004; 65:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/13\">",
"      Kasiske BL, Kalil RS, Lee HS, Rao KV. Histopathologic findings associated with a chronic, progressive decline in renal allograft function. Kidney Int 1991; 40:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/14\">",
"      Gouldesbrough DR, Axelsen RA. Arterial endothelialitis in chronic renal allograft rejection: a histopathological and immunocytochemical study. Nephrol Dial Transplant 1994; 9:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/15\">",
"      Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/16\">",
"      Wang Y, Pratt JR, Hartley B, et al. Expression of tissue type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure. Kidney Int 1997; 52:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/17\">",
"      Gough J, Yilmaz A, Miskulin D, et al. Peritubular capillary basement membrane reduplication in allografts and native kidney disease: a clinicopathologic study of 278 consecutive renal specimens. Transplantation 2001; 71:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/18\">",
"      Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/19\">",
"      Roos-van Groningen MC, Scholten EM, Lelieveld PM, et al. Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol 2006; 17:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/20\">",
"      Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/21\">",
"      Sis B, Jhangri GS, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9:2312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/22\">",
"      Ser&oacute;n D, Moreso F, Bover J, et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997; 51:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/23\">",
"      Nickerson P, Jeffery J, Gough J, et al. Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol 1998; 9:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/24\">",
"      Ser&oacute;n D, Moreso F, Ram&oacute;n JM, et al. Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation 2000; 69:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/25\">",
"      Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011; 378:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/26\">",
"      Andresdottir MB, Assmann KJ, Koene RA, Wetzels JF. Immunohistological and ultrastructural differences between recurrent type I membranoproliferative glomerulonephritis and chronic transplant glomerulopathy. Am J Kidney Dis 1998; 32:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/27\">",
"      Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/28\">",
"      Noris M, Mister M, Pezzotta A, et al. ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. Kidney Int 2003; 64:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/29\">",
"      Krieger NR, Becker BN, Heisey DM, et al. Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related, and living-unrelated grafts. Transplantation 2003; 75:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/30\">",
"      Schwarz A, Mengel M, Gwinner W, et al. Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study. Kidney Int 2005; 67:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/31\">",
"      Watschinger B, Sayegh MH. Endothelin in organ transplantation. Am J Kidney Dis 1996; 27:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/32\">",
"      Chandraker A, Azuma H, Nadeau K, et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998; 101:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/33\">",
"      Orth SR, Odoni G, Amann K, et al. The ET(A) receptor blocker LU 135252 prevents chronic transplant nephropathy in the \"Fisher to Lewis\" model. J Am Soc Nephrol 1999; 10:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/34\">",
"      Jain S, Furness PN, Nicholson ML. The role of transforming growth factor beta in chronic renal allograft nephropathy. Transplantation 2000; 69:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/35\">",
"      Grimm PC, Nickerson P, Jeffery J, et al. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med 2001; 345:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/36\">",
"      Theruvath TP, Saidman SL, Mauiyyedi S, et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001; 72:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/37\">",
"      Laskowski IA, Pratschke J, Wilhelm MJ, et al. Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. J Am Soc Nephrol 2002; 13:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/38\">",
"      Mr&oacute;z A, Durlik M, Cieciura T, et al. C4d complement split product expression in chronic rejection of renal allograft. Transplant Proc 2003; 35:2190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/39\">",
"      Sijpkens YW, Joosten SA, Wong MC, et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004; 65:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/40\">",
"      Akalin E, Dikman S, Murphy B, et al. Glomerular infiltration by CXCR3+ ICOS+ activated T cells in chronic allograft nephropathy with transplant glomerulopathy. Am J Transplant 2003; 3:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/41\">",
"      Koh KP, Wang Y, Yi T, et al. T cell-mediated vascular dysfunction of human allografts results from IFN-gamma dysregulation of NO synthase. J Clin Invest 2004; 114:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/42\">",
"      Joosten SA, Sijpkens YW, van Ham V, et al. Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant 2005; 5:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/43\">",
"      Melenhorst WB, van den Heuvel MC, Stegeman CA, et al. Upregulation of ADAM19 in chronic allograft nephropathy. Am J Transplant 2006; 6:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/44\">",
"      Herrero-Fresneda I, Torras J, Franquesa M, et al. HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic inflammatory-induced mechanisms. Kidney Int 2006; 70:265.",
"     </a>",
"    </li>",
"    <li>",
"     Terasaki, PI, Cecka, JM, Cho, Y, et al. Overview. In: Clinical Transplants, Terasaki, PI (Ed), UCLA Tissue Typing Laboratory, Los Angeles, 1989, p. 585.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/46\">",
"      Opelz G, Collaborative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/47\">",
"      Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/48\">",
"      Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/49\">",
"      Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/50\">",
"      Humar A, Kerr S, Gillingham KJ, Matas AJ. Features of acute rejection that increase risk for chronic rejection. Transplantation 1999; 68:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/51\">",
"      Humar A, Payne WD, Sutherland DE, Matas AJ. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation 2000; 69:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/52\">",
"      Lindholm A, Ohlman S, Albrechtsen D, et al. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993; 56:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/53\">",
"      Arias M, Ser&oacute;n D, Moreso F, et al. Chronic renal allograft damage: existing challenges. Transplantation 2011; 91:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/54\">",
"      Keith DS, DeMattos A, Golconda M, et al. Factors associated with improvement in deceased donor renal allograft function in the 1990s. J Am Soc Nephrol 2005; 16:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/55\">",
"      Bia MJ. Nonimmunologic causes of late renal graft loss. Kidney Int 1995; 47:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/56\">",
"      Melk, A, Gourishankar, S, Halloran, PF. Long-term effects of nonimmune tissue injury in renal transplantation. Curr Opin Organ Transplant 2002; 7:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/57\">",
"      Bhathena DB. Glomerular size and the association of focal glomerulosclerosis in long-surviving human renal allografts. J Am Soc Nephrol 1993; 4:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/58\">",
"      Brenner BM, Cohen RA, Milford EL. In renal transplantation, one size may not fit all. J Am Soc Nephrol 1992; 3:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/59\">",
"      Terasaki PI, Koyama H, Cecka JM, Gjertson DW. The hyperfiltration hypothesis in human renal transplantation. Transplantation 1994; 57:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/60\">",
"      Mackenzie HS, Tullius SG, Heemann UW, et al. Nephron supply is a major determinant of long-term renal allograft outcome in rats. J Clin Invest 1994; 94:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/61\">",
"      Miles AM, Sumrani N, John S, et al. The effect of kidney size on cadaveric renal allograft outcome. Transplantation 1996; 61:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/62\">",
"      Gaston RS, Hudson SL, Julian BA, et al. Impact of donor/recipient size matching on outcomes in renal transplantation. Transplantation 1996; 61:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/63\">",
"      Diaz Encarnacion MM, Griffin MD, Slezak JM, et al. Correlation of quantitative digital image analysis with the glomerular filtration rate in chronic allograft nephropathy. Am J Transplant 2004; 4:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/64\">",
"      Pape L, Henne T, Offner G, et al. Computer-assisted quantification of fibrosis in chronic allograft nephropaty by picosirius red-staining: a new tool for predicting long-term graft function. Transplantation 2003; 76:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/65\">",
"      Yokoyama I, Uchida K, Kobayashi T, et al. Effect of prolonged delayed graft function on long-term graft outcome in cadaveric kidney transplantation. Clin Transplant 1994; 8:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/66\">",
"      Guijarro C, Massy ZA, Kasiske BL. Clinical correlation between renal allograft failure and hyperlipidemia. Kidney Int Suppl 1995; 52:S56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/67\">",
"      de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/68\">",
"      Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/69\">",
"      Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006; 81:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/70\">",
"      Stegall MD, Park WD, Larson TS, et al. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011; 11:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/71\">",
"      Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/72\">",
"      Birnbaum LM, Lipman M, Paraskevas S, et al. Management of chronic allograft nephropathy: a systematic review. Clin J Am Soc Nephrol 2009; 4:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/73\">",
"      Weir MR, Anderson L, Fink JC, et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/74\">",
"      Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/75\">",
"      Gonzalez Molina M, Seron D, Garcia del Moral R, et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 2004; 77:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/76\">",
"      Bakker RC, Hollander AA, Mallat MJ, et al. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 2003; 64:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/77\">",
"      Fran&ccedil;ois H, D&uuml;rrbach A, Amor M, et al. The long-term effect of switching from cyclosporin A to mycophenolate mofetil in chronic renal graft dysfunction compared with conventional management. Nephrol Dial Transplant 2003; 18:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/78\">",
"      Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/79\">",
"      Montagnino G, Banfi G, Campise MR, et al. Impact of chronic allograft nephropathy and subsequent modifications of immunosuppressive therapy on late graft outcomes in renal transplantation. Nephrol Dial Transplant 2004; 19:2622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/80\">",
"      Saunders RN, Bicknell GR, Nicholson ML. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 2003; 75:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/81\">",
"      Gallagher MP, Hall B, Craig J, et al. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004; 78:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/82\">",
"      Cantarovich D, Renou M, Megnigbeto A, et al. Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. Transplantation 2005; 79:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/83\">",
"      Afzali B, Shah S, Chowdhury P, et al. Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation 2005; 79:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/84\">",
"      Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002; 74:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/85\">",
"      Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/86\">",
"      Hazzan M, Labalette M, Copin MC, et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J Am Soc Nephrol 2005; 16:2509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/87\">",
"      Meier M, Nitschke M, Weidtmann B, et al. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. Transplantation 2006; 81:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/88\">",
"      Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16:3755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/89\">",
"      Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005; 5:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/90\">",
"      Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/91\">",
"      Ruiz JC, Campistol JM, Griny&oacute; JM, et al. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 2004; 78:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/92\">",
"      Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/93\">",
"      Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/94\">",
"      Russ G, Segoloni G, Oberbauer R, et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 2005; 80:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/95\">",
"      Frimat L, Cassuto-Viguier E, Charpentier B, et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant 2006; 6:2725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/96\">",
"      Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006; 82:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/97\">",
"      Wali RK, Mohanlal V, Ramos E, et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007; 7:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/98\">",
"      Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/99\">",
"      Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/100\">",
"      Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/101\">",
"      Sharif A, Shabir S, Chand S, et al. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 2011; 22:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/102\">",
"      Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004; 77:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/103\">",
"      Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/104\">",
"      Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation 2006; 81:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/105\">",
"      Moreso F, Ser&oacute;n D, Carrera M, et al. Baseline immunosuppression is associated with histological findings in early protocol biopsies. Transplantation 2004; 78:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/106\">",
"      Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/107\">",
"      Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/108\">",
"      Jevnikar A, Arlen D, Barrett B, et al. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. Transplantation 2008; 86:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/109\">",
"      Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/110\">",
"      Griny&oacute; JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 2006; 6:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/111\">",
"      Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/112\">",
"      Merville P, Berg&eacute; F, Demini&egrave;re C, et al. Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. Am J Transplant 2004; 4:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/113\">",
"      Halloran PF, Langone AJ, Helderman JH, Kaplan B. Assessing long-term nephron loss: is it time to kick the CAN grading system? Am J Transplant 2004; 4:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/114\">",
"      Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the \"creeping creatinine\" study. Transplantation 2005; 79:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/115\">",
"      Weir MR, Blahut S, Drachenburg C, et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/116\">",
"      Moore J, Middleton L, Cockwell P, et al. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation 2009; 87:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/117\">",
"      Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248:564.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.clinicaltrials.gov/ct2/show/NCT00307125?term=ctot-02&amp;rank=1 (Accessed May 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/119\">",
"      Grotz W, Siebig S, Olschewski M, et al. Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. Transplantation 2004; 77:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/120\">",
"      Hiremath S, Fergusson D, Doucette S, et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7:2350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/121\">",
"      Opelz G, Zeier M, Laux G, et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006; 17:3257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/122\">",
"      Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/123\">",
"      Ibrahim HN, Jackson S, Connaire J, et al. Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol 2013; 24:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/124\">",
"      Lin J, Valeri AM, Markowitz GS, et al. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002; 73:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/125\">",
"      Zaltzman JS, Nash M, Chiu R, Prasad R. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. Nephrol Dial Transplant 2004; 19:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/126\">",
"      Artz MA, Hilbrands LB, Borm G, et al. Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 2004; 19:2852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/127\">",
"      O'Herrin JK, Hullett DA, Heisey DM, et al. A retrospective evaluation of 1,25-dihydroxyvitamin D(3) and its potential effects on renal allograft function. Am J Nephrol 2002; 22:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/61/34778/abstract/128\">",
"      Tian J, Liu Y, Williams LA, de Zeeuw D. Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant 2007; 22:321.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7359 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34778=[""].join("\n");
var outline_f33_61_34778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14609957\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS, DIAGNOSIS, AND PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Banff grading system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - C4d deposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      APPROACH TO DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Kidney dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Similar histologic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Immunologic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Importance of acute rejection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Immunosuppressive regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nonimmunologic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Glomerular hyperfiltration and hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Delayed graft function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Hyperlipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Time-dependence of various factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      GENERAL PREVENTION AND TREATMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Immunosuppressive issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Dosing and type of immunosuppressive regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15268107\">",
"      Changes in calcineurin inhibitor exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15268121\">",
"      Use of mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15268114\">",
"      Corticosteroid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Summary immunosuppressive issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Nonimmunologic interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Summary nonimmunosuppressive issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7359\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7359|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/19/10549\" title=\"picture 1A\">",
"      Chronic rejection Light I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/45/39636\" title=\"picture 1B\">",
"      Chronic rejection Light II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/3/33845\" title=\"picture 1C\">",
"      Chronic rejection Light III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/17/5401\" title=\"picture 2A\">",
"      Transplant glomerulopathy Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/6/27753\" title=\"picture 2B\">",
"      Transplant glomerulopathy EM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4938?source=related_link\">",
"      Acute renal allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25946?source=related_link\">",
"      C4d staining in renal allografts and treatment of antibody mediated rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/7/6266?source=related_link\">",
"      Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12505?source=related_link\">",
"      Clinical manifestations and diagnosis of acute renal allograft rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/1/2072?source=related_link\">",
"      Differential diagnosis of renal allograft dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10857?source=related_link\">",
"      Erythrocytosis following renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33722?source=related_link\">",
"      Focal segmental glomerulosclerosis in the transplanted kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34570?source=related_link\">",
"      HLA and ABO sensitization and desensitization in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11159?source=related_link\">",
"      HLA matching and graft survival in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=related_link\">",
"      Hypertension after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=related_link\">",
"      Induction immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=related_link\">",
"      Lipid abnormalities after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/45/42712?source=related_link\">",
"      Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34088?source=related_link\">",
"      Membranous nephropathy and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41353?source=related_link\">",
"      Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39477?source=related_link\">",
"      Possible role of low birth weight in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=related_link\">",
"      Renal disease associated with hepatitis C virus after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=related_link\">",
"      Risk factors for graft failure in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/27/10682?source=related_link\">",
"      Transplantation immunobiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_61_34779="Body art information";
var content_f33_61_34779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Brochures, health education videos, Web sites, and books regarding body art",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Thinking about tattooing or body piercing (715633A). For information: Attn: Corinna Wadleigh, Director, Educational Resources, Channing L. Bete Co., Inc. 1-800-628-7733.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Tattoos: A guide for safety and body piercing: A guide to safety. Available from WR Spence, MD, Health EDCO, Waco, TX 76702-1207. 1-800-299-3366 or",
"        <a href=\"file://www.healthedco.com\" target=\"_blank\">",
"         www.healthedco.com",
"        </a>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Several brochures on tattoing and body art are available from ETR Associates. 1-800-321-4407 or 1-800-435-8433 (fax) or",
"        <a href=\"file://www.etr.org\" target=\"_blank\">",
"         www.etr.org",
"        </a>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4.",
"        <a href=\"file://www.tattoo.about.com\" target=\"_blank\">",
"         www.tattoo.about.com",
"        </a>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Peds-R-Us Medical Education, LLC.",
"        <a href=\"file://www.peds-r-us.com\" target=\"_blank\">",
"         www.peds-r-us.com",
"        </a>",
"        . Addresses body piercing removal kit and training. DVD available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Getting Inked: What to Expect When You Get a Tattoo by Larry Gerber (Rosen Publishing).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Why People Get Tattoos and Other Body Art by Jeanne Nagle (Rosen Publishing).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Tattoo Art Around the World by Diane Bailey (Rosen Publishing).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Erasing the Ink: Getting Rid of Your Tattoo by Frank Spalding (Rosen Publishing).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34779=[""].join("\n");
var outline_f33_61_34779=null;
var title_f33_61_34780="Developmental and behavioral screening tests";
var content_f33_61_34780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected developmental and behavioral screening tests for use in primary care*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Developmental and behavioral screening tests",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Parent report tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parents' Evaluations of Developmental Status (PEDS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PEDS:Developmental Milestones (PEDS:DM)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Direct observation/elicitation tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Battelle Developmental Inventory Screening Test (BDIST)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PEDS:Developmental Milestones (PEDS:DM)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Developmental-only screening tests",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Parent report tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ages and Stages Questionnaire",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infant-Toddler Checklist for Language and Communications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Direct observation/elicitation tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bayley Infant Neurodevelopmental Screen (BINS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brigance Screens-II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Safety Word Inventory and Literacy Screener (SWILS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Behavioral screening tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Broad-band tests (all involve parent report)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ages and Stages Questionnaire:Social Emotional (ASQ:SE)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brief Infant-Toddler Social Emotional Assessment (BITSEA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Conners Rating Scale-Revised (CRS-R)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eyberg Child Behavior Inventory/Sutter-Eyberg Student Behavior Inventory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pediatric Symptom Checklist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Narrow-band tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Attention deficit hyperactivity disorder subscales of the Conners Rating Scale-Revised (CRS-R)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Modified Checklist for Autism in Toddlers (M-CHAT)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Only those screening tests that have been validated against a \"gold standard\" instrument and have been found to be able to correctly identify at least 70 percent of children with and without developmental or behavioral disabilities are included.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Screening tests that assess only one domain of development (eg, motor) are not included.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Glascoe FP and Robertshaw NR. PEDS:DM Professionals Manual PEDSTest.com, LLC, 1013 Austin Court, Nolensville, TN 37135, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34780=[""].join("\n");
var outline_f33_61_34780=null;
var title_f33_61_34781="Pediatric physical findings in hypertensive emergencies";
var content_f33_61_34781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physical findings associated with selected conditions in pediatric hypertensive emergencies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organ",
"       </td>",
"       <td class=\"subtitle1\">",
"        Finding*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Brain",
"       </td>",
"       <td>",
"        <p>",
"         Severe elevation of blood pressure",
"        </p>",
"        <p>",
"         Lethargy",
"        </p>",
"        <p>",
"         Coma",
"        </p>",
"        <p>",
"         Seizures",
"        </p>",
"       </td>",
"       <td>",
"        Hypertensive encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Signs of head trauma",
"        </p>",
"        <p>",
"         Headache",
"        </p>",
"        <p>",
"         Vomiting",
"        </p>",
"        <p>",
"         Altered mental status",
"        </p>",
"        <p>",
"         Seizures",
"        </p>",
"        <p>",
"         Cushing triad",
"        </p>",
"        <p>",
"         Focal neurological deficits",
"        </p>",
"        <p>",
"         Bulging fontanelle",
"        </p>",
"       </td>",
"       <td>",
"        Severe head trauma with intracranial injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         As above and",
"        </p>",
"        <p>",
"         Retinal hemorrhage",
"        </p>",
"        <p>",
"         Fractures in differing stages of healing",
"        </p>",
"        <p>",
"         Suspicious bruising",
"        </p>",
"       </td>",
"       <td>",
"        Child abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         As for head trauma and",
"        </p>",
"        <p>",
"         Ataxia",
"        </p>",
"        <p>",
"         Neck pain",
"        </p>",
"        <p>",
"         Diploplia",
"        </p>",
"        <p>",
"         Papilledema",
"        </p>",
"        <p>",
"         Visual field defects",
"        </p>",
"       </td>",
"       <td>",
"        Mass lesion (CNS tumor or abscess)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eye",
"       </td>",
"       <td>",
"        <p>",
"         Papilledema",
"        </p>",
"        <p>",
"         Exudates",
"        </p>",
"        <p>",
"         Retinal hemorrhage in the absence of signs of abuse",
"        </p>",
"       </td>",
"       <td>",
"        Malignant hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Heart",
"       </td>",
"       <td>",
"        <p>",
"         Dyspnea on exertion",
"        </p>",
"        <p>",
"         Orthopnea",
"        </p>",
"        <p>",
"         Edema",
"        </p>",
"        <p>",
"         Diaphoresis with exercise or feeding (infant)",
"        </p>",
"        <p>",
"         Cyanosis",
"        </p>",
"        <p>",
"         Chest pain",
"        </p>",
"        <p>",
"         Tachycardia",
"        </p>",
"        <p>",
"         Gallop rhythm",
"        </p>",
"        <p>",
"         Apical heave",
"        </p>",
"        <p>",
"         Bibasilar rales",
"        </p>",
"        <p>",
"         Hepatomegaly",
"        </p>",
"       </td>",
"       <td>",
"        Heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper extremity pulse and/or BP greater than lower extremity pulse and signs of heart failure",
"       </td>",
"       <td>",
"        Coarctation of the aorta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Adrenal gland",
"       </td>",
"       <td>",
"        <p>",
"         Headache",
"        </p>",
"        <p>",
"         Diaphoresis",
"        </p>",
"        <p>",
"         Paroxysmal flushing",
"        </p>",
"        <p>",
"         Pallor",
"        </p>",
"        <p>",
"         Tachycardia",
"        </p>",
"       </td>",
"       <td>",
"        Pheochromocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Weight gain",
"        </p>",
"        <p>",
"         Acne",
"        </p>",
"        <p>",
"         Striae",
"        </p>",
"        <p>",
"         Moon facies",
"        </p>",
"        <p>",
"         Upper back adiposity (\"buffalo hump\")",
"        </p>",
"        <p>",
"         Hirsuitism",
"        </p>",
"       </td>",
"       <td>",
"        Cushing syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid gland",
"       </td>",
"       <td>",
"        <p>",
"         Weight loss",
"        </p>",
"        <p>",
"         Anxiety",
"        </p>",
"        <p>",
"         Depression",
"        </p>",
"        <p>",
"         Heat intolerance",
"        </p>",
"        <p>",
"         Exophthalmos",
"        </p>",
"        <p>",
"         Thyromegaly",
"        </p>",
"        <p>",
"         Tachycardia",
"        </p>",
"        <p>",
"         Hyperglycemia",
"        </p>",
"       </td>",
"       <td>",
"        Hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Renal",
"       </td>",
"       <td>",
"        <p>",
"         Hematuria or \"tea-colored\" urine",
"        </p>",
"        <p>",
"         Oliguria/anuria",
"        </p>",
"        <p>",
"         Edema",
"        </p>",
"       </td>",
"       <td>",
"        Renal parenchymal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        As above and recent Group A streptococcal infection/exposure, pharyngitis, or impetigo",
"       </td>",
"       <td>",
"        Post-infectious glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Pallor",
"        </p>",
"        <p>",
"         Bloody diarrhea",
"        </p>",
"        <p>",
"         Microangiopathic anemia",
"        </p>",
"        <p>",
"         Uremia",
"        </p>",
"       </td>",
"       <td>",
"        Hemolytic uremic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal or flank bruit",
"       </td>",
"       <td>",
"        Renovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal mass",
"       </td>",
"       <td>",
"        <p>",
"         Polycystic kidney disease",
"        </p>",
"        <p>",
"         Congenital renal anomalies",
"        </p>",
"        <p>",
"         Wilms tumor",
"        </p>",
"        <p>",
"         Neuroblastoma",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Skin",
"       </td>",
"       <td>",
"        <p>",
"         Caf&eacute;-au-lait spots",
"        </p>",
"        <p>",
"         Axillary freckling",
"        </p>",
"        <p>",
"         Cutaneous neurofibromas",
"        </p>",
"       </td>",
"       <td>",
"        Neurofibromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ash leaf patches",
"       </td>",
"       <td>",
"        Tuberous sclerosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These lists represent common features associated with the given condition. An individual patient with a specific condition may not display all of these findings. Other conditions may exist in patients with these clinical findings.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34781=[""].join("\n");
var outline_f33_61_34781=null;
var title_f33_61_34782="Allergic contact dermatitis";
var content_f33_61_34782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Allergic contact dermatitis is characterized by an erythematous, papular dermatitis with indistinct margins, distributed in areas of exposure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34782=[""].join("\n");
var outline_f33_61_34782=null;
var title_f33_61_34783="Edinburgh depression scale 2";
var content_f33_61_34783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Appendix A: Edinburgh postnatal depression scale (EPDS) (con't)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 537px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A score of 12 or more identifies most women with postpartum depression. Women who report depressive symptoms without suicidal ideation or major functional impairment (or score between 5 and 9 on the EPDS) should be reevaluated within one month.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: JL Cox, JM Holden, R Sagovsky. Department of Psychiatry, University of Edinburgh.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_61_34783=[""].join("\n");
var outline_f33_61_34783=null;
